{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "schemaVersion": "4.0.0",
  "instanceType": "StudyDocument",
  "id": "USDM-D5164C00001-20251209190749",
  "name": "Protocol Extraction: D5164C00001",
  "sourceDocument": {
    "documentId": "DOC-1CBE40CD63F4E2D7",
    "filename": "AZD9291.pdf",
    "sha256Hash": "1cbe40cd63f4e2d72dbaa703dccba8993deea86d27941b69d58d543712a088f4",
    "byteSize": 3564575,
    "uploadTimestamp": "2025-12-09T19:07:49.441430",
    "pageCount": 155
  },
  "extractionMetadata": {
    "extractionTimestamp": "2025-12-09T19:07:49.649821",
    "pipelineVersion": "3.1",
    "primaryModel": "gemini-2.5-pro",
    "agentCount": 16,
    "successfulAgents": [
      "study_metadata",
      "arms_design",
      "endpoints_estimands_sap",
      "adverse_events",
      "safety_decision_points",
      "concomitant_medications",
      "biospecimen_handling",
      "laboratory_specifications",
      "informed_consent",
      "pro_specifications",
      "data_management",
      "site_operations_logistics",
      "quality_management",
      "withdrawal_procedures",
      "imaging_central_reading",
      "pkpd_sampling"
    ],
    "failedAgents": [],
    "qualitySummary": {
      "study_metadata": {
        "overallScore": 0.973939393939394,
        "fromCache": true
      },
      "arms_design": {
        "overallScore": 0.9800000000000001,
        "fromCache": true
      },
      "endpoints_estimands_sap": {
        "overallScore": 0.9789451476793251,
        "fromCache": true
      },
      "adverse_events": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "safety_decision_points": {
        "overallScore": 0.9902747252747254,
        "fromCache": false
      },
      "concomitant_medications": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "biospecimen_handling": {
        "overallScore": 0.8,
        "fromCache": false
      },
      "laboratory_specifications": {
        "overallScore": 0.962445305527135,
        "fromCache": false
      },
      "informed_consent": {
        "overallScore": 0.9993523316062177,
        "fromCache": false
      },
      "pro_specifications": {
        "overallScore": 0.8938775510204082,
        "fromCache": false
      },
      "data_management": {
        "overallScore": 0.9800000000000001,
        "fromCache": false
      },
      "site_operations_logistics": {
        "overallScore": 0.9993169398907104,
        "fromCache": false
      },
      "quality_management": {
        "overallScore": 0.978709677419355,
        "fromCache": false
      },
      "withdrawal_procedures": {
        "overallScore": 0.92,
        "fromCache": false
      },
      "imaging_central_reading": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "pkpd_sampling": {
        "overallScore": 0.9800000000000001,
        "fromCache": false
      }
    },
    "averageQualityScore": 0.9648038170223293
  },
  "study": {
    "instanceType": "Study",
    "id": "D5164C00001",
    "name": "ADAURA",
    "officialTitle": "A Phase III, Double-blind, Randomised, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)",
    "version": "6.0",
    "provenance": {
      "section_number": null,
      "page_number": 1,
      "text_snippet": "Revised Clinical Study Protocol\nDrug Substance AZD9291\nStudy Code D5164C00001\nEdition Number 6.0\nDate 09 August 2023\n\nA Phase III, Double-blind, Randomised, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)"
    },
    "studyPhase": {
      "code": "C15602",
      "decode": "Phase 3",
      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "A Phase III, Double-blind, Randomised, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo"
      }
    },
    "studyType": {
      "code": "C98388",
      "decode": "Interventional",
      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "A Phase III, Double-blind, Randomised, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)"
      }
    },
    "studyIdentifiers": [
      {
        "id": "117879",
        "scopeId": "fda_ind",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Investigational New Drug (IND) Number: 117879"
        }
      },
      {
        "id": "2015-000666-65",
        "scopeId": "eudract",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "European Clinical Trials Database (EudraCT) Number: 2015-000666-65"
        }
      },
      {
        "id": "2023-506524-82",
        "scopeId": "other",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "EU CT Number: 2023-506524-82"
        }
      }
    ],
    "studyProtocolVersions": [
      {
        "versionNumber": "6.0",
        "versionDate": "2023-08-09",
        "amendmentNumber": "5",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "5 09 August 2023"
        }
      },
      {
        "versionNumber": "5.0",
        "versionDate": "2021-01-25",
        "amendmentNumber": "4",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "4 25 January 2021"
        }
      },
      {
        "versionNumber": "4.0",
        "versionDate": "2020-07-02",
        "amendmentNumber": "3",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "3 02 July 2020"
        }
      },
      {
        "versionNumber": "3.0",
        "versionDate": "2019-08-01",
        "amendmentNumber": "2",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "2 01 August 2019"
        }
      },
      {
        "versionNumber": "2.0",
        "versionDate": "2016-11-17",
        "amendmentNumber": "1",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "1 17 November 2016"
        }
      },
      {
        "versionNumber": "1.0",
        "versionDate": "2015-06-22",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "1 22 June 2015"
        }
      },
      {
        "versionNumber": "1.0",
        "versionDate": "2015-06-04",
        "provenance": {
          "section_number": null,
          "page_number": 7,
          "text_snippet": "Version 1.0: 04 June 2015\nInitial creation"
        }
      }
    ],
    "studyPopulation": {
      "targetDisease": {
        "name": "Non-small Cell Lung Carcinoma",
        "stage": "IB-IIIA"
      },
      "ageRange": {
        "minAge": 18,
        "maxAgeNoLimit": true,
        "unit": "years"
      },
      "sex": {
        "allowed": [
          {
            "code": "C20197",
            "decode": "Male",
            "provenance": {
              "section_number": null,
              "page_number": 13,
              "text_snippet": "Male and female patients aged 18 years and over"
            }
          },
          {
            "code": "C16576",
            "decode": "Female",
            "provenance": {
              "section_number": null,
              "page_number": 13,
              "text_snippet": "Male and female patients aged 18 years and over"
            }
          }
        ]
      },
      "keyInclusionSummary": {
        "values": [
          "Histologically confirmed diagnosis of primary non-small cell lung cancer (NSCLC) on predominantly non-squamous histology.",
          "Patients must be classified post-operatively as Stage IB, II or IIIA.",
          "Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).",
          "Complete surgical resection of the primary NSCLC is mandatory.",
          "Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomisation.",
          "World Health Organization Performance Status of 0 to 1."
        ],
        "provenance": {
          "section_number": "3.1",
          "page_number": 43,
          "text_snippet": "3. Histologically confirmed diagnosis of primary non-small cell lung cancer (NSCLC) on predominantly non-squamous histology\n5. Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.\n6. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R)\n7. Complete surgical resection of the primary NSCLC is mandatory.\n8."
        }
      },
      "keyExclusionSummary": {
        "values": [
          "Pre-operative or post-operative or planned radiation therapy for the current lung cancer.",
          "Prior treatment with neoadjuvant or adjuvant EGFR-TKI.",
          "History of other malignancies, except for adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years.",
          "Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.",
          "Mean resting corrected QT interval (QTc) >470 msec.",
          "Inadequate bone marrow reserve or organ function."
        ],
        "provenance": {
          "section_number": "3.2",
          "page_number": 44,
          "text_snippet": "2. Treatment with any of the following:\n- Pre-operative or post-operative or planned radiation therapy for the current lung cancer\n- Prior treatment with neoadjuvant or adjuvant EGFR-TKI\n4. History of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other solid tumours curatively treated with no evidence of disease for > 5 years\n8. Any of the following cardiac criteria:\n- Mean resting corrected QT interval (QTc) >470 msec\n9."
        }
      },
      "provenance": {
        "section_number": null,
        "page_number": 13,
        "text_snippet": "Male and female patients aged 18 years and over (patients from Japan/Taiwan aged at least 20 years) with histologically confirmed diagnosis of primary non-squamous non-small cell carcinoma of the lung, with complete surgical resection of the primary tumour, and who were classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria are eligible for this study."
      }
    },
    "studyMilestones": {
      "enrollmentCompletionDate": {
        "date": "2017-12-31",
        "dateType": "Anticipated"
      },
      "primaryCompletionDate": {
        "date": "2023-03-31",
        "dateType": "Anticipated"
      },
      "estimatedDurations": {
        "screeningPeriodDays": 28,
        "enrollmentPeriodMonths": 28,
        "treatmentPeriodDescription": "The maximum treatment duration period is 3 years (156 weeks).",
        "followUpPeriodDescription": "Patients will be followed for disease recurrence yearly until 5 years, then for overall survival yearly until approximately 10 years after the last patient is randomised.",
        "totalStudyDurationMonths": 165
      },
      "provenance": {
        "section_number": null,
        "page_number": 8,
        "text_snippet": "Estimated date of first subject enrolled August 2015\nEstimated date of last subject completed (OS cut-off) Q1 2023\nEstimated date of last subject completed long-term OS follow-up Q2 2029"
      }
    },
    "studyDesignInfo": {
      "designType": "Parallel Assignment",
      "randomization": {
        "isRandomized": true,
        "allocationRatio": "1:1",
        "provenance": {
          "section_number": null,
          "page_number": 9,
          "text_snippet": "Patients will be randomised 1:1, to receive either AZD9291 or placebo."
        }
      },
      "blinding": {
        "blindingType": "Double-blind",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "A Phase III, Double-blind, Randomised, Placebo-Controlled Multi-centre, study"
        }
      },
      "targetEnrollment": 700,
      "plannedSites": 210,
      "countries": {
        "values": [
          "Japan",
          "Taiwan"
        ],
        "provenance": {
          "section_number": null,
          "page_number": 13,
          "text_snippet": "Male and female patients aged 18 years and over (patients from Japan/Taiwan aged at least 20 years)"
        }
      },
      "provenance": {
        "section_number": null,
        "page_number": 8,
        "text_snippet": "This study will be global, with approximately 700 patients to be randomised from an estimated 210 sites over an estimated 28 months."
      }
    },
    "therapeuticArea": {
      "value": "Oncology",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)"
      }
    },
    "indication": {
      "value": "Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)"
      }
    },
    "sponsorName": {
      "value": "AstraZeneca",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden"
      }
    },
    "isPivotal": true,
    "extensionAttributes": [
      {
        "name": "ich_m11_section",
        "value": {
          "sectionNumber": "1.1",
          "title": "Background and rationale for conducting this study"
        }
      },
      {
        "name": "ich_m11_section",
        "value": {
          "sectionNumber": "1.2",
          "title": "Rationale for study design, doses and control groups"
        }
      },
      {
        "name": "ich_m11_section",
        "value": {
          "sectionNumber": "2",
          "title": "STUDY OBJECTIVES"
        }
      },
      {
        "name": "ich_m11_section",
        "value": {
          "sectionNumber": "3",
          "title": "SUBJECT SELECTION, ENROLMENT, RANDOMISATION, RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL"
        }
      },
      {
        "name": "extractionMetadata",
        "value": {
          "extractedAt": "2024-07-01T12:00:00Z",
          "modelVersion": "gemini-1.5-pro"
        }
      }
    ]
  },
  "domainSections": {
    "studyDesign": {
      "moduleId": "arms_design",
      "instanceType": "StudyDesign",
      "data": {
        "id": "D5164C00001-arms-design",
        "instanceType": "StudyDesign",
        "name": "D5164C00001 Study Design",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "A Phase 3, Double-blind, Randomised, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)"
        },
        "studyArms": [
          {
            "id": "ARM01",
            "instanceType": "StudyArm",
            "name": "Osimertinib",
            "label": "AZD9291",
            "description": "Osimertinib 80 mg administered orally once daily for up to 3 years.",
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "ARM A\n80mg AZD9291\nonce daily"
            },
            "armType": {
              "code": "C174266",
              "decode": "Experimental",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 350,
            "interventions": [
              {
                "id": "INT01",
                "instanceType": "StudyIntervention",
                "name": "Osimertinib",
                "type": "Drug",
                "provenance": {
                  "section_number": null,
                  "page_number": 14,
                  "text_snippet": "Investigational product, dosage and mode of administration\nAZD9291 is an oral, potent, selective, central nervous system (CNS) active, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) effective against both EGFR-TKI sensitising and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. AZD9291 (80 mg orally, once daily) or matching placebo, in accordance with the randomisation schedule, will be administered."
                },
                "role": {
                  "decode": "Investigational"
                },
                "biomedicalConcept": {
                  "conceptName": "Osimertinib",
                  "cdiscCode": "C154976",
                  "domain": "CM"
                },
                "dosingRegimen": {
                  "dose": 80,
                  "doseUnit": "mg",
                  "frequency": "once daily",
                  "route": {
                    "code": "C38288",
                    "decode": "Oral",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "Fixed"
                },
                "isBlinded": true,
                "isPlacebo": false,
                "isComparator": false,
                "doseModifications": {
                  "provenance": {
                    "section_number": "6.9.1",
                    "page_number": 89,
                    "text_snippet": "6.9.1 General dose adjustments on adverse events\nAll patients to commence treatment at the starting dose level as shown in Table 6."
                  },
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 40,
                      "doseUnit": "mg",
                      "percentReduction": 50,
                      "provenance": {
                        "section_number": null,
                        "page_number": 88,
                        "text_snippet": "Table 6 Dose reduction levels\nReduced dose 40 mg AZD9291/ matching placebo"
                      }
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG01",
                      "condition": "CTCAE grade 3 or higher or unacceptable lower grade toxicities not attributable to the disease or disease-related processes.",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Until toxicity resolves or reverts to ≤CTCAE Grade 2 within 3 weeks",
                      "provenance": {
                        "section_number": "6.9.1",
                        "page_number": 89,
                        "text_snippet": "If a patient experiences a CTCAE grade 3 or higher or unacceptable toxicities lower grades not attributable to the disease or disease-related processes under investigation, where the Investigator considers the AE of concern to be specifically associated with the study drug dosing will be interrupted and supportive therapy administered as required in accordance with local practice/guidelines.\nIf the toxicity resolves or reverts to ≤CTCAE Grade 2 within 3 weeks of withholding AZD9291/matching"
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Toxicity does not resolve to ≤CTCAE Grade 2 after 3 weeks of withholding drug",
                    "Confirmed Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)",
                    "Confirmed aplastic anaemia",
                    "QTc interval prolongation with signs/symptoms of serious arrhythmia",
                    "Confirmed ILD/pneumonitis"
                  ]
                }
              }
            ]
          },
          {
            "id": "ARM02",
            "instanceType": "StudyArm",
            "name": "Placebo",
            "label": "Placebo",
            "description": "Matching placebo administered orally once daily for up to 3 years.",
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "ARM B\nPlacebo once\ndaily"
            },
            "armType": {
              "code": "C174268",
              "decode": "Placebo Comparator",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 350,
            "interventions": [
              {
                "id": "INT02",
                "instanceType": "StudyIntervention",
                "name": "Placebo",
                "type": "Drug",
                "provenance": {
                  "section_number": "7.1",
                  "page_number": 92,
                  "text_snippet": "Table 7 Identity of investigational products\nPlacebo\nAZD9291-matching placebo NA"
                },
                "role": {
                  "decode": "Placebo"
                },
                "dosingRegimen": {
                  "dose": 1,
                  "doseUnit": "tablet",
                  "frequency": "once daily",
                  "route": {
                    "code": "C38288",
                    "decode": "Oral",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "Fixed"
                },
                "isBlinded": true,
                "isPlacebo": true,
                "isComparator": true,
                "doseModifications": {
                  "provenance": {
                    "section_number": "6.9.1",
                    "page_number": 89,
                    "text_snippet": "6.9.1 General dose adjustments on adverse events\nAll patients to commence treatment at the starting dose level as shown in Table 6."
                  },
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 1,
                      "doseUnit": "tablet",
                      "provenance": {
                        "section_number": null,
                        "page_number": 88,
                        "text_snippet": "Table 6 Dose reduction levels\nReduced dose 40 mg AZD9291/ matching placebo"
                      }
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG02",
                      "condition": "CTCAE grade 3 or higher or unacceptable lower grade toxicities not attributable to the disease or disease-related processes.",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Until toxicity resolves or reverts to ≤CTCAE Grade 2 within 3 weeks",
                      "provenance": {
                        "section_number": "6.9.1",
                        "page_number": 89,
                        "text_snippet": "If a patient experiences a CTCAE grade 3 or higher or unacceptable toxicities lower grades not attributable to the disease or disease-related processes under investigation, where the Investigator considers the AE of concern to be specifically associated with the study drug dosing will be interrupted and supportive therapy administered as required in accordance with local practice/guidelines.\nIf the toxicity resolves or reverts to ≤CTCAE Grade 2 within 3 weeks of withholding AZD9291/matching"
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Toxicity does not resolve to ≤CTCAE Grade 2 after 3 weeks of withholding drug"
                  ]
                }
              }
            ]
          }
        ],
        "studyEpochs": [
          {
            "id": "EPOCH01",
            "instanceType": "StudyEpoch",
            "name": "Screening",
            "description": "Screening for eligibility, including central confirmation of EGFR mutation status.",
            "provenance": {
              "section_number": "4",
              "page_number": 53,
              "text_snippet": "Table 1 Study plan up to completion of final DFS analysis\nScreening\nVisit Part I Part II a\nTiming\nDay -28 to\nDay -1"
            },
            "epochType": {
              "code": "C48262",
              "decode": "Screening",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 1,
            "durationDays": 28
          },
          {
            "id": "EPOCH02",
            "instanceType": "StudyEpoch",
            "name": "Treatment",
            "description": "Patients receive either AZD9291 or placebo for a maximum of 3 years (156 weeks) or until disease recurrence or discontinuation criteria are met.",
            "provenance": {
              "section_number": null,
              "page_number": 13,
              "text_snippet": "Duration of treatment\nTreatment with AZD9291 (80 mg once daily) or placebo will commence following randomisation. Patients will continue on randomised treatment until recurrence of disease, treatment discontinuation criterion is met or treatment is completed. The maximum treatment duration period is 3 years (156 weeks)."
            },
            "epochType": {
              "code": "C101526",
              "decode": "Treatment",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 2,
            "durationDays": 1092
          },
          {
            "id": "EPOCH03",
            "instanceType": "StudyEpoch",
            "name": "Follow-up",
            "description": "Follow-up for disease recurrence and overall survival after discontinuation of study treatment.",
            "provenance": {
              "section_number": "4.3",
              "page_number": 63,
              "text_snippet": "4.3 Follow-up period"
            },
            "epochType": {
              "code": "C99158",
              "decode": "Follow-up",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 3
          },
          {
            "id": "EPOCH04",
            "instanceType": "StudyEpoch",
            "name": "Long-term OS Follow-up Extension",
            "description": "Optional long-term survival follow-up of patients until approximately 10 years after the last patient is randomised.",
            "provenance": {
              "section_number": "1.7",
              "page_number": 38,
              "text_snippet": "1.7 Study extension for long-term OS follow-up\nAfter the final OS analysis, a study extension has been added to allow the optional longer-term survival follow-up of patients in the ADAURA trial until approximately 10 years after the last patient is randomised, which will further characterise long-term patient outcomes in the adjuvant setting. All patients in survival follow-up will be offered the opportunity to participate in the long-term OS follow-up."
            },
            "epochType": {
              "code": "C48261",
              "decode": "Extension",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 4
          }
        ],
        "studyCells": [
          {
            "id": "CELL01",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH01",
            "interventionIds": [],
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "Figure 1 Study design"
            }
          },
          {
            "id": "CELL02",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH01",
            "interventionIds": [],
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "Figure 1 Study design"
            }
          },
          {
            "id": "CELL03",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT01"
            ],
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "Figure 1 Study design"
            }
          },
          {
            "id": "CELL04",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT02"
            ],
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "Figure 1 Study design"
            }
          },
          {
            "id": "CELL05",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH03",
            "interventionIds": [],
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "Figure 1 Study design"
            }
          },
          {
            "id": "CELL06",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH03",
            "interventionIds": [],
            "provenance": {
              "section_number": null,
              "page_number": 39,
              "text_snippet": "Figure 1 Study design"
            }
          },
          {
            "id": "CELL07",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH04",
            "interventionIds": [],
            "provenance": {
              "section_number": "1.7",
              "page_number": 38,
              "text_snippet": "1.7 Study extension for long-term OS follow-up\nAfter the final OS analysis, a study extension has been added to allow the optional longer-term survival follow-up of patients in the ADAURA trial until approximately 10 years after the last patient is randomised, which will further characterise long-term patient outcomes in the adjuvant setting. All patients in survival follow-up will be offered the opportunity to participate in the long-term OS follow-up."
            }
          },
          {
            "id": "CELL08",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH04",
            "interventionIds": [],
            "provenance": {
              "section_number": "1.7",
              "page_number": 38,
              "text_snippet": "1.7 Study extension for long-term OS follow-up\nAfter the final OS analysis, a study extension has been added to allow the optional longer-term survival follow-up of patients in the ADAURA trial until approximately 10 years after the last patient is randomised, which will further characterise long-term patient outcomes in the adjuvant setting. All patients in survival follow-up will be offered the opportunity to participate in the long-term OS follow-up."
            }
          }
        ],
        "designMetadata": {
          "id": "DESIGN01",
          "provenance": {
            "section_number": null,
            "page_number": 9,
            "text_snippet": "Study Design\nThis is a phase 3 double-blind, randomised, placebo-controlled, study to assess the efficacy and safety of AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without post-operative adjuvant chemotherapy."
          },
          "designType": {
            "code": "C82639",
            "decode": "Parallel",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "24.03e"
          },
          "isRandomized": true,
          "allocationRatio": "1:1",
          "randomizationDetails": {
            "provenance": {
              "section_number": "3.6",
              "page_number": 48,
              "text_snippet": "3.6 Methods for assigning treatment groups\nEligible patients will be centrally randomised to receive either 80 mg AZD9291 orally once daily or matching placebo in a 1:1 ratio using the IVRS/IWRS system."
            },
            "randomization_type": "central",
            "randomization_method": "IVRS/IWRS"
          },
          "blindingType": "Double-blind",
          "whoIsBlinded": [
            "Participant",
            "Investigator"
          ],
          "isPlaceboControlled": true,
          "isActiveControlled": false,
          "stratificationFactors": [
            {
              "id": "STRAT01",
              "name": "Disease Stage",
              "levels": [
                "IB",
                "II",
                "IIIA"
              ],
              "provenance": {
                "section_number": "3.6",
                "page_number": 48,
                "text_snippet": "Patients will be stratified at randomisation based on:\n• Stage (IB vs II vs IIIA)"
              },
              "is_irt_stratification": true,
              "is_analysis_stratification": true
            },
            {
              "id": "STRAT02",
              "name": "EGFR Mutation Type",
              "levels": [
                "Ex19Del",
                "L858R"
              ],
              "provenance": {
                "section_number": "3.6",
                "page_number": 48,
                "text_snippet": "• EGFR mutation (Ex19Del or L858R) In the rare event that a patient has both of these sensitizing mutations, they should be stratified to Ex19Del"
              },
              "is_irt_stratification": true,
              "is_analysis_stratification": true
            },
            {
              "id": "STRAT03",
              "name": "Race",
              "levels": [
                "Asian",
                "Non-Asian"
              ],
              "provenance": {
                "section_number": "3.6",
                "page_number": 48,
                "text_snippet": "• Race (Asian/Non-Asian)"
              },
              "is_irt_stratification": true,
              "is_analysis_stratification": true
            }
          ]
        }
      },
      "_agentDocumentation": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm × epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Generate IRT arm configuration from study arms",
                "sourceDataPath": "studyArms[]",
                "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
                "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
              },
              {
                "ruleId": "EDC_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate treatment assignment dropdown options",
                "sourceDataPath": "studyArms[].name",
                "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DISP_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT dispensing rules from dosing regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
                "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
                "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
              },
              {
                "ruleId": "EDC_DOSE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dispensed dose against protocol regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
                "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT stratification from protocol factors",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
                "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
              },
              {
                "ruleId": "EDC_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate stratification CRF fields",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DOSEMOD_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dose modification follows protocol levels",
                "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
                "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Randomization & Trial Supply Management",
                "description": "Generate kit configuration and depot requirements",
                "sourceDataPath": "designMetadata.drugSupply",
                "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Generate IRT arm configuration from study arms",
            "sourceDataPath": "studyArms[]",
            "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
            "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
          },
          {
            "ruleId": "EDC_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate treatment assignment dropdown options",
            "sourceDataPath": "studyArms[].name",
            "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
            "example": null
          },
          {
            "ruleId": "IRT_DISP_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT dispensing rules from dosing regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
            "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
            "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
          },
          {
            "ruleId": "EDC_DOSE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dispensed dose against protocol regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
            "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
            "example": null
          },
          {
            "ruleId": "IRT_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT stratification from protocol factors",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
            "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
          },
          {
            "ruleId": "EDC_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate stratification CRF fields",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
            "example": null
          },
          {
            "ruleId": "EDC_DOSEMOD_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dose modification follows protocol levels",
            "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
            "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
            "example": null
          },
          {
            "ruleId": "IRT_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Randomization & Trial Supply Management",
            "description": "Generate kit configuration and depot requirements",
            "sourceDataPath": "designMetadata.drugSupply",
            "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_ARMS_SAFETY_001",
            "name": "Dosing + Safety Rules → Complete Dose Management",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining dosing regimens with safety thresholds and lab triggers enables intelligent dose management",
            "combinedInsight": "Protocol doses + reduction levels + lab thresholds = Automated dose recommendation engine",
            "automationEnabled": "EDC can suggest appropriate dose level based on current labs and AEs",
            "exampleOutput": "{\"current_dose\": \"400mg\", \"recommended_action\": \"REDUCE to 300mg\", \"trigger\": \"ANC < 1000\", \"confidence\": 0.95}"
          },
          {
            "synergyId": "SYN_ARMS_SOA_001",
            "name": "Arms + SOA → Visit-Based Dispensing",
            "agentsInvolved": [
              "arms_design",
              "soa_schedule"
            ],
            "description": "Arm-specific dosing matched to visit schedule enables precise dispensing rules",
            "combinedInsight": "Which drug, what dose, at which visits = Complete dispensing matrix",
            "automationEnabled": "IRT auto-dispense based on visit and arm assignment",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_ARMS_001",
            "name": "Arm Allocation Total",
            "agentsInvolved": [
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify arm allocations sum to 100%",
            "checkLogic": "SUM(studyArms[].allocationPercentage) == 100",
            "severity": "error"
          },
          {
            "ruleId": "VAL_ARMS_002",
            "name": "Dose Levels Consistency",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels in arms match safety decision points",
            "checkLogic": "arms.doseModifications.levels SUBSET_OF safety.dose_modification_levels.levels",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Interactive Response Technology",
            "configType": "randomization_module",
            "description": "Complete IRT randomization configuration",
            "dataSources": [
              "studyArms[].id",
              "studyArms[].name",
              "studyArms[].allocationPercentage",
              "designMetadata.stratificationFactors[]",
              "designMetadata.randomizationRatio"
            ],
            "outputFormat": "IRT vendor import (Medidata RTSM, Oracle Siebel CTMS, Parexel ClinPhone)",
            "exampleConfig": {
              "study_arms": [
                {
                  "code": "A",
                  "name": "Drug A + Chemo",
                  "ratio": 2
                },
                {
                  "code": "B",
                  "name": "Placebo + Chemo",
                  "ratio": 1
                }
              ],
              "stratification_factors": [
                {
                  "name": "ECOG Status",
                  "levels": [
                    "0-1",
                    "2"
                  ]
                },
                {
                  "name": "Prior Therapy",
                  "levels": [
                    "Yes",
                    "No"
                  ]
                }
              ],
              "block_size": [
                3,
                6
              ],
              "randomization_method": "permuted_block"
            }
          }
        ]
      }
    },
    "endpointsEstimandsSAP": {
      "moduleId": "endpoints_estimands_sap",
      "instanceType": "EndpointsEstimandsSAP",
      "data": {
        "id": "D5164C00001-endpoints-estimands-sap",
        "instanceType": "EndpointsEstimandsSAP",
        "name": "D5164C00001 Endpoints, Estimands & SAP",
        "documentType": "protocol",
        "protocol_endpoints": {
          "objectives": [
            {
              "id": "objective-001",
              "instanceType": "Objective",
              "name": "Primary Efficacy Objective",
              "text": "To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)",
              "level": {
                "code": "C85826",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-001"
              ],
              "provenance": {
                "section_number": "2.1",
                "page_number": 40,
                "text_snippet": "Primary Objective: To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)"
              }
            },
            {
              "id": "objective-002",
              "instanceType": "Objective",
              "name": "Secondary Objectives",
              "text": "To further assess the efficacy of AZD9291 compared with placebo; to assess the effect on health-related quality of life (HRQoL); to characterise the pharmacokinetics (PK) of AZD9291 and its metabolites.",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-002",
                "endpoint-003",
                "endpoint-004",
                "endpoint-005",
                "endpoint-006"
              ],
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "Secondary Objective:\nTo further assess the efficacy of AZD9291 compared with placebo\nTo assess the effect of AZD9291 compared with placebo on health-related quality of life (HRQoL)\nTo characterise the pharmacokinetics (PK) of AZD9291 and its metabolites (AZ5104 and AZ7550)"
              }
            },
            {
              "id": "objective-003",
              "instanceType": "Objective",
              "name": "Safety Objective",
              "text": "To assess the safety and tolerability profile of AZD9291 compared with placebo",
              "level": {
                "code": "C49657",
                "decode": "Safety",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-007"
              ],
              "provenance": {
                "section_number": "2.3",
                "page_number": 40,
                "text_snippet": "Safety objectives\nSecondary Objective:\nTo assess the safety and tolerability profile of AZD9291 compared with placebo"
              }
            },
            {
              "id": "objective-004",
              "instanceType": "Objective",
              "name": "Exploratory Objectives",
              "text": "To compare health resource use, post recurrence outcomes, efficacy in patients with baseline T790M status, and to collect and store biopsy and plasma samples for exploratory analysis of molecular mechanisms and biomarkers.",
              "level": {
                "code": "C174265",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-008",
                "endpoint-009",
                "endpoint-010",
                "endpoint-011"
              ],
              "provenance": {
                "section_number": "2.4",
                "page_number": 41,
                "text_snippet": "Exploratory objectives\nTo compare health resource use associated with AZD9291 treatment versus Placebo\nTo compare the effects of AZD9291 with placebo on post recurrence outcomes.\nTo assess the efficacy of AZD9291 in patients with confirmed baseline T790M status (positive / negative) using a high sensitivity method yet to be determined (retrospective)\nTo collect and store biopsy material (multiple cores where possible) from all screened patients for exploratory analysis of molecular mechanisms"
              }
            }
          ],
          "endpoints": [
            {
              "id": "endpoint-001",
              "instanceType": "Endpoint",
              "name": "Disease Free Survival (DFS)",
              "label": "Primary Efficacy Endpoint",
              "text": "Time from the date of randomisation until the date of disease recurrence or death from any cause in the absence of disease recurrence.",
              "purpose": "To assess the efficacy of AZD9291 in preventing or delaying disease recurrence.",
              "level": {
                "code": "C98747",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "CT or MRI scan and/or pathological disease on biopsy",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.1.1",
                "page_number": 66,
                "text_snippet": "Disease-free survival is the primary endpoint in this study and is defined as the time from the date of randomisation until the date of disease recurrence or death from any cause in the absence of disease recurrence. Disease recurrence is defined as evidence of disease recurrence on CT or MRI scan and/or pathological disease on biopsy by investigational site assessment."
              }
            },
            {
              "id": "endpoint-002",
              "instanceType": "Endpoint",
              "name": "DFS Rate",
              "label": "Secondary Efficacy Endpoint",
              "text": "Proportion of patients alive and disease free at 2, 3, 4 and 5 years.",
              "purpose": "To assess landmark disease-free survival.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Kaplan-Meier estimate from DFS analysis",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [
                104,
                156,
                208,
                260
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "Outcome Measure:\nAt time of primary analysis:\nDFS rate at 2, 3, 4, and 5 years"
              }
            },
            {
              "id": "endpoint-003",
              "instanceType": "Endpoint",
              "name": "Overall Survival (OS)",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from the date of randomisation until date of death due to any cause.",
              "purpose": "To assess the effect on survival.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Collection of survival status",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "5.1.3",
                "page_number": 68,
                "text_snippet": "Overall survival is defined as the time from randomisation to the date of death (from any cause) or to the date the patient was last known to be alive."
              }
            },
            {
              "id": "endpoint-004",
              "instanceType": "Endpoint",
              "name": "OS Rate",
              "label": "Secondary Efficacy Endpoint",
              "text": "Proportion of patients alive at 2, 3, 4, and 5 years.",
              "purpose": "To assess landmark overall survival.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Kaplan-Meier estimate from OS analysis",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [
                104,
                156,
                208,
                260
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "Outcome Measure:\nAt time of primary analysis:\nOS rate at 2, 3, 4 and 5 years"
              }
            },
            {
              "id": "endpoint-005",
              "instanceType": "Endpoint",
              "name": "Health-Related Quality of Life (HRQoL)",
              "label": "Secondary Efficacy Endpoint",
              "text": "Changes in generic HRQoL as measured by the SF-36 (vers2, standard).",
              "purpose": "To assess the effect of treatment on patient-reported quality of life.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "SF-36 v2 questionnaire",
              "assessor": "Patient",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "To assess the effect of AZD9291 compared with placebo on health-related quality of life (HRQoL)\nOutcome Measure: Changes in generic HRQoL as measured by the SF-36 (vers2, standard)"
              }
            },
            {
              "id": "endpoint-006",
              "instanceType": "Endpoint",
              "name": "Pharmacokinetics (PK)",
              "label": "Secondary Endpoint",
              "text": "PK plasma concentrations of AZD9291, and metabolites AZ5104 and AZ7550.",
              "purpose": "To characterize the pharmacokinetic profile of AZD9291.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Blood sampling and analysis",
              "assessor": "Laboratory",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-003",
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites (AZ5104 and AZ7550)\nOutcome Measure: PK plasma concentrations of AZD9291, and metabolites AZ5104 and AZ7550; and ratio of metabolite to AZD9291 for each PK sample (included in CSR)"
              }
            },
            {
              "id": "endpoint-007",
              "instanceType": "Endpoint",
              "name": "Safety and Tolerability",
              "label": "Safety Endpoint",
              "text": "Incidence of adverse events (graded by CTCAE v4), changes in clinical chemistry, haematology, urinalysis, vital signs, ECG, LVEF, WHO Performance Status, and ophthalmologic assessment.",
              "purpose": "To evaluate the safety profile of AZD9291.",
              "level": {
                "code": "C49656",
                "decode": "Safety",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25463",
                "decode": "Count Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "AE reporting, laboratory tests, physical exams, ECG, Echocardiogram/MUGA",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-002",
              "provenance": {
                "section_number": "2.3",
                "page_number": 40,
                "text_snippet": "Outcome Measure:\nAdverse events (graded by CTCAE v4)\nClinical chemistry, haematology and urinalysis\nVital signs, Physical Examination, Weight\nDigital ECG\nLVEF\nWHO Performance Status\nOphthalmologic assessment"
              }
            },
            {
              "id": "endpoint-008",
              "instanceType": "Endpoint",
              "name": "Health Resource Use",
              "label": "Exploratory Endpoint",
              "text": "Comparison of health resource use associated with AZD9291 treatment versus placebo.",
              "purpose": "To evaluate the economic impact of treatment.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25463",
                "decode": "Count Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Health Resource Use Module",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "2.4",
                "page_number": 41,
                "text_snippet": "Exploratory Objective: To compare health resource use associated with AZD9291 treatment versus Placebo\nOutcome Measure: Health Resource Use Module"
              }
            },
            {
              "id": "endpoint-009",
              "instanceType": "Endpoint",
              "name": "Post Recurrence Outcomes",
              "label": "Exploratory Endpoint",
              "text": "Time to next treatment, type of recurrence, site of recurrence, type of next treatment, and PFS as determined by investigator assessment.",
              "purpose": "To compare the effects of AZD9291 or placebo on outcomes after disease recurrence.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Investigator assessment",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "2.4",
                "page_number": 41,
                "text_snippet": "To compare the effects of AZD9291 with placebo on post recurrence outcomes.\nOutcome Measure:\nTime to next treatment (s)\nType of recurrence (local/regional or distant)\nSite (s) of relapse\nType of next treatment (s) (including procedures, radiotherapy and anticancer agents)\nPFS as determined by investigator assessment"
              }
            },
            {
              "id": "endpoint-010",
              "instanceType": "Endpoint",
              "name": "Efficacy in T790M positive patients",
              "label": "Exploratory Endpoint",
              "text": "DFS and OS in patients with confirmed baseline T790M status (positive / negative).",
              "purpose": "To assess the efficacy of AZD9291 in a specific biomarker subgroup.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Investigator assessment",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "2.4",
                "page_number": 41,
                "text_snippet": "To assess the efficacy of AZD9291 in patients with confirmed baseline T790M status (positive / negative) using a high sensitivity method yet to be determined (retrospective)\nOutcome Measure:\nDFS by investigator assessment\nOS"
              }
            },
            {
              "id": "endpoint-011",
              "instanceType": "Endpoint",
              "name": "Biomarker Analysis",
              "label": "Exploratory Endpoint",
              "text": "Evaluation of circulating DNA, RNA, and/or protein for detection of minimal residual disease (MRD) and prediction of disease recurrence.",
              "purpose": "To explore potential biomarkers for response and recurrence.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Tumour and plasma sample analysis",
              "assessor": "Laboratory",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "2.4",
                "page_number": 42,
                "text_snippet": "Evaluate the feasibility of using circulating DNA, RNA, and/or protein (including but not limited to ctDNA) profiling approaches for detection of minimal residual disease (MRD) in early-stage NSCLC patients after completion of surgery (and chemotherapy in eligible patients). Investigate whether detection of MRD is impacted by tumour staging or adjuvant chemotherapy.\n\nAssess dynamics of circulating DNA, RNA, and/or protein as a proof of principle for early prediction of disease recurrence in the"
              }
            }
          ],
          "estimands": [
            {
              "id": "estimand-001",
              "instanceType": "Estimand",
              "name": "Primary Estimand for DFS",
              "text": "Treatment effect on Disease Free Survival (DFS) comparing AZD9291 vs Placebo in the Full Analysis Set population.",
              "endpoint_id": "endpoint-001",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "AZD9291 80 mg orally, once daily"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98390",
                    "decode": "Placebo Comparator Arm"
                  },
                  "description": "Matching placebo, orally, once daily"
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 31,
                  "text_snippet": "This is phase 3, double-blind, randomised, placebo-controlled study, to assess efficacy and safety of AZD9291 versus placebo in patients with completely resected stage IB-IIIA NSCLC"
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Full Analysis Set (all randomized patients)",
                "provenance": {
                  "section_number": "8.3.1",
                  "page_number": 98,
                  "text_snippet": "The full analysis set (FAS) will include all randomised patients. The full analysis set will be used for all efficacy analyses and treatment groups will be compared on the basis of randomised study treatment, regardless of the treatment actually received."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-001",
                "description": "Time from randomization to disease recurrence or death from any cause.",
                "provenance": {
                  "section_number": "8.4.1.1",
                  "page_number": 99,
                  "text_snippet": "DFS is defined as the time from the date of randomisation until the date of disease recurrence or death (by any cause in the absence of recurrence)."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-001",
                  "name": "Discontinuation of study treatment",
                  "description": "Subject discontinues study treatment for reasons other than disease recurrence (e.g., adverse event, patient decision).",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "The effect of interest is the comparison of treatment strategies regardless of adherence. Patients are followed for DFS until an event occurs or end of study, irrespective of treatment discontinuation.",
                  "provenance": {
                    "section_number": "3.10.1",
                    "page_number": 50,
                    "text_snippet": "“Follow up until disease recurrence” visits should continue according to study plan if the patient discontinues study treatment prior to disease recurrence."
                  }
                },
                {
                  "id": "ice-002",
                  "name": "Use of subsequent anti-cancer therapy",
                  "description": "Subject receives subsequent anti-cancer therapy after recurrence.",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "DFS is measured up to the first recurrence or death, so subsequent therapies do not affect the primary variable.",
                  "provenance": {
                    "section_number": "5.1.1",
                    "page_number": 66,
                    "text_snippet": "Disease-free survival is the primary endpoint in this study and is defined as the time from the date of randomisation until the date of disease recurrence or death from any cause in the absence of disease recurrence."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [
                "sens-001",
                "sens-002"
              ],
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 102,
                "text_snippet": "DFS in the subset of patients with stage II-IIIA cancer will be analysed using a log rank test stratified by stage (II, IIIA), mutation type (Ex19Del, L858R either alone or in combination with other EGFR mutations) and race (Asian, Non-Asian) for the generation of the p-value and using the Breslow approach for handling ties."
              }
            },
            {
              "id": "estimand-002",
              "instanceType": "Estimand",
              "name": "Secondary Estimand for OS",
              "text": "Treatment effect on Overall Survival (OS) comparing AZD9291 vs Placebo in the Full Analysis Set population.",
              "endpoint_id": "endpoint-003",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "AZD9291 80 mg orally, once daily"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98390",
                    "decode": "Placebo Comparator Arm"
                  },
                  "description": "Matching placebo, orally, once daily"
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 31,
                  "text_snippet": "This is phase 3, double-blind, randomised, placebo-controlled study, to assess efficacy and safety of AZD9291 versus placebo in patients with completely resected stage IB-IIIA NSCLC"
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Full Analysis Set (all randomized patients)",
                "provenance": {
                  "section_number": "8.3.1",
                  "page_number": 98,
                  "text_snippet": "The full analysis set (FAS) will include all randomised patients. The full analysis set will be used for all efficacy analyses and treatment groups will be compared on the basis of randomised study treatment, regardless of the treatment actually received."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-003",
                "description": "Time from randomization to death from any cause.",
                "provenance": {
                  "section_number": "8.4.1.2",
                  "page_number": 99,
                  "text_snippet": "OS is defined as the time from the date of randomisation until date of death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-003",
                  "name": "Use of subsequent anti-cancer therapy after recurrence",
                  "description": "Subjects receive subsequent anti-cancer therapies, including potential crossover to open-label osimertinib for the placebo group.",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "The effect of interest is the overall survival benefit of the initial treatment strategy, including the impact of subsequent therapies available in clinical practice.",
                  "provenance": {
                    "section_number": "8.5.2.2",
                    "page_number": 104,
                    "text_snippet": "Additional exploratory analysis of overall survival adjusting for the impact of subjects randomised to placebo who subsequently receive an EGFR-TKI for sensitising mutations and T790M may be conducted if this treatment sequence occurs in a proportion of subjects."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [
                "sens-003"
              ],
              "provenance": {
                "section_number": "8.5.2.2",
                "page_number": 104,
                "text_snippet": "OS data will be analysed using a log rank test stratified by stage (IB, II, IIIA), mutation type (Ex19Del, L858R either alone or in combination with other EGFR mutations) and race (Asian, Non-Asian) for the generation of the p-value and using the Breslow approach for handling ties."
              }
            },
            {
              "id": "estimand-003",
              "instanceType": "Estimand",
              "name": "Secondary Estimand for HRQoL",
              "text": "Treatment effect on Health-Related Quality of Life (HRQoL) comparing AZD9291 vs Placebo in the Full Analysis Set population.",
              "endpoint_id": "endpoint-005",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "AZD9291 80 mg orally, once daily"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98390",
                    "decode": "Placebo Comparator Arm"
                  },
                  "description": "Matching placebo, orally, once daily"
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 31,
                  "text_snippet": "This is phase 3, double-blind, randomised, placebo-controlled study, to assess efficacy and safety of AZD9291 versus placebo in patients with completely resected stage IB-IIIA NSCLC"
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Full Analysis Set (all randomized patients)",
                "provenance": {
                  "section_number": "8.3.1",
                  "page_number": 98,
                  "text_snippet": "The full analysis set (FAS) will include all randomised patients. The full analysis set will be used for all efficacy analyses and treatment groups will be compared on the basis of randomised study treatment, regardless of the treatment actually received."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-005",
                "description": "Change from baseline in SF-36 domain scores.",
                "provenance": {
                  "section_number": "8.5.3",
                  "page_number": 104,
                  "text_snippet": "The scores for each of the 8 health domain scores and for each of the physical and mental component summary measures from the SF-36 v2 will be summarised in terms of mean changes from baseline at each post-baseline assessment."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-004",
                  "name": "Missing HRQoL assessments",
                  "description": "Patient does not complete the SF-36 questionnaire at a scheduled timepoint due to discontinuation, death, or other reasons.",
                  "strategy": {
                    "code": "C178902",
                    "decode": "While on Treatment Strategy"
                  },
                  "strategy_rationale": "The effect of interest is the quality of life while patients are receiving the assigned treatment strategy, before disease recurrence.",
                  "provenance": {
                    "section_number": "8.5.3",
                    "page_number": 104,
                    "text_snippet": "The scores for each of the 8 health domain scores and for each of the physical and mental component summary measures from the SF-36 v2 will be summarised in terms of mean changes from baseline at each post-baseline assessment."
                  }
                }
              ],
              "summary_measure": {
                "code": "C53338",
                "decode": "Difference in Means"
              },
              "sensitivity_analysis_ids": [],
              "provenance": {
                "section_number": "8.5.3",
                "page_number": 104,
                "text_snippet": "Analysis of health-related quality of life\nThe scores for each of the 8 health domain scores and for each of the physical and mental component summary measures from the SF-36 v2 will be summarised in terms of mean changes from baseline at each post-baseline assessment."
              }
            }
          ],
          "analysis_populations": [
            {
              "id": "population-001",
              "instanceType": "AnalysisPopulation",
              "name": "Full Analysis Set",
              "label": "FAS",
              "text": "The full analysis set (FAS) will include all randomised patients. The full analysis set will be used for all efficacy analyses and treatment groups will be compared on the basis of randomised study treatment, regardless of the treatment actually received.",
              "population_type": {
                "code": "C71105",
                "decode": "Full Analysis Set"
              },
              "inclusion_criteria": [
                "All randomized patients"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004",
                "endpoint-005"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.3.1",
                "page_number": 98,
                "text_snippet": "The full analysis set (FAS) will include all randomised patients. The full analysis set will be used for all efficacy analyses and treatment groups will be compared on the basis of randomised study treatment, regardless of the treatment actually received."
              }
            },
            {
              "id": "population-002",
              "instanceType": "AnalysisPopulation",
              "name": "Safety Analysis Set",
              "label": "SAS",
              "text": "The safety analysis set (SAS) will consist of all patients who received at least one dose of study treatment. Safety data will be summarised using the safety analysis set, according to the treatment received.",
              "population_type": {
                "code": "C115932",
                "decode": "Safety Population"
              },
              "inclusion_criteria": [
                "All patients who received at least one dose of study treatment"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-007"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.3.2",
                "page_number": 98,
                "text_snippet": "The safety analysis set (SAS) will consist of all patients who received at least one dose of study treatment. Safety data will not be formally analysed but summarised using the safety analysis set, according to the treatment received; i.e., erroneously treated patients (e.g., those randomised to treatment A but actually given treatment B) will be summarised according to the treatment they actually received."
              }
            },
            {
              "id": "population-003",
              "instanceType": "AnalysisPopulation",
              "name": "Pharmacokinetic Analysis Set",
              "label": "PK Set",
              "text": "The Pharmacokinetic Analysis Set is defined as patients in the FAS who have at least one measurable PK concentration, supported by the relevant date and time of this sample.",
              "population_type": {
                "code": "C93001",
                "decode": "Modified Intent-to-Treat Population"
              },
              "inclusion_criteria": [
                "Patients in the FAS with at least one measurable PK concentration"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-006"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.3.3",
                "page_number": 98,
                "text_snippet": "Pharmacokinetic Analysis Set is defined as patients in the FAS who have at least one measurable PK concentration, supported by the relevant date and time of this sample."
              }
            }
          ],
          "provenance": {
            "section_number": "2",
            "page_number": 40,
            "text_snippet": "STUDY OBJECTIVES"
          }
        },
        "sap_analyses": {
          "sensitivity_analyses": [
            {
              "id": "sens-001",
              "instanceType": "SensitivityAnalysis",
              "name": "Evaluation-time bias analysis",
              "description": "The primary DFS analysis is repeated using the midpoint between the time of recurrence and the previous evaluable assessment.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess possible evaluation-time bias that could occur if scans are not performed at the protocol-scheduled time points.",
              "analysis_population_id": "population-001",
              "missing_data_handling": "Not applicable",
              "statistical_model": "Log rank test stratified by stage, mutation status and race.",
              "covariates": [],
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 103,
                "text_snippet": "(b) Evaluation-time bias\nIn order to assess possible evaluation-time bias that could occur if scans are not performed at the protocol-scheduled time points, the midpoint between the time of recurrence and the previous evaluable assessment will be analysed using a log rank test stratified by stage, mutation status and race."
              }
            },
            {
              "id": "sens-002",
              "instanceType": "SensitivityAnalysis",
              "name": "Attrition bias analysis",
              "description": "The primary DFS analysis is repeated, but patients who take subsequent therapy prior to recurrence or death will be censored at their last evaluable assessment prior to taking the subsequent therapy.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess possible attrition bias.",
              "analysis_population_id": "population-001",
              "missing_data_handling": "Censoring at initiation of subsequent therapy",
              "statistical_model": "Log rank test stratified by stage, mutation status and race.",
              "covariates": [],
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 103,
                "text_snippet": "(c) Attrition bias\nPossible attrition bias will be assessed by repeating the primary DFS analysis, except that the actual DFS times rather than the censored times of patients who recurred or died in the absence of recurrence immediately following 2 or more non-evaluable assessments, will be included. In addition, patients who take subsequent therapy prior to recurrence or death will be censored at their last evaluable assessment prior to taking the subsequent therapy."
              }
            },
            {
              "id": "sens-003",
              "instanceType": "SensitivityAnalysis",
              "name": "OS analysis adjusting for crossover",
              "description": "Exploratory analysis of overall survival adjusting for the impact of subjects randomised to placebo who subsequently receive an EGFR-TKI.",
              "target_estimand_id": "estimand-002",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To estimate the treatment effect on OS accounting for the confounding effect of subsequent EGFR-TKI use in the placebo arm.",
              "analysis_population_id": "population-001",
              "missing_data_handling": "Not applicable",
              "statistical_model": "Rank Preserving Structural Failure Time (RPSFT) or Inverse Probability of Censoring Weighting (IPCW).",
              "covariates": [],
              "provenance": {
                "section_number": "8.5.2.2",
                "page_number": 104,
                "text_snippet": "Additional exploratory analysis of overall survival adjusting for the impact of subjects randomised to placebo who subsequently receive an EGFR-TKI for sensitising mutations and T790M may be conducted if this treatment sequence occurs in a proportion of subjects. Methods such as Rank Preserving Structural Failure Time (RPSFT) (Robins and Tsiatis 1991), Inverse Probability of Censoring Weighting (IPCW) (Robins and Finkelstein 2000) and other methods in development may be explored."
              }
            },
            {
              "id": "sens-004",
              "instanceType": "SensitivityAnalysis",
              "name": "Quantitative interactions analysis",
              "description": "An overall global interaction test will be performed by comparing the fit of a Cox proportional hazards model including treatment, all covariates, and all covariate-by-treatment interaction terms, with one that excludes the interaction terms.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess the consistency of the treatment effect across subgroups.",
              "analysis_population_id": "population-001",
              "missing_data_handling": "Not applicable",
              "statistical_model": "Cox proportional hazards model",
              "covariates": [
                "stage",
                "EGFR mutation type",
                "race",
                "adjuvant chemotherapy",
                "gender",
                "age",
                "smoking history"
              ],
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 102,
                "text_snippet": "(a) Quantitative interactions\nThe presence of quantitative interactions will be assessed by means of an overall global interaction test. This will be performed by comparing the fit of a Cox proportional hazards model including treatment, all covariates, and all covariate-by-treatment interaction terms, with one that excludes the interaction terms and will be assessed at the 2- sided 10% significance level."
              }
            }
          ],
          "statistical_methods": [
            {
              "id": "method-001",
              "instanceType": "StatisticalMethod",
              "name": "Primary Analysis of DFS",
              "description": "A log rank test stratified by stage, mutation type, and race will be used. The hazard ratio and confidence interval will be obtained from the U and V statistics.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "model_type": "Log-rank test",
              "stratification_factors": [
                "stage (IB, II, IIIA)",
                "mutation type (Ex19Del, L858R)",
                "race (Asian, Non-Asian)"
              ],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": {
                "method": "Hierarchical",
                "description": "DFS in the Stage II-IIIA population is tested first. If significant, DFS in the overall population is tested."
              },
              "software_package": null,
              "procedure": "LIFETEST",
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 102,
                "text_snippet": "DFS in the subset of patients with stage II-IIIA cancer will be analysed using a log rank test stratified by stage (II, IIIA), mutation type (Ex19Del, L858R either alone or in combination with other EGFR mutations) and race (Asian, Non-Asian) for the generation of the p-value and using the Breslow approach for handling ties."
              }
            },
            {
              "id": "method-002",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of OS",
              "description": "OS data will be analysed using a log rank test stratified by stage, mutation type, and race. The hazard ratio and confidence interval will be obtained directly from the U and V statistics.",
              "for_endpoint_ids": [
                "endpoint-003"
              ],
              "model_type": "Log-rank test",
              "stratification_factors": [
                "stage (IB, II, IIIA)",
                "mutation type (Ex19Del, L858R)",
                "race (Asian, Non-Asian)"
              ],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": {
                "method": "Hierarchical",
                "description": "OS is tested in the Stage II-IIIA and then overall population, contingent on significance of the DFS endpoints."
              },
              "software_package": null,
              "procedure": "LIFETEST",
              "provenance": {
                "section_number": "8.5.2.2",
                "page_number": 104,
                "text_snippet": "OS data will be analysed using a log rank test stratified by stage (IB, II, IIIA), mutation type (Ex19Del, L858R either alone or in combination with other EGFR mutations) and race (Asian, Non-Asian) for the generation of the p-value and using the Breslow approach for handling ties. The hazard ratio and confidence interval will be obtained directly from the U and V statistics, as described in Section 8.5.1"
              }
            },
            {
              "id": "method-003",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of DFS and OS Rates",
              "description": "Kaplan-Meier plots will be produced to assess recurrence and survival rates. Estimates of DFS/OS rate at 2, 3, 4 and 5 years will be obtained from the plots.",
              "for_endpoint_ids": [
                "endpoint-002",
                "endpoint-004"
              ],
              "model_type": "Kaplan-Meier",
              "stratification_factors": [],
              "covariates": [],
              "alpha": null,
              "multiplicity": {},
              "software_package": null,
              "procedure": "LIFETEST",
              "provenance": {
                "section_number": "8.5.2.1",
                "page_number": 104,
                "text_snippet": "Kaplan-Meier plots will be produced to assess if recurrence rates have reached an apparent plateau. Estimates of DFS rate at 2, 3, 4 and 5 years obtained from the plot will be presented for each arm."
              }
            },
            {
              "id": "method-004",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of HRQoL",
              "description": "The scores for each of the 8 health domain scores and for each of the physical and mental component summary measures from the SF-36 v2 will be summarised in terms of mean changes from baseline at each post-baseline assessment.",
              "for_endpoint_ids": [
                "endpoint-005"
              ],
              "model_type": "Descriptive Statistics",
              "stratification_factors": [],
              "covariates": [],
              "alpha": null,
              "multiplicity": {},
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.5.3",
                "page_number": 104,
                "text_snippet": "The scores for each of the 8 health domain scores and for each of the physical and mental component summary measures from the SF-36 v2 will be summarised in terms of mean changes from baseline at each post-baseline assessment."
              }
            },
            {
              "id": "method-005",
              "instanceType": "StatisticalMethod",
              "name": "Subgroup Analysis Method",
              "description": "Subgroup analyses will be conducted by comparing DFS between treatments using a Cox regression model. The Breslow approach for handling ties will be used.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "model_type": "Cox Proportional Hazards Model",
              "stratification_factors": [],
              "covariates": [
                "subgroup variable",
                "treatment",
                "subgroup*treatment interaction term"
              ],
              "alpha": null,
              "multiplicity": {},
              "software_package": null,
              "procedure": "PHREG",
              "provenance": {
                "section_number": "8.5.2",
                "page_number": 104,
                "text_snippet": "The Breslow approach for handling ties will be used for Cox regression model in subgroup analysis."
              }
            }
          ],
          "subgroup_analyses": [
            {
              "id": "subgroup-001",
              "instanceType": "SubgroupAnalysis",
              "name": "Stage Subgroup Analysis",
              "description": "Primary DFS analysis by disease stage.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Stage",
              "categories": [
                {
                  "name": "Stage IB",
                  "definition": "Patient has Stage IB disease"
                },
                {
                  "name": "Stage II",
                  "definition": "Patient has Stage II disease"
                },
                {
                  "name": "Stage IIIA",
                  "definition": "Patient has Stage IIIA disease"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 103,
                "text_snippet": "Stage (IB, II, IIIA)"
              }
            },
            {
              "id": "subgroup-002",
              "instanceType": "SubgroupAnalysis",
              "name": "EGFR Mutation Type Subgroup Analysis",
              "description": "Primary DFS analysis by EGFR mutation type.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "EGFR mutation type",
              "categories": [
                {
                  "name": "Ex19Del",
                  "definition": "Patient has Exon 19 deletion mutation"
                },
                {
                  "name": "L858R",
                  "definition": "Patient has L858R mutation"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 103,
                "text_snippet": "EGFR mutation type (Ex19Del, L858R either alone or in combination with other EGFR mutations )"
              }
            },
            {
              "id": "subgroup-003",
              "instanceType": "SubgroupAnalysis",
              "name": "Race Subgroup Analysis",
              "description": "Primary DFS analysis by race.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Race",
              "categories": [
                {
                  "name": "Asian",
                  "definition": "Patient is of Asian race"
                },
                {
                  "name": "Non-Asian",
                  "definition": "Patient is not of Asian race"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 103,
                "text_snippet": "Race (Asian, Non-Asian)"
              }
            },
            {
              "id": "subgroup-004",
              "instanceType": "SubgroupAnalysis",
              "name": "Adjuvant Chemotherapy Subgroup Analysis",
              "description": "Primary DFS analysis by receipt of adjuvant chemotherapy.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Adjuvant chemotherapy",
              "categories": [
                {
                  "name": "Yes",
                  "definition": "Patient received adjuvant chemotherapy"
                },
                {
                  "name": "No",
                  "definition": "Patient did not receive adjuvant chemotherapy"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 103,
                "text_snippet": "Adjuvant chemotherapy (Yes, No)"
              }
            },
            {
              "id": "subgroup-005",
              "instanceType": "SubgroupAnalysis",
              "name": "Gender Subgroup Analysis",
              "description": "Primary DFS analysis by gender.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Gender",
              "categories": [
                {
                  "name": "Male",
                  "definition": "Patient is male"
                },
                {
                  "name": "Female",
                  "definition": "Patient is female"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.2",
                "page_number": 104,
                "text_snippet": "Gender (Male, Female)"
              }
            },
            {
              "id": "subgroup-006",
              "instanceType": "SubgroupAnalysis",
              "name": "Age Subgroup Analysis",
              "description": "Primary DFS analysis by age at randomization.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Age",
              "categories": [
                {
                  "name": "<65",
                  "definition": "Patient age is less than 65 years"
                },
                {
                  "name": ">=65",
                  "definition": "Patient age is 65 years or greater"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.2",
                "page_number": 104,
                "text_snippet": "Age at randomisation (<65, ≥65)"
              }
            },
            {
              "id": "subgroup-007",
              "instanceType": "SubgroupAnalysis",
              "name": "Smoking History Subgroup Analysis",
              "description": "Primary DFS analysis by smoking history.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Smoking history",
              "categories": [
                {
                  "name": "Never",
                  "definition": "Patient has never smoked"
                },
                {
                  "name": "Ever",
                  "definition": "Patient is a former or current smoker"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.2",
                "page_number": 104,
                "text_snippet": "Smoking history (Never, Ever)."
              }
            },
            {
              "id": "subgroup-008",
              "instanceType": "SubgroupAnalysis",
              "name": "Pre-treatment T790M Subgroup Analysis",
              "description": "Primary DFS analysis by pre-treatment T790M mutation status.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "T790M mutation status",
              "categories": [
                {
                  "name": "Positive",
                  "definition": "Patient has T790M mutation"
                },
                {
                  "name": "Negative",
                  "definition": "Patient does not have T790M mutation"
                }
              ],
              "analysis_method": "Cox regression model",
              "interaction_test": true,
              "forest_plot": true,
              "provenance": {
                "section_number": "8.5.1",
                "page_number": 103,
                "text_snippet": "Pre-treatment T790M (amino acid substitution at position 790 in EGFR, from a threonine to a methionine) mutation status (Positive, Negative)"
              }
            }
          ],
          "multiplicity_adjustment": {
            "method": "Hierarchical Testing Procedure",
            "description": "A hierarchical approach to the primary analysis will be employed to control the overall type I error rate at 5% (2-sided). The MTP diagram specifies the sequence: DFS in stage II/IIIA, then DFS overall, then OS in stage II/IIIA, then OS overall. O'Brien and Fleming or Haybittle-Peto spending functions are used for interim analyses.",
            "alpha_allocation": "Overall alpha of 0.05 (2-sided)",
            "gatekeeping_strategy": "Sequential gatekeeping: DFS in the stage II-IIIA population is the first gatekeeper. If significant, the test proceeds to DFS in the overall population, and so on for OS.",
            "provenance": {
              "section_number": "8.1",
              "page_number": 96,
              "text_snippet": "The primary endpoint of DFS and secondary endpoint of OS will be tested in the subset of patients with stage IIA-IIIA cancer as well as in the overall population, therefore in order to strongly control the type I error at 5% (2-sided), a hierarchical testing procedure will be employed across these endpoints."
            }
          },
          "missing_data_handling": {
            "primary_method": "Censoring",
            "method_description": "For time-to-event endpoints (DFS, OS), patients without an event at the time of analysis will be censored at the date of their last follow-up assessment. Specific rules apply for censoring due to subsequent therapy in sensitivity analyses.",
            "assumptions": [
              "Censoring is non-informative."
            ],
            "provenance": {
              "section_number": "8.4.1.1",
              "page_number": 99,
              "text_snippet": "Patients who are disease-free and alive at the time of analysis will be censored at the date of their last follow-up assessment."
            }
          },
          "provenance": {
            "section_number": "8",
            "page_number": 96,
            "text_snippet": "STATISTICAL ANALYSES"
          }
        },
        "extraction_statistics": {
          "objectives_count": 4,
          "endpoints_count": 11,
          "estimands_count": 3,
          "populations_count": 3,
          "sensitivity_analyses_count": 4,
          "statistical_methods_count": 5,
          "subgroup_analyses_count": 8,
          "has_multiplicity_adjustment": true,
          "has_missing_data_strategy": true
        },
        "provenance": {
          "section_number": "1",
          "page_number": 1,
          "text_snippet": "Revised Clinical Study Protocol\nDrug Substance AZD9291\nStudy Code D5164C00001\nEdition Number 6.0\nDate 09 August 2023"
        }
      },
      "_agentDocumentation": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_EP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADaM ADEFF specification from primary endpoint",
                "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
                "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAP_EST_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate SAP estimand section from extracted estimands",
                "sourceDataPath": "protocol_endpoints.estimands[]",
                "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_POP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADSL population flags from definitions",
                "sourceDataPath": "protocol_endpoints.analysis_populations[]",
                "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
                "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json",
        "automationRules": [
          {
            "ruleId": "ADAM_EP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADaM ADEFF specification from primary endpoint",
            "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
            "example": null
          },
          {
            "ruleId": "SAP_EST_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate SAP estimand section from extracted estimands",
            "sourceDataPath": "protocol_endpoints.estimands[]",
            "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
            "example": null
          },
          {
            "ruleId": "ADAM_POP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADSL population flags from definitions",
            "sourceDataPath": "protocol_endpoints.analysis_populations[]",
            "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
            "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_EP_SOA_001",
            "name": "Endpoints + SOA → Assessment Schedule Validation",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "soa_schedule"
            ],
            "description": "Endpoint timepoints matched to SOA visits ensures all assessments are scheduled",
            "combinedInsight": "Primary endpoint at Week 12 + SOA Week 12 visit with efficacy assessment = Validated schedule",
            "automationEnabled": "Auto-verify SOA includes all required endpoint assessments",
            "exampleOutput": null
          },
          {
            "synergyId": "SYN_EP_AE_001",
            "name": "Endpoints + AEs + Withdrawal → Complete Estimand Definition",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "adverse_events",
              "withdrawal_procedures"
            ],
            "description": "Combining endpoint definitions with AE handling and withdrawal reasons enables complete ICE specification",
            "combinedInsight": "What happens to endpoint when subject discontinues due to AE = Complete intercurrent event strategy",
            "automationEnabled": "Generate regulatory-ready estimand framework documentation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_EP_001",
            "name": "Endpoint-Objective Linkage",
            "agentsInvolved": [
              "endpoints_estimands_sap"
            ],
            "validationType": "completeness",
            "description": "Every endpoint must link to at least one objective",
            "checkLogic": "FOR EACH endpoint: EXISTS objective WHERE endpoint.id IN objective.endpoint_ids",
            "severity": "error"
          }
        ],
        "systemConfigurations": []
      }
    },
    "adverseEvents": {
      "moduleId": "adverse_events",
      "instanceType": "AdverseEvents",
      "data": {
        "id": "D5164C00001-adverse-events",
        "instanceType": "AdverseEvents",
        "name": "D5164C00001 Adverse Events",
        "ae_definitions": {
          "ae_definition": "An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.",
          "teae_definition": "Adverse events will be collected from the time of signature of main informed consent throughout the Treatment Period and including the safety follow-up period.",
          "collection_start": "Signature of main informed consent",
          "collection_end": "28 days after study drug is discontinued",
          "collection_end_days": 28,
          "pre_existing_condition_handling": "The deterioration of a pre-existing medical condition is considered an adverse event.",
          "provenance": {
            "section_number": "6.1",
            "page_number": 79,
            "text_snippet": "An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product."
          }
        },
        "sae_criteria": {
          "sae_definition": "A serious adverse event is an AE occurring during any study phase (i.e., run-in, treatment, washout, follow-up), that fulfils one or more of the following criteria:",
          "criteria": [
            {
              "id": "sae-001",
              "criterion_type": {
                "code": "C48275",
                "decode": "Death",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Results in death",
              "exclusions": [],
              "provenance": {
                "section_number": "6.2",
                "page_number": 80,
                "text_snippet": "Results in death"
              }
            },
            {
              "id": "sae-002",
              "criterion_type": {
                "code": "C82569",
                "decode": "Life Threatening",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Is immediately life-threatening",
              "exclusions": [],
              "provenance": {
                "section_number": "6.2",
                "page_number": 80,
                "text_snippet": "Is immediately life-threatening"
              }
            },
            {
              "id": "sae-003",
              "criterion_type": {
                "code": "C83052",
                "decode": "Hospitalization Required",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Requires in-patient hospitalisation or prolongation of existing hospitalisation",
              "exclusions": [],
              "provenance": {
                "section_number": "6.2",
                "page_number": 80,
                "text_snippet": "Requires in-patient hospitalisation or prolongation of existing hospitalisation"
              }
            },
            {
              "id": "sae-004",
              "criterion_type": {
                "code": "C82577",
                "decode": "Disability",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions",
              "exclusions": [],
              "provenance": {
                "section_number": "6.2",
                "page_number": 80,
                "text_snippet": "Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions"
              }
            },
            {
              "id": "sae-005",
              "criterion_type": {
                "code": "C82579",
                "decode": "Congenital Anomaly",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Is a congenital abnormality or birth defect",
              "exclusions": [],
              "provenance": {
                "section_number": "6.2",
                "page_number": 80,
                "text_snippet": "Is a congenital abnormality or birth defect"
              }
            },
            {
              "id": "sae-006",
              "criterion_type": {
                "code": "C84265",
                "decode": "Medically Important",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Is an important medical event that may jeopardise the subject or may require medical intervention to prevent one of the outcomes listed above.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.2",
                "page_number": 80,
                "text_snippet": "Is an important medical event that may jeopardise the subject or may require medical intervention to prevent one of the outcomes listed above."
              }
            }
          ],
          "provenance": {
            "section_number": "6.2",
            "page_number": 80,
            "text_snippet": "A serious adverse event is an AE occurring during any study phase (i.e., run-in, treatment, washout, follow-up), that fulfils one or more of the following criteria:"
          }
        },
        "grading_system": {
          "system_name": "CTCAE",
          "system_version": "v4",
          "grade_definitions": [],
          "provenance": {
            "section_number": null,
            "page_number": 11,
            "text_snippet": "Adverse events (graded by CTCAE v4)"
          }
        },
        "causality_assessment": {
          "assessment_question": "Do you consider that there is a reasonable possibility that the event may have been caused by the investigational product?",
          "response_options": [
            "yes",
            "no"
          ],
          "assessment_guidance": "Guidance is provided based on Time Course, Consistency with known drug profile, Dechallenge experience, No alternative cause, Rechallenge experience, and Laboratory tests.",
          "provenance": {
            "section_number": "6.3.4",
            "page_number": 82,
            "text_snippet": "The Investigator will assess causal relationship between IP and each AE, and answer ‘yes’ or ‘no’ to the question: ‘Do you consider that there is a reasonable possibility that the event may have been caused by the investigational product?’"
          }
        },
        "coding_dictionary": {
          "dictionary_name": "MedDRA",
          "dictionary_version": "latest version",
          "provenance": {
            "section_number": "9.4",
            "page_number": 108,
            "text_snippet": "Adverse events and medical/surgical history will be classified according to the terminology of the latest version of MedDRA."
          }
        },
        "reporting_procedures": {
          "routine_ae_reporting": {
            "timeline_description": "Collected at each study visit",
            "method": "eCRF"
          },
          "sae_reporting": {
            "initial_report_hours": 24,
            "followup_report_days": 5,
            "recipients": [
              "sponsor"
            ],
            "method": "EDC system"
          },
          "susar_reporting": {
            "timeline_description": "According to local regulatory requirements and sponsor policy"
          },
          "pregnancy_reporting": {
            "timeline_hours": 24,
            "outcome_tracking": true,
            "partner_pregnancy": true
          },
          "expedited_reporting_criteria": [
            "Cases meeting Hy's Law criteria"
          ],
          "unblinding_procedures": "The treatment code should not be broken except in medical emergencies when the appropriate management of the patient requires knowledge of the treatment randomisation. Individual treatment codes will be available to the investigators from the IVRS/IWRS.",
          "provenance": {
            "section_number": "6.4",
            "page_number": 84,
            "text_snippet": "If any SAE occurs in the course of the study, then Investigators or other site personnel inform the appropriate AstraZeneca representatives within one day, i.e., immediately but no later than 24 hours of when he or she becomes aware of it."
          }
        },
        "aesi_list": [
          {
            "id": "aesi-001",
            "aesi_name": "Interstitial lung disease (ILD)/pneumonitis",
            "special_monitoring": "Full diagnostic workup including HRCT is recommended if symptoms occur. Study drug should be interrupted or permanently discontinued based on diagnosis.",
            "expedited_reporting": true,
            "provenance": {
              "section_number": "6.9.6",
              "page_number": 90,
              "text_snippet": "Interstitial lung disease\nIf a new or worsening of pulmonary symptoms (e.g., dyspnoea) or occurrence of a radiological abnormality suggestive of ILD/pneumonitis is observed, an interruption in study drug dosing is recommended, and the Study Physician should be informed. It is strongly recommended to perform a full diagnostic workup to exclude alternative causes..."
            }
          },
          {
            "id": "aesi-002",
            "aesi_name": "Cardiac failure",
            "special_monitoring": "All serious or non-serious events of cardiac failure in patients on open-label osimertinib must be collected and reported.",
            "expedited_reporting": true,
            "provenance": {
              "section_number": "6.3.1",
              "page_number": 80,
              "text_snippet": "All serious or non-serious events of ILD/pneumonitis and cardiac failure, and all SAEs occurring in patients who are treated with open-label osimertinib must be collected and reported to AstraZeneca using standard timelines and process."
            }
          },
          {
            "id": "aesi-003",
            "aesi_name": "Severe Skin Reactions (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)",
            "special_monitoring": "Patients should be advised of signs and symptoms. If suggestive signs appear, close patient monitoring and drug interruption or discontinuation is required.",
            "expedited_reporting": true,
            "provenance": {
              "section_number": null,
              "page_number": 90,
              "text_snippet": "Erythema multiforme and Stevens-Johnson syndrome, and toxic epidermal necrolysis\nCase reports of Erythema multiforme (EM) and toxic epidermal necrolysis (TEN) have been uncommonly reported, and Stevens-Johnson syndrome (SJS) have been rarely reported, in association with osimertinib treatment. Before initiating treatment, patients should be advised of signs and symptoms of EM, TEN, and SJS."
            }
          },
          {
            "id": "aesi-004",
            "aesi_name": "Aplastic anaemia",
            "special_monitoring": "Patients should be advised of signs and symptoms. If suggestive signs develop, close patient monitoring and drug interruption or discontinuation should be considered. Discontinue in confirmed cases.",
            "expedited_reporting": true,
            "provenance": {
              "section_number": "6.9.3",
              "page_number": 90,
              "text_snippet": "Aplastic anaemia\nRare reports of aplastic anaemia have been reported in association with osimertinib treatment. Some cases had a fatal outcome. Before initiating treatment, patients should be advised of signs and symptoms of aplastic anaemia including but not limited to persistent fever, bruising, bleeding, pallor. If signs and symptoms suggestive of aplastic anaemia develop, close patient monitoring and drug interruption or discontinuation of osimertinib should be considered."
            }
          },
          {
            "id": "aesi-005",
            "aesi_name": "QTc prolongation",
            "special_monitoring": "Electrolyte abnormalities must be corrected prior to first dose and monitored during treatment. Patients with QTcF >500 msec should have treatment interrupted and regular ECGs performed.",
            "expedited_reporting": true,
            "provenance": {
              "section_number": "6.9.5",
              "page_number": 90,
              "text_snippet": "QTc prolongation\nIn light of the potential for QT changes associated with AZD9291, electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia) must be corrected to be within normal ranges prior to first dose and electrolyte levels monitored during study treatment. Patients with QTcF prolongation to >500 msec should have study treatment interrupted and regular ECGs performed until resolution to <481 msec or recovery to baseline if baseline QTcF is ≥ 481 msec..."
            }
          },
          {
            "id": "aesi-006",
            "aesi_name": "Keratitis",
            "special_monitoring": "Patients with signs and symptoms suggestive of keratitis should be referred promptly to an ophthalmology specialist.",
            "expedited_reporting": false,
            "provenance": {
              "section_number": "6.9.7",
              "page_number": 91,
              "text_snippet": "Keratitis\nPatients presenting with signs and symptoms suggestive of keratitis such as acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye should be referred promptly to an ophthalmology specialist."
            }
          },
          {
            "id": "aesi-007",
            "aesi_name": "Changes in cardiac contractility",
            "special_monitoring": "In patients with cardiac risk factors, cardiac monitoring, including an assessment of LVEF at baseline and during treatment, should be considered.",
            "expedited_reporting": false,
            "provenance": {
              "section_number": "6.9.8",
              "page_number": 91,
              "text_snippet": "Changes in cardiac contractility\nBased on the available clinical trial data, a causal relationship between effects on changes in cardiac contractility and AZD9291has not been established. In patients with cardiac risk factors and those with conditions that can affect LVEF, cardiac monitoring, including an assessment of LVEF at baseline and during treatment, should be considered."
            }
          }
        ],
        "dlt_criteria": {
          "has_dlt_criteria": false,
          "provenance": {
            "section_number": null,
            "page_number": 32,
            "text_snippet": "No dose-limiting toxicities (DLTs) have been reported at any dose level in the escalation cohorts during the 21-day DLT evaluation period."
          }
        },
        "safety_committees": [
          {
            "committee_type": {
              "code": "C93494",
              "decode": "Data Monitoring Committee",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "committee_name": "Independent Data Monitoring Committee (IDMC)",
            "responsibilities": [
              "Review safety assessments and make recommendations to continue, amend, or stop the study based on safety findings.",
              "Review futility analysis outcomes and provide a recommendation for whether the study should continue."
            ],
            "provenance": {
              "section_number": "6.10.1",
              "page_number": 91,
              "text_snippet": "An Independent Data Monitoring Committee (IDMC) will be convened and will meet approximately every 6 months for the first 2 years from the first patient randomised and approximately yearly thereafter. Further meetings for review of safety data may be convened at the discretion of IDMC. The IDMC will review safety assessments and make recommendations to continue, amend, or stop the study based on safety findings..."
            }
          }
        ],
        "extraction_statistics": {
          "aesi_count": 7,
          "dlt_criteria_count": 0,
          "sae_criteria_count": 6,
          "has_grading_system": true,
          "has_causality_assessment": true,
          "has_dlt_criteria": false
        },
        "provenance": {
          "section_number": "6",
          "page_number": 79,
          "text_snippet": "SAFETY REPORTING AND MEDICAL MANAGEMENT"
        }
      },
      "_agentDocumentation": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_AE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate AE dates within collection period",
                "sourceDataPath": "ae_definitions",
                "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
                "example": "AE start date must be >= first dose date for TEAE flag"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_SAE_001",
                "ruleType": "alert",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure SAE detection and expedited reporting workflow",
                "sourceDataPath": "sae_criteria.criteria[]",
                "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
                "example": "Death → 24hr initial report, 7-day follow-up"
              },
              {
                "ruleId": "EDC_SAE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Enforce SAE documentation requirements",
                "sourceDataPath": "sae_criteria",
                "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_TIMELINE_001",
                "ruleType": "workflow",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure safety reporting timeline workflows",
                "sourceDataPath": "reporting_procedures",
                "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_AESI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Prompt for AESI-specific data collection",
                "sourceDataPath": "aesi_list[]",
                "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
                "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_DLT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure DLT-based dose escalation rules",
                "sourceDataPath": "dlt_criteria",
                "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
                "example": "3+3 design with 28-day DLT window"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_AE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate AE dates within collection period",
            "sourceDataPath": "ae_definitions",
            "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
            "example": "AE start date must be >= first dose date for TEAE flag"
          },
          {
            "ruleId": "SAFETY_SAE_001",
            "ruleType": "alert",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure SAE detection and expedited reporting workflow",
            "sourceDataPath": "sae_criteria.criteria[]",
            "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
            "example": "Death → 24hr initial report, 7-day follow-up"
          },
          {
            "ruleId": "EDC_SAE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Enforce SAE documentation requirements",
            "sourceDataPath": "sae_criteria",
            "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
            "example": null
          },
          {
            "ruleId": "SAFETY_TIMELINE_001",
            "ruleType": "workflow",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure safety reporting timeline workflows",
            "sourceDataPath": "reporting_procedures",
            "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
            "example": null
          },
          {
            "ruleId": "EDC_AESI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Prompt for AESI-specific data collection",
            "sourceDataPath": "aesi_list[]",
            "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
            "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
          },
          {
            "ruleId": "IRT_DLT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure DLT-based dose escalation rules",
            "sourceDataPath": "dlt_criteria",
            "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
            "example": "3+3 design with 28-day DLT window"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_AE_SAFETY_001",
            "name": "AE Grading + Safety Thresholds → Automated Dose Decisions",
            "agentsInvolved": [
              "adverse_events",
              "safety_decision_points"
            ],
            "description": "CTCAE grades combined with safety thresholds enable automated dose recommendations",
            "combinedInsight": "Grade 3 neutropenia + safety rules = Hold dose, check ANC in 1 week",
            "automationEnabled": "EDC displays recommended action when AE grade is entered",
            "exampleOutput": "{\"ae\": \"Neutropenia Grade 3\", \"action\": \"Hold dose\", \"recheck\": \"7 days\", \"resume_criteria\": \"ANC >= 1500\"}"
          },
          {
            "synergyId": "SYN_AE_CM_001",
            "name": "AE + Concomitant Meds → Drug Interaction Alerts",
            "agentsInvolved": [
              "adverse_events",
              "concomitant_medications"
            ],
            "description": "AE patterns combined with prohibited medications enables interaction detection",
            "combinedInsight": "QT prolongation AE + QT-prolonging concomitant med = Potential drug interaction",
            "automationEnabled": "Real-time drug interaction alert when entering concomitant medications",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_AE_001",
            "name": "CTCAE Version Consistency",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "consistency",
            "description": "Verify CTCAE version is specified and consistent throughout",
            "checkLogic": "ctcae_version IS NOT NULL AND ctcae_version == data_standards.ctcae_version",
            "severity": "error"
          },
          {
            "ruleId": "VAL_AE_002",
            "name": "AESI-SAE Overlap",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "completeness",
            "description": "Check if AESIs have SAE reporting guidance",
            "checkLogic": "FOR EACH aesi: EXISTS sae_guidance OR aesi.always_serious == true",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Safety Database (Pharmacovigilance)",
            "configType": "protocol_profile",
            "description": "Safety database protocol-specific configuration",
            "dataSources": [
              "sae_criteria.criteria[]",
              "reporting_procedures",
              "aesi_list[]",
              "dlt_criteria"
            ],
            "outputFormat": "Safety database import (Argus, ARISg, Oracle Empirica)",
            "exampleConfig": {
              "sae_criteria": [
                {
                  "criterion": "Death",
                  "code": "C48275",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Life-threatening",
                  "code": "C84266",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Hospitalization",
                  "code": "C84268",
                  "timeline_hours": 72
                }
              ],
              "aesi_list": [
                {
                  "term": "Hepatotoxicity",
                  "meddra_codes": [
                    "10019670"
                  ],
                  "enhanced_collection": true
                }
              ],
              "meddra_version": "26.0",
              "ctcae_version": "5.0"
            }
          }
        ]
      }
    },
    "safetyDecisionPoints": {
      "moduleId": "safety_decision_points",
      "instanceType": "SafetyDecisionPoints",
      "data": {
        "id": "D5164C00001-safety-decision-points",
        "instanceType": "SafetyDecisionPoints",
        "name": "D5164C00001 Safety Decision Points",
        "discovered_categories": [
          {
            "category_id": "cat-001",
            "category_name": "General Toxicity",
            "category_description": "General adverse events not otherwise specified",
            "parameters_count": 1,
            "provenance": {
              "section_number": "6.9.1",
              "page_number": 89,
              "text_snippet": "General dose adjustments on adverse events"
            }
          },
          {
            "category_id": "cat-002",
            "category_name": "Dermatologic Toxicity",
            "category_description": "Adverse events related to skin and subcutaneous tissue",
            "parameters_count": 2,
            "provenance": {
              "section_number": "6.9.2",
              "page_number": 89,
              "text_snippet": "Skin reactions"
            }
          },
          {
            "category_id": "cat-003",
            "category_name": "Hematologic Toxicity",
            "category_description": "Adverse events related to blood and bone marrow",
            "parameters_count": 1,
            "provenance": {
              "section_number": "6.9.3",
              "page_number": 90,
              "text_snippet": "Aplastic anaemia"
            }
          },
          {
            "category_id": "cat-004",
            "category_name": "Cardiac Toxicity",
            "category_description": "Adverse events related to heart function",
            "parameters_count": 1,
            "provenance": {
              "section_number": "6.9.5",
              "page_number": 90,
              "text_snippet": "QTc prolongation"
            }
          },
          {
            "category_id": "cat-005",
            "category_name": "Pulmonary Toxicity",
            "category_description": "Adverse events related to lung tissue",
            "parameters_count": 1,
            "provenance": {
              "section_number": "6.9.6",
              "page_number": 90,
              "text_snippet": "Interstitial lung disease"
            }
          },
          {
            "category_id": "cat-006",
            "category_name": "Hepatic Toxicity",
            "category_description": "Adverse events related to liver function",
            "parameters_count": 1,
            "provenance": {
              "section_number": "6.3.7",
              "page_number": 83,
              "text_snippet": "Hy’s Law"
            }
          }
        ],
        "decision_points": [
          {
            "id": "dp-001",
            "parameter_name": "General Adverse Event",
            "parameter_category": "General Toxicity",
            "measurement_type": "CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-001-r1",
                "rule_type": "dose_hold",
                "rule_description": "Hold treatment for Grade 3 or higher, or unacceptable lower grade toxicities.",
                "conditions": {
                  "grade": ">=3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt study drug dosing and administer supportive therapy."
                  }
                ],
                "recovery_criteria": {
                  "grade_required": "<=2",
                  "timeframe": "within 3 weeks"
                },
                "provenance": {
                  "section_number": "6.9.1",
                  "page_number": 89,
                  "text_snippet": "If a patient experiences a CTCAE grade 3 or higher or unacceptable toxicities lower grades not attributable to the disease or disease-related processes under investigation, where the Investigator considers the AE of concern to be specifically associated with the study drug dosing will be interrupted and supportive therapy administered as required in accordance with local practice/guidelines."
                }
              },
              {
                "rule_id": "dp-001-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Restart at same or reduced dose after recovery from Grade 3+ toxicity.",
                "conditions": {
                  "grade": "<=2",
                  "anc_threshold": null,
                  "duration": "within 3 weeks"
                },
                "actions": [
                  {
                    "action_type": "restart_dose",
                    "action_description": "Restart at the same dose (starting dose) or reduced dose (40 mg)."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.1",
                  "page_number": 89,
                  "text_snippet": "If the toxicity resolves or reverts to ≤CTCAE Grade 2 within 3 weeks of withholding AZD9291/matching placebo, study drug may be restarted at the same dose (starting dose) or reduced dose 40 mg AZD9291/matching placebo using the rules for dose modifications (Table 7) at the discretion of the investigator/ and with discussion and agreement with Study Physician if needed."
                }
              },
              {
                "rule_id": "dp-001-r3",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue treatment if Grade 3+ toxicity does not resolve.",
                "conditions": {
                  "grade": ">2",
                  "anc_threshold": null,
                  "duration": ">3 weeks"
                },
                "actions": [
                  {
                    "action_type": "discontinue_dose",
                    "action_description": "Withdraw patient from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.1",
                  "page_number": 89,
                  "text_snippet": "If the toxicity does not resolve to ≤CTCAE Grade 2 after 3 weeks of withholding AZD9291/matching placebo, then the patient can be withdrawn from the study treatment after discussion with the study medical monitor/physician and observed until resolution of the toxicity."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": "6.9.1",
              "page_number": 89,
              "text_snippet": "General dose adjustments on adverse events"
            }
          },
          {
            "id": "dp-002",
            "parameter_name": "Erythema multiforme (EM) / Stevens-Johnson syndrome (SJS) / Toxic epidermal necrolysis (TEN)",
            "parameter_category": "Dermatologic Toxicity",
            "measurement_type": "Clinical Diagnosis",
            "decision_rules": [
              {
                "rule_id": "dp-002-r1",
                "rule_type": "dose_hold",
                "rule_description": "Interrupt treatment for signs/symptoms suggestive of EM or SJS.",
                "conditions": {
                  "grade": null,
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt osimertinib if signs and symptoms suggestive of EM or SJS appear."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.2",
                  "page_number": 90,
                  "text_snippet": "If signs and symptoms suggestive of EM develop, close patient monitoring and drug interruption or discontinuation of osimertinib should be considered. If signs and symptoms suggestive of SJS appear, osimertinib should be interrupted."
                }
              },
              {
                "rule_id": "dp-002-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue treatment if SJS or TEN is diagnosed.",
                "conditions": {
                  "grade": null,
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_dose",
                    "action_description": "Osimertinib should be discontinued immediately if SJS or TEN is diagnosed."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.2",
                  "page_number": 90,
                  "text_snippet": "Osimertinib should be discontinued immediately if SJS or TEN is diagnosed."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "As clinically indicated",
              "method": "Patient monitoring for signs and symptoms of EM, TEN, and SJS."
            },
            "provenance": {
              "section_number": "6.9.2",
              "page_number": 90,
              "text_snippet": "Erythema multiforme and Stevens-Johnson syndrome, and toxic epidermal necrolysis"
            }
          },
          {
            "id": "dp-003",
            "parameter_name": "Aplastic Anaemia",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "Clinical Diagnosis",
            "decision_rules": [
              {
                "rule_id": "dp-003-r1",
                "rule_type": "dose_hold",
                "rule_description": "Interrupt or discontinue treatment for signs/symptoms suggestive of aplastic anaemia.",
                "conditions": {
                  "grade": null,
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Drug interruption or discontinuation of osimertinib should be considered."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.3",
                  "page_number": 90,
                  "text_snippet": "If signs and symptoms suggestive of aplastic anaemia develop, close patient monitoring and drug interruption or discontinuation of osimertinib should be considered."
                }
              },
              {
                "rule_id": "dp-003-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue treatment if aplastic anaemia is confirmed.",
                "conditions": {
                  "grade": null,
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_dose",
                    "action_description": "Osimertinib should be discontinued in patients with confirmed aplastic anaemia."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.3",
                  "page_number": 90,
                  "text_snippet": "osimertinib should be discontinued in patients with confirmed aplastic anaemia."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "As clinically indicated",
              "method": "Patient monitoring for signs and symptoms (persistent fever, bruising, bleeding, pallor)."
            },
            "provenance": {
              "section_number": "6.9.3",
              "page_number": 90,
              "text_snippet": "Aplastic anaemia"
            }
          },
          {
            "id": "dp-004",
            "parameter_name": "QTc Prolongation",
            "parameter_category": "Cardiac Toxicity",
            "measurement_type": "QTcF (msec)",
            "decision_rules": [
              {
                "rule_id": "dp-004-r1",
                "rule_type": "dose_hold",
                "rule_description": "Interrupt treatment for QTc prolongation > 500 msec.",
                "conditions": {
                  "grade": null,
                  "qtc_threshold": ">500",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt study treatment."
                  }
                ],
                "recovery_criteria": {
                  "qtc_required": "<481",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": "6.9.5",
                  "page_number": 90,
                  "text_snippet": "Patients with QTcF prolongation to >500 msec should have study treatment interrupted and regular ECGs performed until resolution to <481 msec or recovery to baseline if baseline QTcF is ≥ 481 msec..."
                }
              },
              {
                "rule_id": "dp-004-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Restart at a reduced dose after recovery from QTc prolongation.",
                "conditions": {
                  "grade": null,
                  "qtc_threshold": "<481",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "restart_dose",
                    "action_description": "Restart at a reduced dose (40 mg) or at 80mg."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.5",
                  "page_number": 90,
                  "text_snippet": "...and then restarted at a reduced dose (40 mg) or at 80mg (at the discretion of the investigator)."
                }
              },
              {
                "rule_id": "dp-004-r3",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue if QTc prolongation does not resolve to Grade <=1 within 21 days.",
                "conditions": {
                  "grade": ">1",
                  "qtc_threshold": null,
                  "duration": "21 days"
                },
                "actions": [
                  {
                    "action_type": "discontinue_dose",
                    "action_description": "Patient will be permanently withdrawn from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.5",
                  "page_number": 90,
                  "text_snippet": "If the toxicity does not resolve to ≤ CTCAE grade 1 within 21 days the patient will be permanently withdrawn from study treatment."
                }
              },
              {
                "rule_id": "dp-004-r4",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue for QTc prolongation with signs/symptoms of serious arrhythmia.",
                "conditions": {
                  "grade": null,
                  "qtc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_dose",
                    "action_description": "Permanently discontinue study drug."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.5",
                  "page_number": 90,
                  "text_snippet": "Patients experiencing QTc interval prolongation with signs/symptoms of serious arrhythmia will not be permitted to restart study drug and it should be permanently discontinued."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Regular ECGs performed until resolution after interruption.",
              "method": "ECG"
            },
            "provenance": {
              "section_number": "6.9.5",
              "page_number": 90,
              "text_snippet": "QTc prolongation"
            }
          },
          {
            "id": "dp-005",
            "parameter_name": "Interstitial Lung Disease (ILD) / Pneumonitis",
            "parameter_category": "Pulmonary Toxicity",
            "measurement_type": "Clinical/Radiological Diagnosis",
            "decision_rules": [
              {
                "rule_id": "dp-005-r1",
                "rule_type": "dose_hold",
                "rule_description": "Interrupt treatment for new/worsening symptoms or radiological abnormality suggestive of ILD/pneumonitis.",
                "conditions": {
                  "grade": null,
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "An interruption in study drug dosing is recommended."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.6",
                  "page_number": 90,
                  "text_snippet": "If a new or worsening of pulmonary symptoms (e.g., dyspnoea) or occurrence of a radiological abnormality suggestive of ILD/pneumonitis is observed, an interruption in study drug dosing is recommended, and the Study Physician should be informed."
                }
              },
              {
                "rule_id": "dp-005-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue treatment if ILD/pneumonitis is confirmed.",
                "conditions": {
                  "grade": null,
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_dose",
                    "action_description": "Study drug permanently discontinued."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.6",
                  "page_number": 91,
                  "text_snippet": "In the presence of confirmatory HRCT scans where other causes of respiratory symptoms have been excluded, a diagnosis of ILD should be considered and study drug permanently discontinued."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "As clinically indicated",
              "method": "Full diagnostic workup including HRCT, blood and sputum culture."
            },
            "provenance": {
              "section_number": "6.9.6",
              "page_number": 90,
              "text_snippet": "Interstitial lung disease"
            }
          },
          {
            "id": "dp-006",
            "parameter_name": "Skin Reactions",
            "parameter_category": "Dermatologic Toxicity",
            "measurement_type": "Clinical Assessment",
            "decision_rules": [
              {
                "rule_id": "dp-006-r1",
                "rule_type": "supportive_care",
                "rule_description": "Provide symptomatic treatment for skin reactions.",
                "conditions": null,
                "actions": [
                  {
                    "action_type": "supportive_care",
                    "action_description": "Use of mild to moderate strength steroid creams, topical or systemic antibiotics, topical or systemic antihistamines, and retinoid creams."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.9.2",
                  "page_number": 89,
                  "text_snippet": "If a patient develops a skin reaction, a variety of agents can be used. These include mild to moderate strength steroid creams, either topical or systemic antibiotics, topical or systemic antihistamines, and retinoid creams, as deemed appropriate by the Investigator upon assessment of the skin reaction. Immediate symptomatic treatment should be provided."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "As clinically indicated",
              "method": "Clinical assessment, sun protective measures recommended."
            },
            "provenance": {
              "section_number": "6.9.2",
              "page_number": 89,
              "text_snippet": "Skin reactions"
            }
          },
          {
            "id": "dp-007",
            "parameter_name": "Elevated Liver Enzymes (Hy's Law)",
            "parameter_category": "Hepatic Toxicity",
            "measurement_type": "AST/ALT, Total Bilirubin",
            "decision_rules": [
              {
                "rule_id": "dp-007-r1",
                "rule_type": "monitoring_increase",
                "rule_description": "Report as SAE and conduct follow-up for potential Hy's Law cases.",
                "conditions": {
                  "ast_alt_threshold": ">=3xULN",
                  "bilirubin_threshold": ">=2xULN"
                },
                "actions": [
                  {
                    "action_type": "report_sae",
                    "action_description": "Report an SAE (report term ‘Hy’s Law’) according to AstraZeneca standard processes."
                  },
                  {
                    "action_type": "monitoring_increase",
                    "action_description": "Monitor the patient until liver biochemistry parameters and appropriate clinical symptoms and signs return to normal or baseline levels."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "5",
                  "page_number": 140,
                  "text_snippet": "Report an SAE (report term ‘Hy’s Law’) according to AstraZeneca standard processes."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Continuous review of data until resolution.",
              "method": "Liver function tests, investigation of etiology."
            },
            "provenance": {
              "section_number": "6.3.7",
              "page_number": 83,
              "text_snippet": "Hy’s Law\nCases where a patient shows an AST or ALT ≥3xULN or total bilirubin ≥2xULN may need to be reported as SAEs. Prompt reporting of cases meeting Hy’s law criteria (via the SAE expedited reporting system) is required for compliance with regulatory guidelines. The Investigator is responsible for, without delay, determining whether a patient meets potential Hy’s Law criteria."
            }
          }
        ],
        "stopping_rules_summary": {
          "total_permanent_stopping_conditions": 10,
          "stopping_conditions": [
            {
              "condition_id": "stop-001",
              "condition_type": "individual_subject",
              "description": "Patient decision to withdraw.",
              "trigger_threshold": "Patient chooses to discontinue participation.",
              "action": "Discontinuation from IP and/or study.",
              "provenance": {
                "section_number": "3.10",
                "page_number": 50,
                "text_snippet": "Patient decision. The patient is at any time free to discontinue his/her participation in the study, without prejudice"
              }
            },
            {
              "condition_id": "stop-002",
              "condition_type": "individual_subject",
              "description": "Adverse event requiring discontinuation.",
              "trigger_threshold": "Toxicity does not resolve to ≤CTCAE Grade 2 after 3 weeks of withholding drug, or other specific AE criteria met.",
              "action": "Permanent discontinuation from study drug.",
              "provenance": {
                "section_number": "3.10",
                "page_number": 50,
                "text_snippet": "Adverse event"
              }
            },
            {
              "condition_id": "stop-003",
              "condition_type": "individual_subject",
              "description": "Pregnancy.",
              "trigger_threshold": "Patient becomes pregnant.",
              "action": "Discontinuation from IP.",
              "provenance": {
                "section_number": "3.10",
                "page_number": 50,
                "text_snippet": "Pregnancy"
              }
            },
            {
              "condition_id": "stop-004",
              "condition_type": "individual_subject",
              "description": "Severe non-compliance with the study protocol.",
              "trigger_threshold": "As judged by the Investigator and/or AstraZeneca representative.",
              "action": "Discontinuation from IP.",
              "provenance": {
                "section_number": "3.10",
                "page_number": 50,
                "text_snippet": "Severe non-compliance with the study protocol as judged by the Investigator and/or AstraZeneca representative"
              }
            },
            {
              "condition_id": "stop-005",
              "condition_type": "individual_subject",
              "description": "Disease recurrence.",
              "trigger_threshold": "Radiological or pathological evidence of disease recurrence.",
              "action": "Discontinuation from IP.",
              "provenance": {
                "section_number": "3.10",
                "page_number": 50,
                "text_snippet": "Disease recurrence (for select patients who might have the option of open-label osimertinib upon recurrence, please also see Section 3.3)"
              }
            },
            {
              "condition_id": "stop-006",
              "condition_type": "individual_subject",
              "description": "Confirmed Interstitial Lung Disease (ILD)/pneumonitis.",
              "trigger_threshold": "Diagnosis of ILD/pneumonitis.",
              "action": "Permanent discontinuation from study drug.",
              "provenance": {
                "section_number": "3.10",
                "page_number": 50,
                "text_snippet": "Patients experiencing ILD/pneumonitis, or QTc prolongation with signs/symptoms of serious arrhythmia will not be permitted to restart study treatment."
              }
            },
            {
              "condition_id": "stop-007",
              "condition_type": "individual_subject",
              "description": "QTc prolongation with signs/symptoms of serious arrhythmia.",
              "trigger_threshold": "Clinical event of serious arrhythmia associated with QTc prolongation.",
              "action": "Permanent discontinuation from study drug.",
              "provenance": {
                "section_number": "3.10",
                "page_number": 50,
                "text_snippet": "Patients experiencing ILD/pneumonitis, or QTc prolongation with signs/symptoms of serious arrhythmia will not be permitted to restart study treatment."
              }
            },
            {
              "condition_id": "stop-008",
              "condition_type": "individual_subject",
              "description": "Diagnosed Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).",
              "trigger_threshold": "Confirmation of SJS or TEN diagnosis.",
              "action": "Permanent discontinuation from study drug.",
              "provenance": {
                "section_number": "6.9.2",
                "page_number": 90,
                "text_snippet": "Osimertinib should be discontinued immediately if SJS or TEN is diagnosed."
              }
            },
            {
              "condition_id": "stop-009",
              "condition_type": "individual_subject",
              "description": "Confirmed aplastic anaemia.",
              "trigger_threshold": "Confirmation of aplastic anaemia diagnosis.",
              "action": "Permanent discontinuation from study drug.",
              "provenance": {
                "section_number": "6.9.3",
                "page_number": 90,
                "text_snippet": "osimertinib should be discontinued in patients with confirmed aplastic anaemia."
              }
            },
            {
              "condition_id": "stop-010",
              "condition_type": "study_level",
              "description": "Undue risk to study patients due to clinically significant findings.",
              "trigger_threshold": "In the judgment of AstraZeneca, findings are assessed as causally related to study drug and inconsistent with continuation of the study.",
              "action": "Study may be stopped.",
              "provenance": {
                "section_number": "3.12",
                "page_number": 52,
                "text_snippet": "The study may be stopped if, in the judgment of AstraZeneca, study patients are placed at undue risk because of clinically significant findings that:\n• Meet individual stopping criteria or are otherwise considered significant.\n• Are assessed as causally related to study drug.\n• Are not considered to be consistent with continuation of the study."
              }
            }
          ],
          "provenance": {
            "section_number": "3.10",
            "page_number": 50,
            "text_snippet": "Discontinuation of investigational product or open-label osimertinib"
          }
        },
        "dose_modification_levels": {
          "has_defined_levels": true,
          "levels": [
            {
              "level_id": "dose-0",
              "level_name": "Starting Dose",
              "dose_percentage": 100,
              "absolute_dose": "80 mg AZD9291/matching placebo",
              "provenance": {
                "section_number": null,
                "page_number": 88,
                "text_snippet": "Starting dose 80 mg AZD9291/matching placebo"
              }
            },
            {
              "level_id": "dose-1",
              "level_name": "Reduced Dose",
              "dose_percentage": 50,
              "absolute_dose": "40 mg AZD9291/matching placebo",
              "provenance": {
                "section_number": null,
                "page_number": 88,
                "text_snippet": "Reduced dose 40 mg AZD9291/ matching placebo"
              }
            }
          ],
          "minimum_dose": "40 mg AZD9291/matching placebo",
          "re_escalation_allowed": false,
          "re_escalation_criteria": "Not specified. Restarting at the same dose (80mg) after interruption is permitted at investigator discretion.",
          "provenance": {
            "section_number": "6.9",
            "page_number": 88,
            "text_snippet": "Table 6 Dose reduction levels"
          }
        },
        "organ_specific_adjustments": [
          {
            "id": "organ-001",
            "organ_system": "Cardiac",
            "organ_system_detail": "QTc Interval Prolongation",
            "adjustment_trigger": "QTcF > 500 msec",
            "adjustment_action": "Interrupt treatment. Upon recovery to <481 msec, restart at 40 mg or 80 mg. Permanently discontinue if associated with serious arrhythmia or if toxicity does not resolve to Grade <=1 within 21 days.",
            "monitoring_requirements": "Regular ECGs until resolution.",
            "provenance": {
              "section_number": "6.9.5",
              "page_number": 90,
              "text_snippet": "Patients with QTcF prolongation to >500 msec should have study treatment interrupted and regular ECGs performed until resolution to <481 msec or recovery to baseline if baseline QTcF is ≥ 481 msec and then restarted at a reduced dose (40 mg) or at 80mg (at the discretion of the investigator). If the toxicity does not resolve to ≤ CTCAE grade 1 within 21 days the patient will be permanently withdrawn from study treatment."
            }
          },
          {
            "id": "organ-002",
            "organ_system": "Pulmonary",
            "organ_system_detail": "Interstitial Lung Disease / Pneumonitis",
            "adjustment_trigger": "Suspicion of ILD/pneumonitis based on symptoms or imaging.",
            "adjustment_action": "Interrupt treatment. Permanently discontinue if ILD/pneumonitis is confirmed.",
            "monitoring_requirements": "Full diagnostic workup including HRCT.",
            "provenance": {
              "section_number": "6.9.6",
              "page_number": 90,
              "text_snippet": "If a new or worsening of pulmonary symptoms (e.g., dyspnoea) or occurrence of a radiological abnormality suggestive of ILD/pneumonitis is observed, an interruption in study drug dosing is recommended... In the presence of confirmatory HRCT scans where other causes of respiratory symptoms have been excluded, a diagnosis of ILD should be considered and study drug permanently discontinued."
            }
          },
          {
            "id": "organ-003",
            "organ_system": "Dermatologic",
            "organ_system_detail": "Severe Skin Reactions (SJS/TEN)",
            "adjustment_trigger": "Suspicion of SJS/TEN.",
            "adjustment_action": "Interrupt treatment. Permanently discontinue if SJS/TEN is confirmed.",
            "monitoring_requirements": "Close patient monitoring.",
            "provenance": {
              "section_number": "6.9.2",
              "page_number": 90,
              "text_snippet": "If signs and symptoms suggestive of SJS appear, osimertinib should be interrupted. Osimertinib should be discontinued immediately if SJS or TEN is diagnosed."
            }
          },
          {
            "id": "organ-004",
            "organ_system": "Bone Marrow",
            "organ_system_detail": "Aplastic Anaemia",
            "adjustment_trigger": "Suspicion of aplastic anaemia.",
            "adjustment_action": "Interrupt or discontinue treatment. Permanently discontinue if confirmed.",
            "monitoring_requirements": "Close patient monitoring for signs and symptoms.",
            "provenance": {
              "section_number": "6.9.3",
              "page_number": 90,
              "text_snippet": "If signs and symptoms suggestive of aplastic anaemia develop, close patient monitoring and drug interruption or discontinuation of osimertinib should be considered. osimertinib should be discontinued in patients with confirmed aplastic anaemia."
            }
          }
        ],
        "extraction_statistics": {
          "decision_points_count": 7,
          "stopping_rules_count": 10,
          "organ_adjustments_count": 4,
          "dose_levels_count": 2,
          "categories_count": 6
        },
        "provenance": {
          "section_number": "6.9",
          "page_number": 88,
          "text_snippet": "Management of investigational product-related toxicities"
        }
      },
      "_agentDocumentation": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DOSELEVEL_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure allowed dose levels in IRT",
                "sourceDataPath": "dose_modification_levels.levels[]",
                "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
                "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_DECISION_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate edit checks from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
                "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
              },
              {
                "ruleId": "ALERT_DECISION_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Configure real-time safety alerts from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STOP_001",
                "ruleType": "workflow",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure enrollment stops based on stopping rules",
                "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
                "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_ORGAN_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate lab-triggered dose recommendations",
                "sourceDataPath": "organ_specific_adjustments[]",
                "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
                "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_DOSELEVEL_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure allowed dose levels in IRT",
            "sourceDataPath": "dose_modification_levels.levels[]",
            "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
            "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
          },
          {
            "ruleId": "EDC_DECISION_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate edit checks from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
            "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
          },
          {
            "ruleId": "ALERT_DECISION_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Configure real-time safety alerts from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
            "example": null
          },
          {
            "ruleId": "IRT_STOP_001",
            "ruleType": "workflow",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure enrollment stops based on stopping rules",
            "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
            "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
            "example": null
          },
          {
            "ruleId": "EDC_ORGAN_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate lab-triggered dose recommendations",
            "sourceDataPath": "organ_specific_adjustments[]",
            "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
            "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_SAFETY_LAB_001",
            "name": "Safety Thresholds + Lab Specs → Smart Lab Alerts",
            "agentsInvolved": [
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining safety thresholds with lab panel definitions enables intelligent lab alerting",
            "combinedInsight": "Which labs to monitor + what thresholds trigger action = Complete lab safety system",
            "automationEnabled": "EDC auto-calculates if labs trigger dose modification upon data entry",
            "exampleOutput": "{\"lab\": \"ANC\", \"value\": 800, \"threshold\": \"<1000\", \"action\": \"Hold dose\", \"triggered\": true}"
          },
          {
            "synergyId": "SYN_SAFETY_ARMS_001",
            "name": "Safety Rules + Arms → Arm-Specific Modifications",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "description": "Safety rules applied to specific arm dosing enables precise modification tracking",
            "combinedInsight": "Which dose level applies to which arm = Accurate dose tracking per subject",
            "automationEnabled": "IRT knows exact dose options for each arm based on safety rules",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_SAFETY_001",
            "name": "Dose Level Consistency",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels align with arm dosing regimens",
            "checkLogic": "FOR EACH level: level.absolute_dose IN arms.interventions.possible_doses",
            "severity": "error"
          },
          {
            "ruleId": "VAL_SAFETY_002",
            "name": "Stopping Rule Completeness",
            "agentsInvolved": [
              "safety_decision_points"
            ],
            "validationType": "completeness",
            "description": "Verify all stopping rules have clear conditions and actions",
            "checkLogic": "FOR EACH stop_rule: condition IS NOT NULL AND action IS NOT NULL",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "edit_check_library",
            "description": "Complete set of safety-related edit checks",
            "dataSources": [
              "decision_points[].decision_rules[]",
              "dose_modification_levels.levels[]",
              "organ_specific_adjustments[]"
            ],
            "outputFormat": "EDC edit check specification (Medidata, Oracle, Veeva)",
            "exampleConfig": {
              "edit_checks": [
                {
                  "id": "EC_ALT_001",
                  "condition": "ALT > 5 * ULN",
                  "action": "FIRE",
                  "message": "ALT elevation requires dose hold per protocol section 6.2",
                  "severity": "HARD_STOP"
                },
                {
                  "id": "EC_ANC_001",
                  "condition": "ANC < 1000",
                  "action": "FIRE",
                  "message": "Neutropenia requires dose modification per Table 6-1",
                  "severity": "SOFT_STOP"
                }
              ]
            }
          }
        ]
      }
    },
    "concomitantMedications": {
      "moduleId": "concomitant_medications",
      "instanceType": "ConcomitantMedications",
      "data": {
        "id": "D5164C00001-concomitant-medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "name": "D5164C00001 Concomitant Medication Restrictions",
        "description": "Medication restrictions and requirements for D5164C00001",
        "prohibited_medications": [
          {
            "id": "proh-001",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Strong CYP3A4 Inducers",
            "specific_drugs": [
              "carbamazepine",
              "phenobarbital",
              "phenytoin",
              "rifampicin",
              "rifabutin",
              "rifapentin"
            ],
            "prohibition_reason": {
              "decode": "pk_interaction"
            },
            "prohibition_reason_detail": "Potent inducers of CYP3A4 that may decrease concentrations of AZD9291.",
            "prohibition_period": {
              "decode": "entire_study"
            },
            "prohibition_period_detail": "Prohibited during the study and require a washout period prior to starting study treatment.",
            "provenance": {
              "section_number": "1",
              "page_number": 145,
              "text_snippet": "DRUGS INDUCING CYP3A4 METABOLISM THAT ASTRAZENECA STRONGLY RECOMMEND ARE NOT COMBINED WITH AZD9291\n\nAZD9291 is metabolized by CYP3A4 and CYP3A5 enzymes.\nA drug-drug interaction study of AZD9291 evaluated in patients showed that there is potential for AZD9291 being a victim when co-administered with strong inducers of CYP3A4 (AZD9291 concentrations are decreased when co-dosed with rifampicin).\nThe following potent inducers of CYP3A4 should not be used during this study for any patient receiving"
            }
          },
          {
            "id": "proh-002",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Prior Anti-Cancer Therapy",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "study_design"
            },
            "prohibition_reason_detail": "Prior neoadjuvant or adjuvant EGFR-TKI therapy is prohibited. Prior neoadjuvant platinum-based or other chemotherapy is prohibited.",
            "prohibition_period": {
              "decode": "screening_only"
            },
            "prohibition_period_detail": "Prohibited prior to study entry.",
            "provenance": {
              "section_number": "3.2",
              "page_number": 44,
              "text_snippet": "Treatment with any of the following:\n- Pre-operative or post-operative or planned radiation therapy for the current lung cancer\n- Pre-operative (neo-adjuvant) platinum based or other chemotherapy\n- Any prior anticancer therapy, including investigational therapy, for treatment of NSCLC other than standard platinum based doublet post-operative adjuvant chemotherapy\n- Prior treatment with neoadjuvant or adjuvant EGFR-TKI"
            }
          },
          {
            "id": "proh-003",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Concurrent Anti-Cancer Therapy",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "efficacy_interference"
            },
            "prohibition_reason_detail": "Other anti-cancer therapies including investigational agents and radiotherapy are not allowed while the patient is on study drug and has no disease recurrence.",
            "prohibition_period": {
              "decode": "treatment_period"
            },
            "prohibition_period_detail": "Prohibited while on study drug and without disease recurrence.",
            "provenance": {
              "section_number": "3.9",
              "page_number": 49,
              "text_snippet": "Other anti-cancer therapies including investigational agents, and radiotherapy should not be given while the patient is still on study drug and/or has no disease recurrence"
            }
          }
        ],
        "restricted_medications": [
          {
            "id": "rest-001",
            "instanceType": "RestrictedMedication",
            "medication_class": "BCRP and P-gp Substrates",
            "specific_drugs": [
              "rosuvastatin",
              "sulfasalazine",
              "doxorubicin",
              "daunorubicin",
              "topotecan",
              "dabigatran",
              "aliskiren",
              "digoxin"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": "Patients should be monitored closely for possible drug interactions. Patients taking rosuvastatin should have creatine phosphokinase levels monitored.",
              "timing_restriction": null,
              "clinical_scenario": null
            },
            "rationale": "AZD9291 may increase the concentration of sensitive BCRP and P-gp substrates, potentially increasing their toxicity.",
            "provenance": {
              "section_number": "2",
              "page_number": 146,
              "text_snippet": "Table 2 Exposure, pharmacological action and toxicity may be increased by AZD9291\nWarning of possible interaction Advice\nRosuvastatin\nSulfasalazine\nDoxorubicin\nDaunorubicin\nTopotecan\nDabigatran\nAliskiren\nDigoxin\nDrugs are permitted but caution should be exercised and patients monitored closely for possible drug interactions. Please refer to full prescribing information for all drugs prior to co-administration with AZD9291."
            }
          },
          {
            "id": "rest-002",
            "instanceType": "RestrictedMedication",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [],
            "restriction_type": {
              "decode": "avoid_if_possible"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": "If co-administration is essential for patient clinical management, close monitoring with ECGs and electrolytes is recommended.",
              "timing_restriction": null,
              "clinical_scenario": "Applies to drugs with known, possible, or conditional risk of Torsades de Pointes (TdP)."
            },
            "rationale": "To avoid additive effects on QT interval prolongation and reduce the risk of TdP.",
            "provenance": {
              "section_number": "3.1.2",
              "page_number": 147,
              "text_snippet": "During study treatment\nIt is recommended that drugs in the category of known risk of TdP are not co-administered with study treatment (AZD9291) and for a period of two weeks after discontinuing study treatment. However, if it is considered essential for patient clinical management to co-administer these drugs with study treatment (AZD9291) close monitoring with ECGs is recommended."
            }
          }
        ],
        "required_medications": [],
        "rescue_medications": [
          {
            "id": "resc-001",
            "instanceType": "RescueMedication",
            "medication_name": null,
            "medication_class": "Anti-emetics",
            "indication": "Nausea and vomiting",
            "dosing_instructions": "As per local clinical practice.",
            "documentation_required": true,
            "impact_on_endpoints": null,
            "provenance": {
              "section_number": "6.9.4",
              "page_number": 90,
              "text_snippet": "Nausea, vomiting, or both may be controlled with anti-emetic therapy."
            }
          },
          {
            "id": "resc-002",
            "instanceType": "RescueMedication",
            "medication_name": null,
            "medication_class": "Agents for skin reactions",
            "indication": "Study drug-related skin reactions",
            "dosing_instructions": "Includes mild to moderate strength steroid creams, topical or systemic antibiotics, topical or systemic antihistamines, and retinoid creams, as deemed appropriate by the Investigator.",
            "documentation_required": true,
            "impact_on_endpoints": null,
            "provenance": {
              "section_number": "6.9.2",
              "page_number": 89,
              "text_snippet": "If a patient develops a skin reaction, a variety of agents can be used. These include mild to moderate strength steroid creams, either topical or systemic antibiotics, topical or systemic antihistamines, and retinoid creams, as deemed appropriate by the Investigator upon assessment of the skin reaction. Immediate symptomatic treatment should be provided."
            }
          },
          {
            "id": "resc-003",
            "instanceType": "RescueMedication",
            "medication_name": null,
            "medication_class": "Anti-diarrheals",
            "indication": "Diarrhea",
            "dosing_instructions": "Management should be based on local clinical practice.",
            "documentation_required": true,
            "impact_on_endpoints": null,
            "provenance": {
              "section_number": "6.9.4",
              "page_number": 90,
              "text_snippet": "Management of diarrhoea should be based on local clinical practice. Changes in CTCAE grade of diarrhoea will be captured in the AE eCRF."
            }
          }
        ],
        "washout_requirements": [
          {
            "id": "wash-001",
            "instanceType": "WashoutRequirement",
            "medication_class": "Investigational Drugs",
            "specific_drugs": [],
            "washout_duration_days": null,
            "washout_description": "Discontinue within five half-lives of the compound before study entry.",
            "rationale": "To avoid confounding effects and overlapping toxicity from prior investigational agents.",
            "applies_to": {
              "decode": "enrollment"
            },
            "provenance": {
              "section_number": "3.2",
              "page_number": 44,
              "text_snippet": "Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known."
            }
          },
          {
            "id": "wash-002",
            "instanceType": "WashoutRequirement",
            "medication_class": "Strong CYP3A4 Inducers",
            "specific_drugs": [
              "carbamazepine",
              "phenytoin",
              "rifampicin",
              "rifabutin",
              "rifapentin"
            ],
            "washout_duration_days": 21,
            "washout_description": "3 weeks before first dose of AZD9291.",
            "rationale": "To allow clearance of potent CYP3A4 inducers that could decrease AZD9291 exposure.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "1",
              "page_number": 145,
              "text_snippet": "Table 1 Drugs inducing CYP3A4\nContraindicated drugs Withdrawal period prior to AZD9291 start\nCarbamazepine, phenobarbital, phenytoin\nRifampicin, rifabutin, rifapentin\nSt John’s Wort\n3 weeks"
            }
          },
          {
            "id": "wash-003",
            "instanceType": "WashoutRequirement",
            "medication_class": "Strong CYP3A4 Inducers",
            "specific_drugs": [
              "phenobarbital"
            ],
            "washout_duration_days": 35,
            "washout_description": "5 weeks before first dose of AZD9291.",
            "rationale": "To allow clearance of potent CYP3A4 inducers that could decrease AZD9291 exposure.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "1",
              "page_number": 145,
              "text_snippet": "Table 1 Drugs inducing CYP3A4\nContraindicated drugs Withdrawal period prior to AZD9291 start\nPhenobarbitone 5 weeks"
            }
          },
          {
            "id": "wash-004",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "aclarubicin",
              "anagrelide",
              "ciprofloxacin",
              "clarithromycin",
              "cocaine",
              "droperidol",
              "erythromycin",
              "levofloxacin",
              "ondansetron",
              "papaverine hydrochloride",
              "procainamide",
              "sulpiride",
              "sultopride",
              "terfenadine",
              "terlipressin"
            ],
            "washout_duration_days": 2,
            "washout_description": "2 days before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Aclarubicin, Anagrelide, Ciprofloxacin, Clarithromycin, Cocaine, Droperidol, Erythromycin, Levofloxacin, Ondansetron, Papaverine hydrochloride, Procainamide, Sulpiride, Sultopride, Terfenadine Terlipressin\n2 days"
            }
          },
          {
            "id": "wash-005",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "cilostazol",
              "cisapride",
              "disopyramide",
              "dofetilide",
              "domperidone",
              "flecainide",
              "gatifloxacin",
              "grepafloxacin",
              "ibutilide",
              "moxifloxacin",
              "oxaliplatin",
              "propofol",
              "quinidine",
              "roxithromycin",
              "sevoflurane",
              "sotalol",
              "sparfloxacin",
              "thioridazine"
            ],
            "washout_duration_days": 7,
            "washout_description": "7 days before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Cilostazol, Cisapride, Disopyramide, Dofetilide, Domperidone, Flecainide, Gatifloxacin, Grepafloxacin, Ibutilide, Moxifloxacin, Oxaliplatin, Propofol, Quinidine, Roxithromycin, Sevoflurane, Sotalol, Sparfloxacin, Thioridazine\n7 days"
            }
          },
          {
            "id": "wash-006",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "azithromycin",
              "bepridil",
              "citalopram",
              "chlorpromazine",
              "dronedarone",
              "escitalopram",
              "fluconazole",
              "halofantrine",
              "haloperidol",
              "levomepromazine",
              "levosulpiride",
              "mesoridazine"
            ],
            "washout_duration_days": 14,
            "washout_description": "14 days before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Azithromycin, Bepridil, Citalopram, Chlorpromazine, Dronedarone, escitalopram, Fluconazole, Halofantrine, Haloperidol, Levomepromazine, Levosulpiride, Mesoridazine\n14 days"
            }
          },
          {
            "id": "wash-007",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "donepezil",
              "terodiline"
            ],
            "washout_duration_days": 21,
            "washout_description": "3 weeks before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Donepezil, Terodiline 3 weeks"
            }
          },
          {
            "id": "wash-008",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "levomethadyl",
              "methadone",
              "pimozide"
            ],
            "washout_duration_days": 28,
            "washout_description": "4 weeks before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Levomethadyl, methadone, pimozide 4 weeks"
            }
          },
          {
            "id": "wash-009",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "arsenic trioxide",
              "ibogaine"
            ],
            "washout_duration_days": 42,
            "washout_description": "6 weeks before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Arsenic trioxideb, Ibogaine 6 weeks"
            }
          },
          {
            "id": "wash-010",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "pentamidine"
            ],
            "washout_duration_days": 56,
            "washout_description": "8 weeks before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Pentamidine 8 weeks"
            }
          },
          {
            "id": "wash-011",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "astemizole",
              "probucol",
              "vandetanib"
            ],
            "washout_duration_days": 120,
            "washout_description": "4 months before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Astemizole, Probucol, Vandetanib 4 months"
            }
          },
          {
            "id": "wash-012",
            "instanceType": "WashoutRequirement",
            "medication_class": "QT Prolonging Drugs",
            "specific_drugs": [
              "amiodarone",
              "chloroquine"
            ],
            "washout_duration_days": 365,
            "washout_description": "1 year before first dose of AZD9291.",
            "rationale": "To minimize risk of additive QT prolongation due to long half-life.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": null,
              "page_number": 147,
              "text_snippet": "Amiodarone, chloroquine 1 year"
            }
          },
          {
            "id": "wash-013",
            "instanceType": "WashoutRequirement",
            "medication_class": "Prior Anti-Cancer Therapy",
            "specific_drugs": [],
            "washout_duration_days": 1825,
            "washout_description": "No prior anticancer therapy in preceding 5 years, with the exception of standard post-operative adjuvant chemotherapy for NSCLC.",
            "rationale": "To avoid confounding effects from prior therapies.",
            "applies_to": {
              "decode": "enrollment"
            },
            "provenance": {
              "section_number": "7.8.1",
              "page_number": 95,
              "text_snippet": "No prior anticancer therapy in preceding 5 years, including investigational therapy, with the exception of standard post-operative adjuvant chemotherapy for the treatment of NSCLC."
            }
          }
        ],
        "drug_interactions": [
          {
            "id": "int-001",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "CYP3A4_inducer"
            },
            "severity": {
              "decode": "strong"
            },
            "affected_drugs": [
              "carbamazepine",
              "phenobarbital",
              "phenytoin",
              "rifampicin",
              "rifabutin",
              "rifapentin"
            ],
            "clinical_effect": "Decreased concentrations of AZD9291.",
            "management": {
              "decode": "prohibited"
            },
            "management_detail": "Strong inducers of CYP3A4 should not be used during this study.",
            "provenance": {
              "section_number": "1",
              "page_number": 145,
              "text_snippet": "A drug-drug interaction study of AZD9291 evaluated in patients showed that there is potential for AZD9291 being a victim when co-administered with strong inducers of CYP3A4 (AZD9291 concentrations are decreased when co-dosed with rifampicin).\nThe following potent inducers of CYP3A4 should not be used during this study for any patient receiving study treatment."
            }
          },
          {
            "id": "int-002",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "BCRP_inhibitor"
            },
            "severity": {
              "decode": "not_specified"
            },
            "affected_drugs": [
              "rosuvastatin",
              "sulfasalazine"
            ],
            "clinical_effect": "AZD9291 may increase the concentration of sensitive BCRP substrates.",
            "management": {
              "decode": "allowed_with_caution"
            },
            "management_detail": "Drugs are permitted but caution should be exercised and patients monitored closely for possible drug interactions. For rosuvastatin, creatine phosphokinase levels should be monitored.",
            "provenance": {
              "section_number": "2",
              "page_number": 145,
              "text_snippet": "AZD9291 may increase the concentration of sensitive BCRP and Pgp substrates (concentration of the sensitive BCRP substrate, rosuvastatin and sensitive Pgp substrate, fexofenadine, are increased)."
            }
          },
          {
            "id": "int-003",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "P_gp_inhibitor"
            },
            "severity": {
              "decode": "not_specified"
            },
            "affected_drugs": [
              "doxorubicin",
              "daunorubicin",
              "topotecan",
              "dabigatran",
              "aliskiren",
              "digoxin"
            ],
            "clinical_effect": "AZD9291 may increase the concentration of sensitive P-gp substrates.",
            "management": {
              "decode": "allowed_with_caution"
            },
            "management_detail": "Drugs are permitted but caution should be exercised and patients monitored closely for possible drug interactions.",
            "provenance": {
              "section_number": "2",
              "page_number": 145,
              "text_snippet": "AZD9291 may increase the concentration of sensitive BCRP and Pgp substrates (concentration of the sensitive BCRP substrate, rosuvastatin and sensitive Pgp substrate, fexofenadine, are increased)."
            }
          },
          {
            "id": "int-004",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "QT_prolonging"
            },
            "severity": {
              "decode": "not_specified"
            },
            "affected_drugs": [],
            "clinical_effect": "Additive QT interval prolongation, increasing risk of Torsades de Pointes.",
            "management": {
              "decode": "avoid_if_possible"
            },
            "management_detail": "It is recommended that drugs with a known risk of TdP are not co-administered. If essential, close monitoring with ECGs and electrolytes is recommended.",
            "provenance": {
              "section_number": "3.1.2",
              "page_number": 147,
              "text_snippet": "It is recommended that drugs in the category of known risk of TdP are not co-administered with study treatment (AZD9291) and for a period of two weeks after discontinuing study treatment. However, if it is considered essential for patient clinical management to co-administer these drugs with study treatment (AZD9291) close monitoring with ECGs is recommended."
            }
          }
        ],
        "allowed_medications": [],
        "vaccine_policy": {},
        "herbal_supplements_policy": {
          "instanceType": "HerbalSupplementsPolicy",
          "prohibited_supplements": [
            "St. John's Wort"
          ],
          "rationale": "St. John's Wort is a potent inducer of CYP3A4 and is prohibited. The use of any other natural/herbal products or folk remedies should be discouraged.",
          "provenance": {
            "section_number": "1",
            "page_number": 145,
            "text_snippet": "Table 1 Drugs inducing CYP3A4\nContraindicated drugs Withdrawal period prior to AZD9291 start\nSt John’s Wort 3 weeks"
          }
        },
        "provenance": {
          "section_number": "7.8",
          "page_number": 95,
          "text_snippet": "Concomitant and other treatments"
        }
      },
      "_agentDocumentation": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_PROHIB_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Alert when prohibited medication is entered",
                "sourceDataPath": "prohibited_medications[]",
                "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
                "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_WASHOUT_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate washout period for prior medications",
                "sourceDataPath": "washout_requirements[]",
                "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
                "example": "Prior chemotherapy end date + 28 days must be before first dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DDI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Real-time drug interaction checking",
                "sourceDataPath": "drug_interactions[]",
                "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_PREMED_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Verify required premedications were administered",
                "sourceDataPath": "required_medications[]",
                "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
                "example": "Diphenhydramine 50mg IV required 30 min before infusion"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_PROHIB_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Alert when prohibited medication is entered",
            "sourceDataPath": "prohibited_medications[]",
            "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
            "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
          },
          {
            "ruleId": "EDC_WASHOUT_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate washout period for prior medications",
            "sourceDataPath": "washout_requirements[]",
            "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
            "example": "Prior chemotherapy end date + 28 days must be before first dose"
          },
          {
            "ruleId": "EDC_DDI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Real-time drug interaction checking",
            "sourceDataPath": "drug_interactions[]",
            "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
            "example": null
          },
          {
            "ruleId": "EDC_PREMED_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Verify required premedications were administered",
            "sourceDataPath": "required_medications[]",
            "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
            "example": "Diphenhydramine 50mg IV required 30 min before infusion"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_CM_ELIG_001",
            "name": "Washouts + Eligibility → Complete Screening Tool",
            "agentsInvolved": [
              "concomitant_medications",
              "eligibility_criteria"
            ],
            "description": "Washout requirements combined with eligibility criteria enables smart screening",
            "combinedInsight": "Prior therapy exclusions + washout periods = Earliest eligible date calculator",
            "automationEnabled": "Site tool that calculates when patient becomes eligible based on prior meds",
            "exampleOutput": "{\"prior_med\": \"Irinotecan\", \"last_dose\": \"2024-01-15\", \"washout\": \"28 days\", \"earliest_eligible\": \"2024-02-12\"}"
          }
        ],
        "validationRules": [],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "drug_dictionary_config",
            "description": "Configure drug dictionary with protocol-specific flags",
            "dataSources": [
              "prohibited_medications[]",
              "restricted_medications[]",
              "drug_interactions[]"
            ],
            "outputFormat": "WHODrug/MedDRA mapping with protocol flags",
            "exampleConfig": {
              "drug_flags": [
                {
                  "atc_class": "L01",
                  "flag": "PRIOR_CHEMO",
                  "washout_days": 28
                },
                {
                  "drug_name": "Ketoconazole",
                  "flag": "CYP3A4_INHIBITOR",
                  "status": "PROHIBITED"
                }
              ]
            }
          }
        ]
      }
    },
    "biospecimenHandling": {
      "moduleId": "biospecimen_handling",
      "instanceType": "BiospecimenHandling",
      "data": {
        "discovered_specimen_types": [
          {
            "specimen_id": "SPEC-TUMOR-MANDATORY",
            "specimen_name": "Tumour tissue",
            "specimen_category": "tissue",
            "specimen_subtype": "tumour",
            "collection_method": "biopsy",
            "purpose": "mutation_analysis",
            "purpose_description": "Mandatory for central confirmation of EGFR mutation status, retrospective T790M testing and for exploratory analyses",
            "provenance": {
              "section_number": "4.1.3",
              "page_number": 62,
              "text_snippet": "Mandatory screening tumour biopsy sample for mutation analysis\nTumour sample must be formalin fixed and paraffin embedded (FFPE). Cytology samples are unsuitable for testing and should not be provided. Sites should ship the FFPE tumour sample to the testing laboratory as soon as it is available. Blocks (multiple cores) must be provided wherever possible."
            }
          },
          {
            "specimen_id": "SPEC-PLASMA-CTDNA",
            "specimen_name": "Plasma for ctDNA and blood borne biomarkers",
            "specimen_category": "blood",
            "specimen_subtype": "plasma",
            "collection_method": "venipuncture",
            "purpose": "biomarker_analysis",
            "purpose_description": "To explore the relationship between emergence and dynamic changes of EGFR mutation including T790M in ctDNA and time to disease recurrence.",
            "provenance": {
              "section_number": "5.7.3",
              "page_number": 77,
              "text_snippet": "Collection of plasma samples for analysis: blood-borne biomarkers and circulating deoxyribonucleic acid\nAll patients will be requested to provide a series of blood samples to generate plasma samples. These samples will be used for the extraction and analysis of ctDNA. The ctDNA will be used to explore the relationship between emergence and dynamic changes of EGFR mutation including T790M (as well as other known markers of TKI resistance) in ctDNA and time to disease recurrence."
            }
          },
          {
            "specimen_id": "SPEC-BLOOD-PK",
            "specimen_name": "Blood for PK analysis",
            "specimen_category": "blood",
            "specimen_subtype": null,
            "collection_method": "venipuncture",
            "purpose": "pk",
            "purpose_description": "To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites",
            "provenance": {
              "section_number": "5.4.1",
              "page_number": 74,
              "text_snippet": "Pharmacokinetics blood sampling (2 mL each) will be performed for all patients at pre-dose, 0.5 to 1.5 hours, and 2 to 4 hours post dose on Week 4, Week 24, Week 48 and Week 96."
            }
          },
          {
            "specimen_id": "SPEC-BLOOD-PGX",
            "specimen_name": "Blood for pharmacogenetics research",
            "specimen_category": "blood",
            "specimen_subtype": null,
            "collection_method": "venipuncture",
            "purpose": "pharmacogenomics",
            "purpose_description": "To explore how genetic variations may affect the clinical parameters associated with AZD9291.",
            "provenance": {
              "section_number": "5.6",
              "page_number": 76,
              "text_snippet": "If a patient agrees to participate in the host pharmacogenetics research component of the study, a blood sample will be collected.\nAstraZeneca intends to perform genetic research in the AZD9291 clinical development programme to explore how genetic variations may affect the clinical parameters associated with AZD9291."
            }
          },
          {
            "specimen_id": "SPEC-BLOOD-SAFETY",
            "specimen_name": "Blood for safety labs",
            "specimen_category": "blood",
            "specimen_subtype": null,
            "collection_method": "venipuncture",
            "purpose": "safety",
            "purpose_description": "For determination of clinical chemistry and haematology.",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 68,
              "text_snippet": "Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis will be taken at the times indicated in the Study Plan Table 1."
            }
          },
          {
            "specimen_id": "SPEC-URINE-SAFETY",
            "specimen_name": "Urine for safety labs",
            "specimen_category": "urine",
            "specimen_subtype": null,
            "collection_method": "midstream_clean_catch",
            "purpose": "safety",
            "purpose_description": "For determination of urinalysis.",
            "provenance": {
              "section_number": "5.2.1",
              "page_number": 68,
              "text_snippet": "Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis will be taken at the times indicated in the Study Plan Table 1."
            }
          }
        ],
        "collection_containers": [],
        "collection_schedule": [
          {
            "schedule_id": "COL-001",
            "specimen_ref": [
              "SPEC-001"
            ],
            "timepoint_name": "Screening Part I",
            "timepoint_type": "screening",
            "relative_time": "Day -28 to Day -1",
            "collection_window": {
              "value": 28,
              "unit": "days",
              "description": "From Day -28 up to Day -1 relative to randomization"
            },
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 53,
              "text_snippet": "Visit: Part I, Timing (timing of each visit to be calculated based on date of randomisation visit): Day -28 to Day -1, Tumour sample f: X"
            }
          },
          {
            "schedule_id": "COL-002",
            "specimen_ref": [
              "SPEC-005"
            ],
            "timepoint_name": "Screening Part II",
            "timepoint_type": "screening",
            "relative_time": "Day -28 to Day -1",
            "collection_window": {
              "value": 28,
              "unit": "days",
              "description": "From Day -28 up to Day -1 relative to randomization"
            },
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 55,
              "text_snippet": "Visit: Part II a, Timing (timing of each visit to be calculated based on date of randomisation visit): Day -28 to Day -1, Genetic consent and blood sample (optional) n: X"
            }
          },
          {
            "schedule_id": "COL-003",
            "specimen_ref": [
              "SPEC-006",
              "SPEC-007"
            ],
            "timepoint_name": "Screening Part II",
            "timepoint_type": "screening",
            "relative_time": "Day -28 to Day -1",
            "collection_window": {
              "value": 28,
              "unit": "days",
              "description": "From Day -28 up to Day -1 relative to randomization"
            },
            "number_of_samples": 1,
            "fasting_required": true,
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Glucose (fasting, on PK days only)a\na Patients will be required to fast (water only) for at least 8 hours prior to the collection of a fasting glucose sample required on PK days. Random glucose sample will be collected on non-PK days."
            }
          },
          {
            "schedule_id": "COL-004",
            "specimen_ref": [
              "SPEC-003"
            ],
            "timepoint_name": "Day 1",
            "timepoint_type": "baseline",
            "relative_time": "Day 1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 56,
              "text_snippet": "Visit: Randomisation, Timing: Day 1, Plasma sample for ctDNA and blood borne biomarkers o: X (pre dose)"
            }
          },
          {
            "schedule_id": "COL-005",
            "specimen_ref": [
              "SPEC-006",
              "SPEC-007"
            ],
            "timepoint_name": "Day 1",
            "timepoint_type": "baseline",
            "relative_time": "Day 1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 54,
              "text_snippet": "Visit: Randomisation, Timing: Day 1, Clinical Chemistry/Haematology/Urinanalysis: Xh"
            }
          },
          {
            "schedule_id": "COL-006",
            "specimen_ref": [
              "SPEC-006",
              "SPEC-007"
            ],
            "timepoint_name": "Week 2",
            "timepoint_type": "treatment",
            "relative_time": "Week 2",
            "collection_window": {
              "value": 1,
              "unit": "day",
              "description": "Within 1 day of the scheduled Week 2 visit"
            },
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 54,
              "text_snippet": "Visit: Week 2, Timing: Week 2, Visit window: +/- 1 day, Clinical Chemistry/Haematology/Urinanalysis: X"
            }
          },
          {
            "schedule_id": "COL-007",
            "specimen_ref": [
              "SPEC-004",
              "SPEC-006",
              "SPEC-007"
            ],
            "timepoint_name": "Week 4",
            "timepoint_type": "treatment",
            "relative_time": "Week 4",
            "collection_window": {
              "value": 3,
              "unit": "days",
              "description": "Within 3 days of the scheduled Week 4 visit"
            },
            "number_of_samples": 1,
            "fasting_required": true,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 56,
              "text_snippet": "Visit: Week 4, Timing: Week 4, Visit window: +/- 3 days, PK blood sample (AZD9291 and metabolites): X p"
            }
          },
          {
            "schedule_id": "COL-008",
            "specimen_ref": [
              "SPEC-003",
              "SPEC-004",
              "SPEC-006",
              "SPEC-007"
            ],
            "timepoint_name": "On treatment",
            "timepoint_type": "treatment",
            "relative_time": "Week 12 then every 12 weeks until 3 years",
            "collection_window": {
              "value": 7,
              "unit": "days",
              "description": "Within 7 days of the scheduled visit"
            },
            "number_of_samples": 13,
            "fasting_required": true,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 56,
              "text_snippet": "Visit: On treatment, Timing: Week 12 then every 12 weeks until 3 years (156 weeks), Visit window: +/-7 days, Plasma sample for ctDNA...: X, PK blood sample...: X p"
            }
          },
          {
            "schedule_id": "COL-009",
            "specimen_ref": [
              "SPEC-002",
              "SPEC-003"
            ],
            "timepoint_name": "Follow-up until disease recurrence",
            "timepoint_type": "follow_up",
            "relative_time": "Week 12, Week 24, then every 24 weeks until 5 years",
            "collection_window": {
              "value": 7,
              "unit": "days",
              "description": "Within 7 days of the scheduled visit"
            },
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "Table 1",
              "page_number": 56,
              "text_snippet": "Visit: Follow-up until disease recurrence d, Timing: Week 12, Week 24 and then every 24 weeks until 5 years (264 weeks) / yearly thereafter, Visit window: +/-7 days, Plasma sample for ctDNA...: X"
            }
          }
        ],
        "processing_requirements": [
          {
            "processing_id": "PROC-001",
            "specimen_ref": [
              "SPEC-001",
              "SPEC-002"
            ],
            "description": "Tumour sample must be formalin fixed and paraffin embedded (FFPE). Cytology samples are unsuitable for testing and should not be provided.",
            "provenance": {
              "section_number": "4.1.3",
              "page_number": 62,
              "text_snippet": "Tumour sample must be formalin fixed and paraffin embedded (FFPE). Cytology samples are unsuitable for testing and should not be provided."
            }
          },
          {
            "processing_id": "PROC-002",
            "specimen_ref": [
              "SPEC-003"
            ],
            "description": "Samples will be used for the extraction and analysis of ctDNA to explore the relationship between emergence and dynamic changes of EGFR mutation including T790M in ctDNA and time to disease recurrence.",
            "provenance": {
              "section_number": "5.7.3",
              "page_number": 77,
              "text_snippet": "All patients will be requested to provide a series of blood samples to generate plasma samples. These samples will be used for the extraction and analysis of ctDNA. The ctDNA will be used to explore the relationship between emergence and dynamic changes of EGFR mutation including T790M (as well as other known markers of TKI resistance) in ctDNA and time to disease recurrence."
            }
          },
          {
            "processing_id": "PROC-003",
            "specimen_ref": [
              "SPEC-005"
            ],
            "description": "DNA will be extracted from the blood or tumour tissue sample. The DNA sample will be assigned a unique number replacing the information on the sample tube.",
            "provenance": {
              "section_number": "Appendix D, 3.3",
              "page_number": 133,
              "text_snippet": "For all samples irrespective of the type of coding used the DNA will be extracted from the blood or tumour tissue sample. The DNA sample will be assigned a unique number replacing the information on the sample tube."
            }
          }
        ],
        "storage_requirements": [
          {
            "storage_id": "STORE-001",
            "specimen_ref": "SPEC-TUMOR-MANDATORY",
            "storage_duration": "15 years",
            "storage_temperature": null,
            "provenance": {
              "section_number": "5.7.1",
              "page_number": 77,
              "text_snippet": "Unused tumour tissue samples will be stored for a period of 15 years unless it is requested to be repatriated."
            }
          },
          {
            "storage_id": "STORE-002",
            "specimen_ref": "SPEC-BLOOD-PGX",
            "storage_duration": "15 years",
            "storage_temperature": null,
            "provenance": {
              "section_number": "5.6.2",
              "page_number": 76,
              "text_snippet": "Samples will be stored for a maximum of 15 years from the date of the last patient last visit (LPLV), after which they will be destroyed."
            }
          },
          {
            "storage_id": "STORE-003",
            "specimen_ref": "SPEC-PLASMA-CTDNA",
            "storage_duration": "15 years",
            "storage_temperature": null,
            "provenance": {
              "section_number": "5.7.4",
              "page_number": 78,
              "text_snippet": "Samples will be stored for a maximum of 15 years from the date of the LPLV, after which they will be destroyed."
            }
          }
        ],
        "shipping_requirements": [
          {
            "shipping_id": "SHIP-001",
            "specimen_ref": null,
            "shipping_conditions": "Samples are labelled and shipped in accordance with the Laboratory Manual and the Biological Substance, Category B Regulations (IATA 6.2 Guidance Document).",
            "provenance": {
              "section_number": "5.7.5",
              "page_number": 78,
              "text_snippet": "The Principal Investigator ensures that samples are labelled and shipped in accordance with the Laboratory Manual and the Biological Substance, Category B Regulations (materials containing or suspected to contain infectious substances that do not meet Category A criteria), see Appendix C ‘ International Air Transport Association (IATA) 6.2 Guidance Document’."
            }
          },
          {
            "shipping_id": "SHIP-002",
            "specimen_ref": "SPEC-TUMOR-MANDATORY",
            "shipping_conditions": "Shipped at ambient temperature directly to the testing laboratory.",
            "provenance": {
              "section_number": "5.7.5",
              "page_number": 78,
              "text_snippet": "All tumour samples should be shipped at ambient temperature as per the Laboratory Manual directly to the testing laboratory."
            }
          }
        ],
        "central_laboratory": null,
        "kit_specifications": null,
        "quality_requirements": null,
        "regulatory_requirements": null,
        "volume_summary": {
          "total_mandatory_volume": "674-844 mL",
          "specimen_category": "blood",
          "provenance": {
            "section_number": "5.2.1.1",
            "page_number": 69,
            "text_snippet": "Total mandatory blood volume in the 5 years study period (including 3 years (156 weeks) treatment) is 674-844 mL (4)."
          }
        },
        "id": "biospecimen-handling-001",
        "instanceType": "BiospecimenHandling",
        "name": "D5164C00001 Biospecimen Handling"
      },
      "_agentDocumentation": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements for central lab and biobank setup.",
        "scope": "Specimen types, tube types/volumes, processing instructions, storage conditions, shipping requirements, biobanking.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate lab kit contents from specimen requirements",
                "sourceDataPath": "specimens[]",
                "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate lab kit contents from specimen requirements",
            "sourceDataPath": "specimens[]",
            "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_BIO_SOA_001",
            "name": "Specimens + SOA → Visit-Based Lab Kits",
            "agentsInvolved": [
              "biospecimen_handling",
              "soa_schedule"
            ],
            "description": "Specimen requirements + visit schedule = visit-specific lab kit configurations",
            "combinedInsight": "What samples at which visits = Complete lab kit manifest per visit",
            "automationEnabled": "Central lab auto-generates visit-specific kit labels",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "laboratorySpecifications": {
      "moduleId": "laboratory_specifications",
      "instanceType": "LaboratorySpecifications",
      "data": {
        "id": "LS-001",
        "instanceType": "LaboratorySpecifications",
        "name": "Laboratory Specifications",
        "description": "Protocol-discovered laboratory testing requirements for study D5164C00001 (ADAURA).",
        "central_laboratory": {
          "vendor_name": "Designated central laboratory",
          "accreditations": [],
          "data_transfer_method": null,
          "provenance": {
            "section_number": "4.1",
            "page_number": 61,
            "text_snippet": "It is recommended that the screening assessments are performed in a stepwise process beginning with the confirmation of EGFR mutation status determined by the designated central laboratory."
          }
        },
        "discovered_panels": [
          {
            "panel_id": "PNL-001",
            "panel_name": "Clinical Chemistry",
            "panel_code": null,
            "panel_description": "Panel of serum/plasma chemistry tests to monitor organ function and metabolic status.",
            "panel_category": "chemistry",
            "test_count": 14,
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "Table 4 Laboratory safety variables\nClinical chemistry"
            }
          },
          {
            "panel_id": "PNL-002",
            "panel_name": "Haematology",
            "panel_code": null,
            "panel_description": "Panel of whole blood tests to assess bone marrow function and blood cell counts.",
            "panel_category": "hematology",
            "test_count": 12,
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "Table 4 Laboratory safety variables\nHaematology"
            }
          },
          {
            "panel_id": "PNL-003",
            "panel_name": "Urinalysis",
            "panel_code": null,
            "panel_description": "Panel of urine tests to assess renal function and detect abnormalities.",
            "panel_category": "urinalysis",
            "test_count": 3,
            "provenance": {
              "section_number": "Table",
              "page_number": 69,
              "text_snippet": "Urinalysis\nU-Glucose\nU-Protein\nU-Blood"
            }
          }
        ],
        "laboratory_tests": [
          {
            "test_id": "LAB-001",
            "test_name": "S/P-Albumin",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors liver function and nutritional status.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "S/P-Albumin"
            }
          },
          {
            "test_id": "LAB-002",
            "test_name": "S/P-ALT",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors liver function; key component of Hy's Law assessment.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "S/P-ALT"
            }
          },
          {
            "test_id": "LAB-003",
            "test_name": "S/P-AST",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors liver function; key component of Hy's Law assessment.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "S/P-AST"
            }
          },
          {
            "test_id": "LAB-004",
            "test_name": "S/P-Alkaline phosphatase",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors liver and bone status.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "S/P-Alkaline phosphatase"
            }
          },
          {
            "test_id": "LAB-005",
            "test_name": "S/P-Bilirubin, total",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors liver function; key component of Hy's Law assessment.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "S/P-Bilirubin, total"
            }
          },
          {
            "test_id": "LAB-006",
            "test_name": "S/P-Calcium, total",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors electrolyte balance, relevant for cardiac function.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Calcium, total"
            }
          },
          {
            "test_id": "LAB-007",
            "test_name": "S/P-Creatinine",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors renal function.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Creatinine"
            }
          },
          {
            "test_id": "LAB-008",
            "test_name": "S/P-Glucose",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": true,
            "special_handling": "Fasting (water only) for at least 8 hours required on PK days. Random glucose on non-PK days.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors glucose metabolism.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Glucose (fasting, on PK days only)a"
            }
          },
          {
            "test_id": "LAB-009",
            "test_name": "S/P-LDH",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": "Collected at Screening visit only.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "General marker of tissue damage.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-LDHb"
            }
          },
          {
            "test_id": "LAB-010",
            "test_name": "S/P-HbA1C",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors long-term glucose control.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-HbA1C"
            }
          },
          {
            "test_id": "LAB-011",
            "test_name": "S/P-Magnesium",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors electrolyte balance, relevant for cardiac function.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Magnesium"
            }
          },
          {
            "test_id": "LAB-012",
            "test_name": "S/P-Potassium",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors electrolyte balance, relevant for cardiac function.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Potassium"
            }
          },
          {
            "test_id": "LAB-013",
            "test_name": "S/P-Sodium",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors electrolyte balance.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Sodium"
            }
          },
          {
            "test_id": "LAB-014",
            "test_name": "S/P-Urea nitrogen/BUN",
            "test_code": null,
            "panel_ref": "PNL-001",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors renal function.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "S/P-Urea nitrogen/BUN"
            }
          },
          {
            "test_id": "LAB-015",
            "test_name": "B-Haemoglobin",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": "g/L",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for anemia.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "B-Haemoglobin"
            }
          },
          {
            "test_id": "LAB-016",
            "test_name": "B-Leukocyte",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors white blood cell count.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "B-Leukocyte"
            }
          },
          {
            "test_id": "LAB-017",
            "test_name": "B-Haematocrit",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors red blood cell volume.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "B-Haematocrit"
            }
          },
          {
            "test_id": "LAB-018",
            "test_name": "B-RBC count",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors red blood cell count.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "B-RBC count"
            }
          },
          {
            "test_id": "LAB-019",
            "test_name": "B-Absolute leukocyte differential count",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": "Includes Neutrophils, Lymphocytes, Monocytes, Basophils, Eosinophils.",
            "unit": "10^9/L",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors specific white blood cell populations.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 68,
              "text_snippet": "B-Absolute leukocyte differential count:"
            }
          },
          {
            "test_id": "LAB-020",
            "test_name": "B-Platelet count",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": "10^9/L",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for thrombocytopenia.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "B-Platelet count"
            }
          },
          {
            "test_id": "LAB-021",
            "test_name": "B-Reticulocytes",
            "test_code": null,
            "panel_ref": "PNL-002",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors bone marrow production of red blood cells.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "B-Reticulocytes"
            }
          },
          {
            "test_id": "LAB-022",
            "test_name": "U-Glucose",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Screens for glucosuria.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "U-Glucose"
            }
          },
          {
            "test_id": "LAB-023",
            "test_name": "U-Protein",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Screens for proteinuria.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "U-Protein"
            }
          },
          {
            "test_id": "LAB-024",
            "test_name": "U-Blood",
            "test_code": null,
            "panel_ref": "PNL-003",
            "specimen_type": "urine",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Screens for hematuria.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 69,
              "text_snippet": "U-Blood"
            }
          },
          {
            "test_id": "LAB-025",
            "test_name": "ECG",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "other",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": "12-lead ECG. 3 recordings at 5 minute intervals. Digital collection for first year.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors cardiac electrical activity, specifically QTc interval.",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 55,
              "text_snippet": "ECG i"
            }
          },
          {
            "test_id": "LAB-026",
            "test_name": "Echocardiogram/MUGA scan",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "other",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": "Assesses Left Ventricular Ejection Fraction (LVEF). Modality must be consistent throughout study.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors cardiac contractility.",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 55,
              "text_snippet": "Echocardiogram/MUGA (for LVEF)"
            }
          },
          {
            "test_id": "LAB-027",
            "test_name": "Creatinine Clearance",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": false,
            "special_handling": "Calculated by Cockcroft and Gault equation; confirmation only required when serum creatinine is >1.5xULN.",
            "unit": "mL/min",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors renal function for eligibility.",
            "provenance": {
              "section_number": "3.2",
              "page_number": 46,
              "text_snippet": "Creatinine >1.5xULN concurrent with creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is >1.5xULN."
            }
          }
        ],
        "testing_schedule": [
          {
            "schedule_id": "SCH-001",
            "test_or_panel_ref": "PNL-001",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Day -28 to Day -1",
                "conditions": null
              },
              {
                "timepoint_name": "Day 1",
                "timepoint_type": "baseline",
                "window": null,
                "conditions": "Pre-dose"
              },
              {
                "timepoint_name": "Week 2",
                "timepoint_type": "treatment",
                "window": "+/- 1 day",
                "conditions": null
              },
              {
                "timepoint_name": "Week 4",
                "timepoint_type": "treatment",
                "window": "+/- 3 days",
                "conditions": null
              },
              {
                "timepoint_name": "On treatment",
                "timepoint_type": "treatment",
                "window": "+/- 7 days",
                "conditions": "Starting at Week 12"
              }
            ],
            "frequency": "Screening, Day 1, Week 2, Week 4, then every 12 weeks until end of treatment.",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 54,
              "text_snippet": "Clinical Chemistry/Haematology/Urinalysis: X at Part II, X at Randomisation, X at Week 2, X at Week 4, X at On treatment"
            }
          },
          {
            "schedule_id": "SCH-002",
            "test_or_panel_ref": "PNL-002",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Day -28 to Day -1",
                "conditions": null
              },
              {
                "timepoint_name": "Day 1",
                "timepoint_type": "baseline",
                "window": null,
                "conditions": "Pre-dose"
              },
              {
                "timepoint_name": "Week 2",
                "timepoint_type": "treatment",
                "window": "+/- 1 day",
                "conditions": null
              },
              {
                "timepoint_name": "Week 4",
                "timepoint_type": "treatment",
                "window": "+/- 3 days",
                "conditions": null
              },
              {
                "timepoint_name": "On treatment",
                "timepoint_type": "treatment",
                "window": "+/- 7 days",
                "conditions": "Starting at Week 12"
              }
            ],
            "frequency": "Screening, Day 1, Week 2, Week 4, then every 12 weeks until end of treatment.",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 54,
              "text_snippet": "Clinical Chemistry/Haematology/Urinalysis: X at Part II, X at Randomisation, X at Week 2, X at Week 4, X at On treatment"
            }
          },
          {
            "schedule_id": "SCH-003",
            "test_or_panel_ref": "PNL-003",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Day -28 to Day -1",
                "conditions": null
              },
              {
                "timepoint_name": "Day 1",
                "timepoint_type": "baseline",
                "window": null,
                "conditions": "Pre-dose"
              },
              {
                "timepoint_name": "Week 2",
                "timepoint_type": "treatment",
                "window": "+/- 1 day",
                "conditions": null
              },
              {
                "timepoint_name": "Week 4",
                "timepoint_type": "treatment",
                "window": "+/- 3 days",
                "conditions": null
              },
              {
                "timepoint_name": "On treatment",
                "timepoint_type": "treatment",
                "window": "+/- 7 days",
                "conditions": "Starting at Week 12"
              }
            ],
            "frequency": "Screening, Day 1, Week 2, Week 4, then every 12 weeks until end of treatment.",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 54,
              "text_snippet": "Clinical Chemistry/Haematology/Urinalysis: X at Part II, X at Randomisation, X at Week 2, X at Week 4, X at On treatment"
            }
          },
          {
            "schedule_id": "SCH-004",
            "test_or_panel_ref": "LAB-025",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Day -28 to Day -1",
                "conditions": null
              },
              {
                "timepoint_name": "Day 1",
                "timepoint_type": "baseline",
                "window": null,
                "conditions": "Pre-dose"
              },
              {
                "timepoint_name": "Week 4",
                "timepoint_type": "treatment",
                "window": "+/- 3 days",
                "conditions": null
              },
              {
                "timepoint_name": "On treatment",
                "timepoint_type": "treatment",
                "window": "+/- 7 days",
                "conditions": "Starting at Week 12"
              }
            ],
            "frequency": "Screening, Day 1, Week 4, then every 12 weeks until end of treatment.",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 55,
              "text_snippet": "ECG: X at Part II, X at Randomisation, X at Week 4, X at On treatment"
            }
          },
          {
            "schedule_id": "SCH-005",
            "test_or_panel_ref": "LAB-026",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Day -28 to Day -1",
                "conditions": null
              },
              {
                "timepoint_name": "On treatment",
                "timepoint_type": "treatment",
                "window": "+/- 7 days",
                "conditions": "Starting at Week 12"
              }
            ],
            "frequency": "Screening, then every 12 weeks until end of treatment.",
            "provenance": {
              "section_number": "Table 1",
              "page_number": 55,
              "text_snippet": "Echocardiogram/MUGA (for LVEF): X at Part II, X at On treatment"
            }
          }
        ],
        "sample_collection_requirements": {
          "fasting_requirements": "Patients will be required to fast (water only) for at least 8 hours prior to the collection of a fasting glucose sample required on PK days.",
          "timing_requirements": "On site visit days on which PK samples are scheduled, the dosing should be delayed until arrival at the site.",
          "processing_requirements": "Samples will be collected, labelled, stored, and shipped as detailed in the Laboratory Manual.",
          "storage_requirements": "Biological samples will be stored for a maximum of 15 years from the date of the LPLV.",
          "shipping_requirements": "Samples are shipped as Biological Substance, Category B, in accordance with IATA 6.2 Guidance Document.",
          "provenance": {
            "section_number": "5.2.1",
            "page_number": 69,
            "text_snippet": "Patients will be required to fast (water only) for at least 8 hours prior to the collection of a fasting glucose sample required on PK days."
          }
        },
        "lab_based_dose_modifications": [
          {
            "modification_id": "MOD-001",
            "parameter_name": "General Toxicity",
            "trigger_condition": "CTCAE grade 3 or higher or unacceptable toxicities lower grades not attributable to the disease",
            "operator": "gte",
            "threshold_value": 3,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "If the toxicity resolves or reverts to <=CTCAE Grade 2 within 3 weeks of withholding, study drug may be restarted at the same dose or reduced dose (40 mg).",
            "provenance": {
              "section_number": "6.9.1",
              "page_number": 89,
              "text_snippet": "If a patient experiences a CTCAE grade 3 or higher or unacceptable toxicities lower grades...dosing will be interrupted...If the toxicity resolves or reverts to ≤CTCAE Grade 2 within 3 weeks...study drug may be restarted at the same dose (starting dose) or reduced dose 40 mg"
            }
          },
          {
            "modification_id": "MOD-002",
            "parameter_name": "General Toxicity",
            "trigger_condition": "Toxicity does not resolve to <=CTCAE Grade 2 after 3 weeks of withholding",
            "operator": "gt",
            "threshold_value": 2,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_discontinue",
            "recovery_criteria": "Patient can be withdrawn from study treatment.",
            "provenance": {
              "section_number": "6.9.1",
              "page_number": 89,
              "text_snippet": "If the toxicity does not resolve to ≤CTCAE Grade 2 after 3 weeks of withholding AZD9291/matching placebo, then the patient can be withdrawn from the study treatment"
            }
          },
          {
            "modification_id": "MOD-003",
            "parameter_name": "QTcF",
            "trigger_condition": "QTcF prolongation to >500 msec",
            "operator": "gt",
            "threshold_value": 500,
            "threshold_unit": "msec",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Restart at a reduced dose (40 mg) or at 80mg if QTcF resolves to <481 msec or recovery to baseline if baseline QTcF is >= 481 msec.",
            "provenance": {
              "section_number": "6.9.5",
              "page_number": 90,
              "text_snippet": "Patients with QTcF prolongation to >500 msec should have study treatment interrupted and regular ECGs performed until resolution to <481 msec or recovery to baseline if baseline QTcF is ≥ 481 msec and then restarted at a reduced dose (40 mg) or at 80mg"
            }
          },
          {
            "modification_id": "MOD-004",
            "parameter_name": "QTcF",
            "trigger_condition": "QTc prolongation toxicity does not resolve to <= CTCAE grade 1 within 21 days",
            "operator": "gt",
            "threshold_value": 1,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_discontinue",
            "recovery_criteria": "Patient will be permanently withdrawn from study treatment.",
            "provenance": {
              "section_number": "6.9.5",
              "page_number": 90,
              "text_snippet": "If the toxicity does not resolve to ≤ CTCAE grade 1 within 21 days the patient will be permanently withdrawn from study treatment."
            }
          },
          {
            "modification_id": "MOD-005",
            "parameter_name": "QTc Prolongation with serious arrhythmia",
            "trigger_condition": "QTc interval prolongation with signs/symptoms of serious arrhythmia",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "reference_type": null,
            "required_action": "dose_discontinue",
            "recovery_criteria": "Patient will not be permitted to restart study drug and it should be permanently discontinued.",
            "provenance": {
              "section_number": "6.9.5",
              "page_number": 90,
              "text_snippet": "Patients experiencing QTc interval prolongation with signs/symptoms of serious arrhythmia will not be permitted to restart study drug and it should be permanently discontinued."
            }
          },
          {
            "modification_id": "MOD-006",
            "parameter_name": "Interstitial lung disease (ILD)/pneumonitis",
            "trigger_condition": "Confirmed ILD/pneumonitis",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "reference_type": null,
            "required_action": "dose_discontinue",
            "recovery_criteria": "Permanently discontinued.",
            "provenance": {
              "section_number": "6.9.6",
              "page_number": 91,
              "text_snippet": "Patients experiencing confirmed ILD/pneumonitis will not be permitted to restart study drug, which should be permanently discontinued."
            }
          },
          {
            "modification_id": "MOD-007",
            "parameter_name": "Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)",
            "trigger_condition": "Diagnosed SJS or TEN",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "reference_type": null,
            "required_action": "dose_discontinue",
            "recovery_criteria": "Permanently discontinued.",
            "provenance": {
              "section_number": "6.9.2",
              "page_number": 90,
              "text_snippet": "Osimertinib should be discontinued immediately if SJS or TEN is diagnosed."
            }
          },
          {
            "modification_id": "MOD-008",
            "parameter_name": "Aplastic anaemia",
            "trigger_condition": "Confirmed aplastic anaemia",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "reference_type": null,
            "required_action": "dose_discontinue",
            "recovery_criteria": "Permanently discontinued.",
            "provenance": {
              "section_number": "6.9.3",
              "page_number": 90,
              "text_snippet": "osimertinib should be discontinued in patients with confirmed aplastic anaemia."
            }
          }
        ],
        "eligibility_lab_criteria": [
          {
            "criteria_id": "ELIG-001",
            "criteria_type": "exclusion",
            "parameter_name": "QTc",
            "condition": "Mean resting corrected QT interval (QTc) >470 msec",
            "operator": "gt",
            "threshold_value": 470,
            "threshold_unit": "msec",
            "provenance": {
              "section_number": "3.2",
              "page_number": 45,
              "text_snippet": "Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTcF value."
            }
          },
          {
            "criteria_id": "ELIG-002",
            "criteria_type": "exclusion",
            "parameter_name": "Absolute neutrophil count",
            "condition": "Absolute neutrophil count <1.5 x 10^9/L",
            "operator": "lt",
            "threshold_value": 1.5,
            "threshold_unit": "10^9/L",
            "provenance": {
              "section_number": "3.2",
              "page_number": 45,
              "text_snippet": "Absolute neutrophil count <1.5 x 10^9/L."
            }
          },
          {
            "criteria_id": "ELIG-003",
            "criteria_type": "exclusion",
            "parameter_name": "Platelet count",
            "condition": "Platelet count <100 x 10^9/L",
            "operator": "lt",
            "threshold_value": 100,
            "threshold_unit": "10^9/L",
            "provenance": {
              "section_number": "3.2",
              "page_number": 45,
              "text_snippet": "Platelet count <100 x 10^9/L."
            }
          },
          {
            "criteria_id": "ELIG-004",
            "criteria_type": "exclusion",
            "parameter_name": "Haemoglobin",
            "condition": "Haemoglobin <90 g/L",
            "operator": "lt",
            "threshold_value": 90,
            "threshold_unit": "g/L",
            "provenance": {
              "section_number": "3.2",
              "page_number": 45,
              "text_snippet": "Haemoglobin <90 g/L."
            }
          },
          {
            "criteria_id": "ELIG-005",
            "criteria_type": "exclusion",
            "parameter_name": "Alanine aminotransferase (ALT)",
            "condition": "Alanine aminotransferase (ALT) >2.5x the upper limit of normal (ULN)",
            "operator": "gt",
            "threshold_value": 2.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "3.2",
              "page_number": 45,
              "text_snippet": "Alanine aminotransferase (ALT) >2.5x the upper limit of normal (ULN)."
            }
          },
          {
            "criteria_id": "ELIG-006",
            "criteria_type": "exclusion",
            "parameter_name": "Aspartate aminotransferase (AST)",
            "condition": "Aspartate aminotransferase (AST) >2.5xULN",
            "operator": "gt",
            "threshold_value": 2.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "3.2",
              "page_number": 45,
              "text_snippet": "Aspartate aminotransferase (AST) >2.5xULN."
            }
          },
          {
            "criteria_id": "ELIG-007",
            "criteria_type": "exclusion",
            "parameter_name": "Total bilirubin",
            "condition": "Total bilirubin >1.5xULN or >3xULN in the presence of documented Gilbert’s Syndrome",
            "operator": "gt",
            "threshold_value": 1.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "3.2",
              "page_number": 46,
              "text_snippet": "Total bilirubin >1.5xULN or >3xULN in the presence of documented Gilbert’s Syndrome (unconjugated hyperbilirubinaemia)."
            }
          },
          {
            "criteria_id": "ELIG-008",
            "criteria_type": "exclusion",
            "parameter_name": "Creatinine",
            "condition": "Creatinine >1.5xULN concurrent with creatinine clearance <50 mL/min",
            "operator": "gt",
            "threshold_value": 1.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "3.2",
              "page_number": 46,
              "text_snippet": "Creatinine >1.5xULN concurrent with creatinine clearance <50 mL/min"
            }
          },
          {
            "criteria_id": "ELIG-009",
            "criteria_type": "exclusion",
            "parameter_name": "Creatinine clearance",
            "condition": "Creatinine >1.5xULN concurrent with creatinine clearance <50 mL/min",
            "operator": "lt",
            "threshold_value": 50,
            "threshold_unit": "mL/min",
            "provenance": {
              "section_number": "3.2",
              "page_number": 46,
              "text_snippet": "Creatinine >1.5xULN concurrent with creatinine clearance <50 mL/min"
            }
          }
        ],
        "critical_value_reporting": {
          "notification_timeline": "Prompt reporting of cases meeting Hy’s law criteria (via the SAE expedited reporting system) is required.",
          "notification_recipients": [
            "AstraZeneca"
          ],
          "documentation_requirements": "Details of identification of Hy’s Law cases and actions to take are detailed in Appendix E.",
          "critical_value_list": [
            {
              "parameter": "AST or ALT",
              "critical_low": null,
              "critical_high": 3,
              "unit": "xULN",
              "clinical_action": "May need to be reported as SAEs. Follow Hy's Law procedure in Appendix E."
            },
            {
              "parameter": "Total bilirubin",
              "critical_low": null,
              "critical_high": 2,
              "unit": "xULN",
              "clinical_action": "May need to be reported as SAEs. Follow Hy's Law procedure in Appendix E."
            }
          ],
          "provenance": {
            "section_number": "6.3.7",
            "page_number": 83,
            "text_snippet": "Cases where a patient shows an AST or ALT ≥3xULN or total bilirubin ≥2xULN may need to be reported as SAEs. Prompt reporting of cases meeting Hy’s law criteria (via the SAE expedited reporting system) is required for compliance with regulatory guidelines."
          }
        },
        "abnormal_result_grading": {
          "grading_system": "CTCAE",
          "grading_version": "v4",
          "clinically_significant_threshold": null,
          "ae_reporting_threshold": null,
          "provenance": {
            "section_number": "Safety Objective",
            "page_number": 11,
            "text_snippet": "Adverse events (graded by CTCAE v4)"
          }
        },
        "pregnancy_testing": {
          "required": true,
          "applicable_population": "Female patients of child-bearing potential (WoCBP)",
          "test_type": "serum or urine",
          "timing": "At Screening, prior to first dose of study drug. Further testing at Investigator's discretion.",
          "sensitivity": null,
          "action_if_positive": "Patient is not eligible for the study. If pregnancy occurs during the study, IP should be discontinued immediately.",
          "provenance": {
            "section_number": "3.1",
            "page_number": 44,
            "text_snippet": "Female patients should be using highly reliable contraceptive measures, should not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug;"
          }
        },
        "pharmacokinetic_samples": {
          "pk_sampling_required": true,
          "analytes": [
            "AZD9291",
            "AZ5104",
            "AZ7550"
          ],
          "sample_type": "plasma",
          "timepoints_description": "Blood sampling at Week 4, Week 24, and Week 48. Blood draw to occur 3 times at each visit: pre-dose, between 0.5-1.5h post dose, and between 2-4h post dose. Week 96 PK sample post IDMC7 analysis will not be collected.",
          "volume_per_sample": "2 mL each",
          "processing_requirements": "Samples will be collected, labelled, stored, and shipped as detailed in the Laboratory Manual.",
          "provenance": {
            "section_number": "5.4.1",
            "page_number": 74,
            "text_snippet": "Pharmacokinetics blood sampling (2 mL each) will be performed for all patients at pre-dose, 0.5 to 1.5 hours, and 2 to 4 hours post dose on Week 4, Week 24, Week 48 and Week 96."
          }
        },
        "biomarker_samples": {
          "biomarker_sampling_required": true,
          "biomarkers": [
            {
              "name": "EGFR mutation status",
              "purpose": "Central confirmation for eligibility, retrospective T790M testing, and exploratory analyses.",
              "sample_type": "tumour tissue (FFPE)",
              "timing": "Screening (mandatory)",
              "provenance": {
                "section_number": "4.1.3",
                "page_number": 62,
                "text_snippet": "Mandatory screening tumour biopsy sample for mutation analysis\nTumour sample must be formalin fixed and paraffin embedded (FFPE)."
              }
            },
            {
              "name": "ctDNA",
              "purpose": "Explore relationship between emergence and changes of EGFR mutation in ctDNA and time to disease recurrence.",
              "sample_type": "plasma",
              "timing": "Day 1 (pre-dose), every 12 weeks during treatment, and during follow-up until disease recurrence.",
              "provenance": {
                "section_number": "5.7.3",
                "page_number": 77,
                "text_snippet": "Collection of plasma samples for analysis: blood-borne biomarkers and circulating deoxyribonucleic acid\nAll patients will be requested to provide a series of blood samples to generate plasma samples. These samples will be used for the extraction and analysis of ctDNA."
              }
            },
            {
              "name": "Pharmacogenetics (DNA)",
              "purpose": "Explore how genetic variations may affect clinical parameters associated with AZD9291.",
              "sample_type": "whole_blood",
              "timing": "Screening (prior to first administration of AZD9291)",
              "provenance": {
                "section_number": "5.6.1",
                "page_number": 76,
                "text_snippet": "The single blood sample (10 mL) for genetic research will be obtained from the patients prior to the first administration of AZD9291 in the study."
              }
            },
            {
              "name": "Tumour biopsy at recurrence",
              "purpose": "Exploratory biomarker analyses.",
              "sample_type": "tumour tissue (FFPE)",
              "timing": "At disease recurrence (optional)",
              "provenance": {
                "section_number": "5.7.2",
                "page_number": 77,
                "text_snippet": "Collection of tumour biopsy samples at disease recurrence\nParaffin embedded tumour tissue will be collected at disease recurrence from patients who agreed with this optional assessment and if consent has been obtained for this research."
              }
            }
          ],
          "optional_consent_required": true,
          "provenance": {
            "section_number": "5.7",
            "page_number": 77,
            "text_snippet": "Exploratory research\nTumour and blood samples will be collected (as described in the Study Plan (Table 1) and may be analysed for exploratory biomarkers to assess correlations with disease activity, effects of study drug, and clinical outcomes."
          }
        },
        "local_lab_requirements": {
          "local_lab_allowed": true,
          "allowed_tests": [
            "Clinical chemistry",
            "Haematology",
            "Urinalysis"
          ],
          "certification_requirements": null,
          "provenance": {
            "section_number": "5.2.1",
            "page_number": 68,
            "text_snippet": "The clinical chemistry, haematology, and urinalysis will be performed at a local laboratory at or near to the Investigator site."
          }
        },
        "extraction_statistics": {
          "total_panels_discovered": 3,
          "total_tests_discovered": 27,
          "total_schedule_entries": 5,
          "dose_modification_rules": 8,
          "eligibility_criteria_count": 9,
          "critical_values_defined": 2
        },
        "provenance": {
          "section_number": "5.2.1",
          "page_number": 68,
          "text_snippet": "Laboratory safety assessments\nBlood and urine samples for determination of clinical chemistry, haematology, and urinalysis will be taken at the times indicated in the Study Plan Table 1."
        }
      },
      "_agentDocumentation": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, eligibility criteria, and lab-triggered dose modifications for central lab and EDC setup.",
        "scope": "Lab panels, individual tests, eligibility lab criteria, lab-triggered dose modifications, hepatotoxicity monitoring.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_PANEL_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate central lab requisition from panel definitions",
                "sourceDataPath": "panels[]",
                "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_LABELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate screening labs against eligibility criteria",
                "sourceDataPath": "eligibility_lab_criteria[]",
                "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
                "example": "ANC >= 1500/µL required for eligibility"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry",
          "Create eligibility screening lab checklists"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_PANEL_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate central lab requisition from panel definitions",
            "sourceDataPath": "panels[]",
            "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
            "example": null
          },
          {
            "ruleId": "EDC_LABELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate screening labs against eligibility criteria",
            "sourceDataPath": "eligibility_lab_criteria[]",
            "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
            "example": "ANC >= 1500/µL required for eligibility"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_LAB_SAFETY_001",
            "name": "Lab Panels + Safety Thresholds → Lab Alert System",
            "agentsInvolved": [
              "laboratory_specifications",
              "safety_decision_points"
            ],
            "description": "Lab test definitions + safety thresholds = complete lab alerting system",
            "combinedInsight": "Normal ranges + dose modification thresholds = Tiered lab alerts (normal, caution, action required)",
            "automationEnabled": "EDC displays color-coded lab values with action recommendations",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "informedConsent": {
      "moduleId": "informed_consent",
      "instanceType": "InformedConsentElements",
      "data": {
        "id": "D5164C00001-informed-consent",
        "instanceType": "InformedConsentElements",
        "name": "D5164C00001 Informed Consent Elements",
        "description": "ICF content elements for D5164C00001",
        "study_overview": {
          "study_purpose": "To assess the efficacy and safety of AZD9291 (osimertinib) versus placebo as adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer (NSCLC) with EGFR mutations, following complete tumour resection.",
          "study_duration_for_participant": "Up to 3 years of treatment, with follow-up for up to 10 years.",
          "number_of_visits": null,
          "total_time_commitment": null,
          "number_of_participants": "Approximately 700 patients will be randomised.",
          "study_locations": "The study is global, with approximately 210 sites. Approximately 60% of patients will be recruited from Asia and 40% from non-Asian countries.",
          "provenance": {
            "section_number": null,
            "page_number": 8,
            "text_snippet": "A Phase III, Double-blind, Randomised, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)"
          }
        },
        "study_procedures": {
          "screening_procedures": [
            {
              "procedure_id": "PROC-001",
              "procedure_name": "Informed Consent",
              "description": "Provision of informed consent prior to any study-specific procedures.",
              "frequency": "Once, before screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "3.1",
                "page_number": 43,
                "text_snippet": "1. Provision of informed consent prior to any study specific procedures, sampling, and analyses"
              }
            },
            {
              "procedure_id": "PROC-002",
              "procedure_name": "Tumour Sample Submission",
              "description": "A mandatory formalin-fixed, paraffin-embedded (FFPE) tumour tissue sample from the surgical resection will be sent to a central laboratory to confirm EGFR mutation status.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "4.1.3",
                "page_number": 62,
                "text_snippet": "Mandatory screening tumour biopsy sample for mutation analysis\nTumour sample must be formalin fixed and paraffin embedded (FFPE)."
              }
            },
            {
              "procedure_id": "PROC-003",
              "procedure_name": "Medical History and Demographics",
              "description": "Collection of demographic data, medical/surgical history, and smoking history.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 53,
                "text_snippet": "Demographics X\nMedical/surgical history X X"
              }
            },
            {
              "procedure_id": "PROC-004",
              "procedure_name": "Physical Examination",
              "description": "Includes height, weight, and assessment of general appearance, skin, head and neck, respiratory, cardiovascular, abdomen, lymph nodes, thyroid, musculoskeletal, and neurological systems.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.2.2",
                "page_number": 70,
                "text_snippet": "All patients will have a physical examination performed and weight assessed at the time points indicated in the Study Table 1,which includes an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), respiratory, cardiovascular, abdomen, lymph nodes, thyroid, musculoskeletal (including spine and extremities), and neurological systems."
              }
            },
            {
              "procedure_id": "PROC-005",
              "procedure_name": "Vital Signs",
              "description": "Measurement of pulse and blood pressure.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 54,
                "text_snippet": "Vital signs X Xh X X X X"
              }
            },
            {
              "procedure_id": "PROC-006",
              "procedure_name": "Laboratory Tests",
              "description": "Blood and urine samples for clinical chemistry, haematology, and urinalysis.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.2.1",
                "page_number": 68,
                "text_snippet": "Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis will be taken at the times indicated in the Study Plan Table 1."
              }
            },
            {
              "procedure_id": "PROC-007",
              "procedure_name": "Electrocardiogram (ECG)",
              "description": "A 12-lead ECG will be performed to assess cardiac function.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.2.3",
                "page_number": 70,
                "text_snippet": "Twelve-lead ECGs will be obtained after the patient has been resting semi-supine for at least 10 minutes prior to times indicated."
              }
            },
            {
              "procedure_id": "PROC-008",
              "procedure_name": "Cardiac Imaging (Echocardiogram/MUGA)",
              "description": "Assessment of Left Ventricular Ejection Fraction (LVEF).",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.2.4",
                "page_number": 71,
                "text_snippet": "An Echocardiogram or MUGA scan to assess LVEF will be performed at the visits as shown in the Study Plan (Table 1)."
              }
            },
            {
              "procedure_id": "PROC-009",
              "procedure_name": "Brain Imaging (MRI/CT)",
              "description": "An MRI or CT scan of the brain with contrast must be performed to rule out metastases.",
              "frequency": "Once, during screening (if not done prior to surgery)",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "3.1",
                "page_number": 43,
                "text_snippet": "4. MRI or CT scan of the brain must be done prior to surgery as it is considered standard of care. Patients in whom this was not done prior to surgery may still be enrolled if appropriate imaging is performed prior to randomisation, i.e., MRI or CT of brain."
              }
            },
            {
              "procedure_id": "PROC-010",
              "procedure_name": "Chest and Abdomen CT Scan",
              "description": "A baseline CT scan of the chest and abdomen (including liver and adrenal glands) with contrast to confirm no evidence of disease.",
              "frequency": "Once, during screening (within 28 days of first dose)",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "3.6",
                "page_number": 37,
                "text_snippet": "Following complete resection and prior to treatment initiation, all patients will be required to have a baseline CT scan (chest and abdomen including liver and adrenal glands) within 28 days of treatment initiation to confirm that disease is not present."
              }
            },
            {
              "procedure_id": "PROC-011",
              "procedure_name": "Pregnancy Test",
              "description": "For women of childbearing potential.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 54,
                "text_snippet": "Pregnancy test (WOCBP only)"
              }
            },
            {
              "procedure_id": "PROC-012",
              "procedure_name": "Ophthalmologic Assessment",
              "description": "Full ophthalmic assessment, including slit lamp examination.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.2.6.1",
                "page_number": 72,
                "text_snippet": "Full ophthalmic assessment, including slit lamp examination, should be performed at screening and if a patient experiences any visual symptoms (including blurring of vision), with additional tests if clinically indicated."
              }
            },
            {
              "procedure_id": "PROC-013",
              "procedure_name": "WHO Performance Status",
              "description": "Assessment of patient's functional status.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 54,
                "text_snippet": "WHO performance status"
              }
            }
          ],
          "treatment_procedures": [
            {
              "procedure_id": "PROC-014",
              "procedure_name": "Investigational Product Administration",
              "description": "Oral administration of AZD9291 (80 mg) or matching placebo once daily.",
              "frequency": "Daily for up to 3 years",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": null,
                "page_number": 14,
                "text_snippet": "AZD9291 (80 mg orally, once daily) or matching placebo, in accordance with the randomisation schedule, will be administered."
              }
            },
            {
              "procedure_id": "PROC-015",
              "procedure_name": "Safety Assessments",
              "description": "Physical examination, vital signs, and laboratory tests (blood and urine).",
              "frequency": "At baseline, Week 2, Week 4, Week 12, and every 12 weeks thereafter until treatment completion.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "3.6",
                "page_number": 37,
                "text_snippet": "Patients will undergo safety assessments at baseline, 2 weeks, 4 weeks, 12 weeks and every 12 weeks until treatment is completed or discontinued."
              }
            },
            {
              "procedure_id": "PROC-016",
              "procedure_name": "Pharmacokinetic (PK) Blood Samples",
              "description": "Blood samples to measure drug concentration.",
              "frequency": "At Week 4, 24, 48, and 96 (pre-dose and post-dose).",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.4.1",
                "page_number": 74,
                "text_snippet": "Pharmacokinetics blood sampling (2 mL each) will be performed for all patients at pre-dose, 0.5 to 1.5 hours, and 2 to 4 hours post dose on Week 4, Week 24, Week 48 and Week 96."
              }
            },
            {
              "procedure_id": "PROC-017",
              "procedure_name": "Plasma Samples for ctDNA",
              "description": "Blood samples for circulating tumor DNA and other blood-borne biomarkers.",
              "frequency": "Pre-dose on Day 1, then every 12 weeks.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 58,
                "text_snippet": "o) Plasma samples 10ml prior to first randomised dose on Day 1; 20-30 ml at every 12 weeks visits."
              }
            },
            {
              "procedure_id": "PROC-018",
              "procedure_name": "SF-36 Questionnaire",
              "description": "Patient-reported outcome questionnaire to assess health-related quality of life.",
              "frequency": "Pre-dose on Day 1, then at Week 12, Week 24, and every 24 weeks thereafter until disease recurrence.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 58,
                "text_snippet": "q) SF 36 at 12 weeks, 24 weeks and then every 24 weeks relative to randomisation (± 7 days) until disease recurrence"
              }
            },
            {
              "procedure_id": "PROC-019",
              "procedure_name": "Health Resource Use Module",
              "description": "Collection of data on healthcare resource use between visits.",
              "frequency": "At every scheduled visit during the study.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 58,
                "text_snippet": "r) Patients will be asked about any health resource use between visits (i.e., excluding routine follow-up clinic visits associated with the clinical trial but including both planned and unplanned admissions) at every scheduled visit during the study."
              }
            },
            {
              "procedure_id": "PROC-020",
              "procedure_name": "Adverse Event Review",
              "description": "Monitoring and recording of any adverse events.",
              "frequency": "At every visit",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 56,
                "text_snippet": "Adverse event review"
              }
            }
          ],
          "follow_up_procedures": [
            {
              "procedure_id": "PROC-021",
              "procedure_name": "Disease Recurrence Imaging",
              "description": "CT scans of the chest and abdomen (including liver and adrenal glands) to monitor for disease recurrence.",
              "frequency": "At Week 12, Week 24, then every 24 weeks until 5 years, and yearly thereafter.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "3.6",
                "page_number": 37,
                "text_snippet": "Patients will undergo regular radiological assessments for disease recurrence at 12 weeks, 24 weeks and then every 24 weeks until 5 years (264 weeks), then yearly thereafter."
              }
            },
            {
              "procedure_id": "PROC-022",
              "procedure_name": "Survival Follow-up",
              "description": "Contacting the patient, family, or physician to determine survival status.",
              "frequency": "Every 24 weeks until 5 years, then yearly; extension yearly to 10 years.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "4.3.4",
                "page_number": 64,
                "text_snippet": "Assessments for survival should be made every 24 weeks up to 5 years (264 weeks) after randomisation and yearly thereafter following disease recurrence."
              }
            },
            {
              "procedure_id": "PROC-023",
              "procedure_name": "28-day Safety Follow-up",
              "description": "A follow-up contact (minimum telephone) 28 days after the last dose of study drug to collect information on new or ongoing adverse events.",
              "frequency": "Once, 28 days after treatment discontinuation",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "4.3.2",
                "page_number": 63,
                "text_snippet": "As a minimum, telephone contact should be made with the patient 28 days (+ 7 days) following the discontinuation of study drug to collect new AEs and follow up on any ongoing AEs and concomitant medications (including any subsequent cancer therapy)."
              }
            },
            {
              "procedure_id": "PROC-024",
              "procedure_name": "Post-Recurrence Data Collection",
              "description": "Collection of information on subsequent anti-cancer therapies and progression data.",
              "frequency": "Following disease recurrence",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "4.3.4",
                "page_number": 64,
                "text_snippet": "In addition to the survival status, the following assessments are required post recurrence as detailed in the study plan (Table 2).\n\nAnti-cancer therapy, radiotherapy and surgery\nSerious Adverse event collection (causally related)\nSubsequent response and progression data (PFS) in accordance with local practice until the first confirmed disease progression on a subsequent treatment"
              }
            }
          ],
          "optional_procedures": [
            {
              "procedure_id": "PROC-025",
              "procedure_name": "Genetic Research Sample",
              "description": "A single blood sample (10 mL) for optional pharmacogenetics research to explore how genetic variations may affect clinical parameters.",
              "frequency": "Once, prior to first administration of study drug",
              "duration": null,
              "is_optional": true,
              "provenance": {
                "section_number": "5.6.1",
                "page_number": 76,
                "text_snippet": "The patient’s consent to participate in the pharmacogenetic research components of the study is optional.\n\nThe single blood sample (10 mL) for genetic research will be obtained from the patients prior to the first administration of AZD9291 in the study."
              }
            },
            {
              "procedure_id": "PROC-026",
              "procedure_name": "Tumour Biopsy at Disease Recurrence",
              "description": "Collection of a paraffin-embedded tumour tissue sample at the time of disease recurrence for exploratory biomarker analyses.",
              "frequency": "Once, at disease recurrence",
              "duration": null,
              "is_optional": true,
              "provenance": {
                "section_number": "5.7.2",
                "page_number": 77,
                "text_snippet": "Collection of tumour biopsy samples at disease recurrence\nParaffin embedded tumour tissue will be collected at disease recurrence from patients who agreed with this optional assessment and if consent has been obtained for this research."
              }
            },
            {
              "procedure_id": "PROC-027",
              "procedure_name": "Long-term OS Follow-up Extension",
              "description": "Participation in an optional study extension for longer-term survival follow-up until approximately 10 years after the last patient is randomized.",
              "frequency": "Yearly contacts after the main study follow-up period",
              "duration": null,
              "is_optional": true,
              "provenance": {
                "section_number": "1.7",
                "page_number": 38,
                "text_snippet": "After the final OS analysis, a study extension has been added to allow the optional longer-term survival follow-up of patients in the ADAURA trial until approximately 10 years after the last patient is randomised, which will further characterise long-term patient outcomes in the adjuvant setting. All patients in survival follow-up will be offered the opportunity to participate in the long-term OS follow-up."
              }
            }
          ],
          "provenance": {
            "section_number": "4",
            "page_number": 53,
            "text_snippet": "4. STUDY PLAN AND TIMING OF PROCEDURES"
          }
        },
        "risks": {
          "known_risks": [
            {
              "risk_id": "RISK-001",
              "risk_description": "Interstitial lung disease (ILD) or ILD-like adverse drug reactions (e.g., pneumonitis)",
              "severity": "life-threatening",
              "frequency": "common",
              "management": "Treatment interruption or permanent discontinuation. Patients with a history of ILD are excluded.",
              "provenance": {
                "section_number": null,
                "page_number": 36,
                "text_snippet": "Interstitial lung disease (ILD) or ILD-like adverse drug reactions (e.g., pneumonitis) are commonly reported (3.9% of patients in Phase I-III studies), and occasionally fatal (0.4%) for patients receiving AZD9291."
              }
            },
            {
              "risk_id": "RISK-002",
              "risk_description": "QTc interval prolongation",
              "severity": "severe",
              "frequency": null,
              "management": "Electrolyte monitoring and correction, regular ECGs, treatment interruption or dose reduction for significant prolongation.",
              "provenance": {
                "section_number": "6.9.5",
                "page_number": 90,
                "text_snippet": "In light of the potential for QT changes associated with AZD9291, electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia) must be corrected to be within normal ranges prior to first dose and electrolyte levels monitored during study treatment."
              }
            },
            {
              "risk_id": "RISK-003",
              "risk_description": "Skin reactions (e.g., rash, dry skin)",
              "severity": "moderate",
              "frequency": "very_common",
              "management": "Sun protective measures, topical or systemic medications (steroids, antibiotics). Dose adjustments for severe reactions.",
              "provenance": {
                "section_number": "6.9.2",
                "page_number": 89,
                "text_snippet": "Skin reactions\nIt is recommended that all patients follow a program of sun protective measures while receiving study drug and for 3 to 4 weeks after discontinuing study drug."
              }
            },
            {
              "risk_id": "RISK-004",
              "risk_description": "Diarrhoea",
              "severity": "moderate",
              "frequency": "very_common",
              "management": "Management based on local clinical practice. Dose adjustments for severe reactions.",
              "provenance": {
                "section_number": "6.9.4",
                "page_number": 90,
                "text_snippet": "Gastrointestinal toxicities\nNausea, vomiting, or both may be controlled with anti-emetic therapy.\nManagement of diarrhoea should be based on local clinical practice."
              }
            },
            {
              "risk_id": "RISK-005",
              "risk_description": "Aplastic anaemia",
              "severity": "life-threatening",
              "frequency": "rare",
              "management": "Monitoring for signs like fever, bruising, bleeding. Discontinuation if confirmed.",
              "provenance": {
                "section_number": "6.9.3",
                "page_number": 90,
                "text_snippet": "Aplastic anaemia\nRare reports of aplastic anaemia have been reported in association with osimertinib treatment. Some cases had a fatal outcome."
              }
            },
            {
              "risk_id": "RISK-006",
              "risk_description": "Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN)",
              "severity": "life-threatening",
              "frequency": "rare",
              "management": "Immediate discontinuation if diagnosed.",
              "provenance": {
                "section_number": null,
                "page_number": 90,
                "text_snippet": "Erythema multiforme and Stevens-Johnson syndrome, and toxic epidermal necrolysis\nCase reports of Erythema multiforme (EM) and toxic epidermal necrolysis (TEN) have been uncommonly reported, and Stevens-Johnson syndrome (SJS) have been rarely reported, in association with osimertinib treatment."
              }
            },
            {
              "risk_id": "RISK-007",
              "risk_description": "Changes in cardiac contractility (LVEF reduction)",
              "severity": "severe",
              "frequency": null,
              "management": "Cardiac monitoring for patients with risk factors.",
              "provenance": {
                "section_number": "6.9.8",
                "page_number": 91,
                "text_snippet": "Changes in cardiac contractility\nBased on the available clinical trial data, a causal relationship between effects on changes in cardiac contractility and AZD9291has not been established. In patients with cardiac risk factors and those with conditions that can affect LVEF, cardiac monitoring, including an assessment of LVEF at baseline and during treatment, should be considered."
              }
            },
            {
              "risk_id": "RISK-008",
              "risk_description": "Keratitis (eye inflammation)",
              "severity": "severe",
              "frequency": null,
              "management": "Prompt referral to an ophthalmology specialist.",
              "provenance": {
                "section_number": "6.9.7",
                "page_number": 91,
                "text_snippet": "Keratitis\nPatients presenting with signs and symptoms suggestive of keratitis such as acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye should be referred promptly to an ophthalmology specialist."
              }
            },
            {
              "risk_id": "RISK-009",
              "risk_description": "Elevated liver enzymes (AST/ALT)",
              "severity": "severe",
              "frequency": null,
              "management": "Monitoring of liver function tests. Prompt reporting of cases meeting Hy's Law criteria.",
              "provenance": {
                "section_number": "6.3.7",
                "page_number": 83,
                "text_snippet": "Hy’s Law\nCases where a patient shows an AST or ALT ≥3xULN or total bilirubin ≥2xULN may need to be reported as SAEs."
              }
            }
          ],
          "potential_risks": [],
          "reproductive_risks": "The effects of AZD9291 on an unborn baby or a nursing infant are unknown. Female patients must not be pregnant or breastfeeding and must use highly reliable contraception. Male patients must also use contraception to prevent pregnancy in their partners.",
          "unknown_risks_statement": "Details of important identified and potential risk for AZD9291 can be found in the Investigators’ brochure.",
          "risk_mitigation_measures": "Patients will be closely monitored for side effects. Dose interruptions or reductions may be used to manage toxicities. Specific management guidelines are provided for known risks like skin reactions, ILD, and QTc prolongation.",
          "provenance": {
            "section_number": "1.5",
            "page_number": 35,
            "text_snippet": "Benefit/risk and ethical assessment for conducting the ADAURA study"
          }
        },
        "benefits": {
          "potential_benefits": [
            "The preclinical and clinical profile of AZD9291 suggest that it could offer prolonged disease-free survival (DFS) in the adjuvant EGFRm+ NSCLC setting."
          ],
          "no_benefit_statement": "Although there can be no certainty of clinical benefit to patients, success of other targeted agents in the adjuvant setting... all support the notion that EGFR mutation inhibition may be a valid strategy.",
          "societal_benefits": "The study aims to provide definitive evidence of the clinical utility of AZD9291 in this setting, which could help future patients with this type of lung cancer.",
          "provenance": {
            "section_number": "1.5",
            "page_number": 35,
            "text_snippet": "Benefit/risk and ethical assessment for conducting the ADAURA study"
          }
        },
        "alternatives": {
          "alternative_treatments": [
            {
              "treatment_name": "Standard of Care",
              "description": "Adjuvant post-operative platinum-based chemotherapy is a standard of care in patients with resected stage II and III NSCLC. The benefit in stage IB remains uncertain.",
              "provenance": {
                "section_number": null,
                "page_number": 27,
                "text_snippet": "Based on these findings, adjuvant post-operative platinum-based chemotherapy has become a standard of care in patients with resected stage II and III NSCLC. The benefit of post-operative chemotherapy in patients with stage IB NSCLC remains uncertain."
              }
            }
          ],
          "no_treatment_option": true,
          "standard_of_care_description": "No EGFR-TKI is currently approved for the adjuvant treatment of completely resected EGFR m+ NSCLC. Standard of care may include adjuvant chemotherapy.",
          "provenance": {
            "section_number": "1.2",
            "page_number": 31,
            "text_snippet": "It is appropriate to select placebo as a comparator as no EGFR-TKI is currently approved for the adjuvant treatment of completely resected EGFR m+ NSCLC."
          }
        },
        "compensation_costs": {
          "participant_compensation": null,
          "payment_schedule": null,
          "travel_reimbursement": null,
          "participant_costs": [],
          "covered_costs": [
            "The investigational product (AZD9291 or placebo) will be supplied by the sponsor, AstraZeneca."
          ],
          "injury_compensation": null,
          "provenance": {
            "section_number": "10.4",
            "page_number": 112,
            "text_snippet": "Ensure that any incentives for patients who participate in the study as well as any provisions for patients harmed as a consequence of study participation are described in the informed consent form that is approved by an EC/IRB."
          }
        },
        "confidentiality": {
          "data_protection_statement": "The ICF will incorporate wording that complies with relevant data protection and privacy legislation. Extra precautions are taken to preserve confidentiality and prevent genetic data being linked to the identity of the patient.",
          "who_has_access": [
            "AstraZeneca representatives",
            "Regulatory authorities (e.g., FDA)",
            "Ethics Committees (EC/IRB)",
            "Investigator and study site staff"
          ],
          "hipaa_authorization": null,
          "data_retention_period": "A minimum of 25 years after study archiving.",
          "international_data_transfer": true,
          "data_sharing": "Results of this biomarker research may be pooled with biomarker data from other studies. Any results both technical and lay summaries for this trial, will be submitted to EU CTIS. A description of this clinical study will be available on public registries like clinicaltrials.gov.",
          "provenance": {
            "section_number": "10.2",
            "page_number": 110,
            "text_snippet": "Patient data protection\nThe ICF will incorporate (or, in some cases, be accompanied by a separate document incorporating) wording that complies with relevant data protection and privacy legislation."
          }
        },
        "voluntary_participation": {
          "voluntary_statement": "Provision of informed consent prior to any study specific procedures, sampling, and analyses is required. Participation is voluntary.",
          "withdrawal_rights": "Patients are free to withdraw from the study at any time, without prejudice to further treatment. A patient who decides to discontinue IP treatment will always be asked about the reason(s).",
          "withdrawal_consequences": "On discontinuation of randomised study drug, patients will be treated in accordance with the local Standard of Care.",
          "data_after_withdrawal": "For patients who withdraw consent entirely, the vital status may still be obtained from publicly available resources where possible under local laws. If a patient withdraws consent for donated biological samples, the samples will be repatriated/destroyed.",
          "provenance": {
            "section_number": "3.11",
            "page_number": 51,
            "text_snippet": "Criteria for withdrawal from study\nAt any time, patients are free to withdraw from the study without prejudice to further treatment."
          }
        },
        "special_consents": {
          "genetic_testing": {
            "required": false,
            "description": "Patients will be given the option to consent to the host pharmacogenetics research component of the study. A blood sample will be collected to explore how genetic variations may affect efficacy, safety, and tolerability.",
            "opt_out_allowed": true,
            "future_use": true,
            "results_disclosure": "AstraZeneca will not provide individual genotype results to patients, any insurance company, any employer, their family members, general physician or any other third party, unless required to do so by law.",
            "provenance": {
              "section_number": "5.6",
              "page_number": 76,
              "text_snippet": "If a patient agrees to participate in the host pharmacogenetics research component of the study, a blood sample will be collected."
            }
          },
          "biobanking": {
            "required": false,
            "storage_duration": "Up to 15 years from the date of the last patient last visit (LPLV).",
            "future_research_use": true,
            "commercialization_statement": null,
            "destruction_option": true,
            "provenance": {
              "section_number": "5.7.4",
              "page_number": 78,
              "text_snippet": "Samples will be stored for a maximum of 15 years from the date of the LPLV, after which they will be destroyed. The results of this biomarker research will be reported either in the CSR itself or as an addendum, or separately in a scientific report or publication. The results of this biomarker research may be pooled with biomarker data from other studies with the study drug to generate hypotheses to be tested in future research."
            }
          },
          "photography_recording": {
            "required": false,
            "purpose": "To record any clinically significant ophthalmologic findings.",
            "usage": "Photographs should be available for central review by AstraZeneca and AstraZeneca representatives if necessary.",
            "provenance": {
              "section_number": "5.2.6.1",
              "page_number": 72,
              "text_snippet": "Photographs should be performed to record any clinically significant findings. These photographs should be available for central review by AstraZeneca and AstraZeneca representatives if necessary."
            }
          },
          "provenance": {
            "section_number": "10.4",
            "page_number": 112,
            "text_snippet": "Informed consent"
          }
        },
        "contacts": {
          "study_questions_contact": "If there is equivocal progression medical monitor/study physician should be contacted.",
          "rights_questions_contact": "The protocol and other relevant documents must be submitted to an IRB/IEC for review and approval.",
          "emergency_contact": null,
          "twenty_four_hour_contact": null,
          "provenance": {
            "section_number": "10.3",
            "page_number": 111,
            "text_snippet": "An Ethics Committee (EC)/IRB should approve the final study protocol, including the final version of the ICF and any other written information and/or materials to be provided to the patients."
          }
        },
        "reproductive_requirements": {
          "pregnancy_testing_required": true,
          "contraception_requirements": "Female patients of child-bearing potential should use highly reliable methods of contraception.",
          "contraception_duration": "From the time of screening until 6 weeks after discontinuing study drug.",
          "pregnancy_reporting": "All pregnancies and outcomes of pregnancy should be reported to AstraZeneca during the study and within 6 weeks of the last dose of AZD9291.",
          "breastfeeding_restrictions": "Female patients should not be breast feeding.",
          "male_requirements": "Male patients should use barrier contraceptives (i.e., condoms) during sex with all partners during the trial and for a washout period of 4 months after completion of study drug. They should also refrain from donating sperm during this period.",
          "provenance": {
            "section_number": "3.9",
            "page_number": 49,
            "text_snippet": "1. Female patients of child-bearing potential should use highly reliable methods of contraception from the time of screening until 6 weeks after discontinuing study drug.\n2. Male patients should be asked to use barrier contraceptives (i.e., by use of condoms) during sex with all partners during the trial and for a washout period of 4 months."
          }
        },
        "extraction_statistics": {
          "has_risks": true,
          "has_benefits": true,
          "has_alternatives": true,
          "has_compensation": true,
          "has_genetic_consent": true,
          "has_biobanking": true,
          "risk_count": 9,
          "procedure_count": 27
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Revised Clinical Study Protocol\nDrug Substance AZD9291\nStudy Code D5164C00001\nEdition Number 6.0\nDate 09 August 2023"
        }
      },
      "_agentDocumentation": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements for ICF template generation and IRB submission.",
        "scope": "Key risks, potential benefits, treatment alternatives, compensation, genetic/biobanking consents, witness requirements.",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "proSpecifications": {
      "moduleId": "pro_specifications",
      "instanceType": "PROSpecifications",
      "data": {
        "id": "D5164C00001-pro-specifications",
        "instanceType": "PROSpecifications",
        "name": "D5164C00001 PRO Specifications",
        "description": "PRO/COA specifications for D5164C00001",
        "pro_instruments": [
          {
            "instrument_id": "PRO-001",
            "instrument_name": "SF-36 Health Survey Version 2",
            "instrument_abbreviation": "SF-36",
            "instrument_type": "generic_hrqol",
            "instrument_version": "2.0",
            "copyright_holder": "QualityMetric Incorporated",
            "license_required": true,
            "administration": {
              "mode": "paper",
              "device_type": "paper",
              "completion_location": "clinic",
              "language_versions": null,
              "estimated_completion_time": null,
              "provenance": {
                "section_number": "5.3.4.1",
                "page_number": 73,
                "text_snippet": "Patients will be asked to complete a paper based version of the SF-36 v 2 standard (Appendix G) at the clinic according to the Study Plan (Table 1)."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Randomisation",
                  "visit_reference": "Day 1 (pre-dose)",
                  "window_before_days": 0,
                  "window_after_days": 1,
                  "is_required": true,
                  "provenance": {
                    "section_number": null,
                    "page_number": 56,
                    "text_snippet": "SF - 36: X (pre dose) [under Randomisation column, Day 1]"
                  }
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Week 12",
                  "visit_reference": "Week 12",
                  "window_before_days": 7,
                  "window_after_days": 7,
                  "is_required": true,
                  "provenance": {
                    "section_number": null,
                    "page_number": 58,
                    "text_snippet": "q) SF 36 at 12 weeks, 24 weeks and then every 24 weeks relative to randomisation (± 7 days) until disease recurrence"
                  }
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Week 24",
                  "visit_reference": "Week 24",
                  "window_before_days": 7,
                  "window_after_days": 7,
                  "is_required": true,
                  "provenance": {
                    "section_number": null,
                    "page_number": 58,
                    "text_snippet": "q) SF 36 at 12 weeks, 24 weeks and then every 24 weeks relative to randomisation (± 7 days) until disease recurrence"
                  }
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Every 24 weeks until disease recurrence",
                  "visit_reference": "Every 24 weeks",
                  "window_before_days": 7,
                  "window_after_days": 7,
                  "is_required": true,
                  "provenance": {
                    "section_number": null,
                    "page_number": 58,
                    "text_snippet": "q) SF 36 at 12 weeks, 24 weeks and then every 24 weeks relative to randomisation (± 7 days) until disease recurrence"
                  }
                }
              ],
              "recall_period": "past 4 weeks",
              "completion_window_hours": null,
              "provenance": {
                "section_number": "5.3.4.1",
                "page_number": 73,
                "text_snippet": "The standard version of SF-36 (Appendix G) has a recall period of four weeks."
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Physical Functioning (PF)",
                  "domain_description": "Domain for physical functioning",
                  "items_included": [
                    "3a",
                    "3b",
                    "3c",
                    "3d",
                    "3e",
                    "3f",
                    "3g",
                    "3h",
                    "3i",
                    "3j"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": true
                },
                {
                  "domain_name": "Role-Physical (RP)",
                  "domain_description": "Domain for role limitations due to physical health",
                  "items_included": [
                    "4a",
                    "4b",
                    "4c",
                    "4d"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": false
                },
                {
                  "domain_name": "Bodily Pain (BP)",
                  "domain_description": "Domain for bodily pain",
                  "items_included": [
                    "7",
                    "8"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": true
                },
                {
                  "domain_name": "General Health (GH)",
                  "domain_description": "Domain for general health perceptions",
                  "items_included": [
                    "1",
                    "11a",
                    "11b",
                    "11c",
                    "11d"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": true
                },
                {
                  "domain_name": "Vitality (VT)",
                  "domain_description": "Domain for vitality (energy/fatigue)",
                  "items_included": [
                    "9a",
                    "9e",
                    "9g",
                    "9i"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": true
                },
                {
                  "domain_name": "Social Functioning (SF)",
                  "domain_description": "Domain for social functioning",
                  "items_included": [
                    "6",
                    "10"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": true
                },
                {
                  "domain_name": "Role-Emotional (RE)",
                  "domain_description": "Domain for role limitations due to emotional problems",
                  "items_included": [
                    "5a",
                    "5b",
                    "5c"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": false
                },
                {
                  "domain_name": "Mental Health (MH)",
                  "domain_description": "Domain for mental health",
                  "items_included": [
                    "9b",
                    "9c",
                    "9d",
                    "9f",
                    "9h"
                  ],
                  "score_range": "0-100",
                  "higher_is_better": true
                },
                {
                  "domain_name": "Physical Component Summary (PCS)",
                  "domain_description": "Aggregated summary score for physical health",
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": true
                },
                {
                  "domain_name": "Mental Component Summary (MCS)",
                  "domain_description": "Aggregated summary score for mental health",
                  "items_included": null,
                  "score_range": null,
                  "higher_is_better": true
                }
              ],
              "total_score_available": false,
              "scoring_algorithm": "Raw scores are transformed via a weighting system to a 0-100 domain score.",
              "mcid": null,
              "responder_definition": null,
              "provenance": {
                "section_number": "5.3.4.2",
                "page_number": 73,
                "text_snippet": "The eight domains of the SF-36v2 standard includes items as described previously. The items use Likert scales with 3-6 points. Raw scores for the scales are computed across items in the same domain and are then transformed via a weighting system to a 0-100 domain with higher scores indicating better health."
              }
            },
            "missing_data": null,
            "training_requirements": {
              "site_training_required": true,
              "patient_training_required": false,
              "training_materials": [
                "Standardized procedure for administration"
              ],
              "provenance": {
                "section_number": "5.3.4.3",
                "page_number": 73,
                "text_snippet": "Appropriate procedures for minimising bias and enhancing compliance will be followed throughout the study. To ensure this, all study personnel will be trained to instruct the patient in a standardised way and further be responsible for providing all relevant instructions and training to the patients. A standardised procedure for the administration of the PRO questionnaire should be applied."
              }
            },
            "provenance": {
              "section_number": "5.3.4.1",
              "page_number": 73,
              "text_snippet": "The PRO questionnaire used in this study is SF-36. Patients will be asked to complete a paper based version of the SF-36 v 2 standard (Appendix G) at the clinic according to the Study Plan (Table 1). The SF-36 v2 is a validated instrument measuring general health status."
            }
          },
          {
            "instrument_id": "PRO-002",
            "instrument_name": "Health Resource Use Module",
            "instrument_abbreviation": "HRUM",
            "instrument_type": "utility",
            "instrument_version": null,
            "copyright_holder": null,
            "license_required": false,
            "administration": {
              "mode": "interviewer",
              "device_type": "paper",
              "completion_location": "clinic",
              "language_versions": null,
              "estimated_completion_time": null,
              "provenance": {
                "section_number": "5.3.4.4",
                "page_number": 74,
                "text_snippet": "Healthcare Resource Use Module will be completed by the investigational site for any healthcare resource use between visits. The site will ask patients for any health resource use between visits (i.e., excluding routine follow-up clinic visits associated with the clinical trial but including both planned and unplanned admissions) during treatment period."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-005",
                  "timepoint_name": "Every scheduled visit during the study",
                  "visit_reference": "Day 1, Wk 2, Wk 4, Wk 12, then every 12 weeks",
                  "window_before_days": 7,
                  "window_after_days": 7,
                  "is_required": true
                }
              ],
              "recall_period": "between visits",
              "completion_window_hours": null,
              "provenance": {
                "section_number": null,
                "page_number": 58,
                "text_snippet": "r) Patients will be asked about any health resource use between visits (i.e., excluding routine follow-up clinic visits associated with the clinical trial but including both planned and unplanned admissions) at every scheduled visit during the study."
              }
            },
            "scoring": null,
            "missing_data": null,
            "training_requirements": null,
            "provenance": {
              "section_number": "5.3.4.4",
              "page_number": 74,
              "text_snippet": "Health Resource Use Module"
            }
          }
        ],
        "epro_system": null,
        "clinro_instruments": [
          {
            "instrument_id": "CLINRO-001",
            "instrument_name": "WHO Performance Status",
            "assessor": "investigator",
            "training_certification_required": false,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Screening",
              "Randomisation (Day 1)",
              "Week 2",
              "Week 4",
              "On treatment (every 12 weeks)",
              "Treatment Discontinuation",
              "Follow-up until disease recurrence"
            ],
            "provenance": {
              "section_number": "5.3.1",
              "page_number": 72,
              "text_snippet": "Performance status will be assessed at the scheduled visits indicated in the Study Plan (Table 1) according to WHO criteria as follows:"
            }
          },
          {
            "instrument_id": "CLINRO-002",
            "instrument_name": "Common Terminology Criteria for Adverse Events",
            "instrument_abbreviation": "CTCAE",
            "instrument_version": "4.0",
            "assessor": "investigator",
            "training_certification_required": false,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Ongoing for all adverse events"
            ],
            "provenance": {
              "section_number": "2.3",
              "page_number": 11,
              "text_snippet": "Safety Objective: To assess the safety and tolerability profile of AZD9291 compared with placebo\nOutcome Measure: Adverse events (graded by CTCAE v4)"
            }
          }
        ],
        "obsro_instruments": [],
        "perfo_instruments": [],
        "daily_diary": null,
        "analysis_specifications": {
          "primary_pro_endpoint": null,
          "secondary_pro_endpoints": [
            "Changes in generic HRQoL as measured by the SF-36 (vers2, standard)"
          ],
          "analysis_population": "Full Analysis Set (FAS)",
          "statistical_methods": [
            "Summarised in terms of mean changes from baseline at each post-baseline assessment for all SF-36 domain and summary scores."
          ],
          "sensitivity_analyses": [],
          "responder_analysis_planned": false,
          "time_to_event_analysis_planned": false,
          "provenance": {
            "section_number": "8.5.3",
            "page_number": 104,
            "text_snippet": "The scores for each of the 8 health domain scores and for each of the physical and mental component summary measures from the SF-36 v2 will be summarised in terms of mean changes from baseline at each post-baseline assessment."
          }
        },
        "extraction_statistics": {
          "pro_instrument_count": 2,
          "clinro_count": 2,
          "obsro_count": 0,
          "perfo_count": 0,
          "has_epro": false,
          "has_daily_diary": false,
          "total_assessment_timepoints": 14
        },
        "provenance": {
          "section_number": "5.3.4",
          "page_number": 73,
          "text_snippet": "Patient Reported Outcomes"
        }
      },
      "_agentDocumentation": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome specifications for ePRO/eCOA vendor configuration.",
        "scope": "PRO instruments, ePRO system config, ClinRO/ObsRO/PerfO instruments, daily diaries, compliance thresholds.",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EPRO_CONFIG_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Patient-Reported Outcomes",
                "description": "Generate ePRO vendor configuration from PRO specifications",
                "sourceDataPath": "pro_instruments[]",
                "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "EPRO_CONFIG_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Patient-Reported Outcomes",
            "description": "Generate ePRO vendor configuration from PRO specifications",
            "sourceDataPath": "pro_instruments[]",
            "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_PRO_SOA_001",
            "name": "PRO + SOA → Complete ePRO Schedule",
            "agentsInvolved": [
              "pro_specifications",
              "soa_schedule"
            ],
            "description": "PRO instruments + visit timing = exact ePRO administration schedule",
            "combinedInsight": "Which PRO at which visit with what window = Complete ePRO schedule",
            "automationEnabled": "ePRO system auto-schedules assessments based on subject visit dates",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "dataManagement": {
      "moduleId": "data_management",
      "instanceType": "DataManagement",
      "data": {
        "id": "D5164C00001-data-management",
        "instanceType": "DataManagementPlan",
        "name": "D5164C00001 Data Management Plan",
        "edc_specifications": {
          "instanceType": "EDCSpecifications",
          "vendor_name": "PAREXEL",
          "system_capabilities": [
            "randomization",
            "ePRO",
            "central_lab_integration",
            "IWRS_integration",
            "safety_database_integration",
            "coding_integration",
            "audit_trail",
            "electronic_signature"
          ],
          "integration_systems": [
            {
              "id": "integration-001",
              "system_type": "IWRS",
              "vendor_name": null,
              "transfer_frequency": "real_time",
              "transfer_method": "IVRS/IWRS",
              "provenance": {
                "section_number": "3.6",
                "page_number": 48,
                "text_snippet": "Eligible patients will be centrally randomised to receive either 80 mg AZD9291 orally once daily or matching placebo in a 1:1 ratio using the IVRS/IWRS system."
              }
            },
            {
              "id": "integration-002",
              "system_type": "central_lab",
              "vendor_name": null,
              "transfer_frequency": "per_visit",
              "transfer_method": "SFTP",
              "provenance": {
                "section_number": "4.1.3",
                "page_number": 62,
                "text_snippet": "This biopsy sample will be submitted for central testing in pre-screening period (Screening Part I)."
              }
            },
            {
              "id": "integration-003",
              "system_type": "safety_database",
              "vendor_name": "AstraZeneca Patient Safety",
              "transfer_frequency": "real_time",
              "transfer_method": "Automated email alert",
              "provenance": {
                "section_number": "6.4",
                "page_number": 84,
                "text_snippet": "Once the Investigators or other site personnel indicate an AE is serious in the EDC system, an automated email alert is sent to the designated AstraZeneca representative."
              }
            },
            {
              "id": "integration-004",
              "system_type": "coding_system",
              "vendor_name": "PAREXEL",
              "transfer_frequency": null,
              "transfer_method": "Internal",
              "provenance": {
                "section_number": "9.4",
                "page_number": 108,
                "text_snippet": "Adverse events and medical/surgical history will be classified according to the terminology of the latest version of MedDRA. Medications will be classified according to the AstraZeneca Drug Dictionary. Classification coding will be performed by the Medical Coding Team at PAREXEL (or alternate vendor)."
              }
            }
          ],
          "language_requirements": [
            "English"
          ],
          "crf_modules": [
            {
              "id": "crf-001",
              "module_name": "Screening and Enrollment",
              "forms": [
                "Informed Consent",
                "Inclusion/Exclusion Criteria",
                "Demographics",
                "Medical/Surgical History",
                "Smoking History"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 53,
                "text_snippet": "Table 1 Study plan up to completion of final DFS analysis"
              }
            },
            {
              "id": "crf-002",
              "module_name": "Baseline Assessments",
              "forms": [
                "Physical Examination",
                "WHO Performance Status",
                "Vital Signs",
                "ECG",
                "Echocardiogram/MUGA",
                "Ophthalmologic Assessment",
                "Pregnancy Test"
              ],
              "visit_schedule": [
                "Screening",
                "Day 1"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 54,
                "text_snippet": "Table 1 Study plan up to completion of final DFS analysis"
              }
            },
            {
              "id": "crf-003",
              "module_name": "Treatment and Dosing",
              "forms": [
                "Study Drug Administration",
                "Treatment Dispensed/Returned"
              ],
              "visit_schedule": [
                "Day 1",
                "Week 2",
                "Week 4",
                "On treatment"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 56,
                "text_snippet": "Treatment dispensed/returned"
              }
            },
            {
              "id": "crf-004",
              "module_name": "Safety Assessments",
              "forms": [
                "Adverse Events",
                "Serious Adverse Events",
                "Concomitant Medications",
                "Clinical Laboratory Results",
                "Vital Signs",
                "ECG",
                "Echocardiogram/MUGA"
              ],
              "visit_schedule": [
                "Day 1",
                "Week 2",
                "Week 4",
                "On treatment",
                "Treatment discontinuation",
                "28 day Follow up"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 56,
                "text_snippet": "Adverse event review; Concomitant medication"
              }
            },
            {
              "id": "crf-005",
              "module_name": "Efficacy Assessments",
              "forms": [
                "Tumor Assessments (CT/MRI)",
                "Disease Recurrence",
                "Survival Status"
              ],
              "visit_schedule": [
                "On treatment",
                "Follow-up until disease recurrence",
                "Follow up for survival"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 55,
                "text_snippet": "CT of Chest and abdomen (including liver and adrenal glands) with contrast for disease control"
              }
            },
            {
              "id": "crf-006",
              "module_name": "Pharmacokinetics and Biomarkers",
              "forms": [
                "PK Blood Sample Collection",
                "Plasma Sample for ctDNA Collection"
              ],
              "visit_schedule": [
                "Day 1",
                "Week 4",
                "On treatment"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 56,
                "text_snippet": "Plasma sample for ctDNA and blood borne biomarkers; PK blood sample (AZD9291 and metabolites)"
              }
            },
            {
              "id": "crf-007",
              "module_name": "Patient Reported Outcomes",
              "forms": [
                "SF-36",
                "Health Resource Use Module"
              ],
              "visit_schedule": [
                "Day 1",
                "On treatment"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1",
                "page_number": 56,
                "text_snippet": "SF - 36; Health Resource Module"
              }
            },
            {
              "id": "crf-008",
              "module_name": "Study Discontinuation",
              "forms": [
                "End of Treatment",
                "End of Study"
              ],
              "visit_schedule": [
                "Treatment discontinuation"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "3.12",
                "page_number": 52,
                "text_snippet": "Discontinuation of the study\nThe study may be stopped if, in the judgment of AstraZeneca, study patients are placed at undue risk because of clinically significant findings"
              }
            }
          ],
          "provenance": {
            "section_number": "9.4",
            "page_number": 108,
            "text_snippet": "Data management will be performed by PAREXEL (or alternate vendor) according to the Data Management Plan."
          }
        },
        "data_standards": {
          "instanceType": "DataStandards",
          "sdtm_version": null,
          "sdtm_ig_version": null,
          "adam_version": null,
          "controlled_terminology": {
            "cdisc_ct_version": null,
            "meddra_version": "latest version",
            "whodrug_version": null,
            "snomed_version": null
          },
          "define_xml_required": false,
          "define_xml_version": null,
          "adrg_required": false,
          "sdrg_required": false,
          "provenance": {
            "section_number": "9.4",
            "page_number": 108,
            "text_snippet": "Adverse events and medical/surgical history will be classified according to the terminology of the latest version of MedDRA. Medications will be classified according to the AstraZeneca Drug Dictionary."
          }
        },
        "data_quality": {
          "instanceType": "DataQuality",
          "edit_checks": {
            "standard_checks": [
              "range_checks",
              "consistency_checks",
              "required_fields",
              "date_logic"
            ],
            "protocol_specific_checks": [],
            "auto_query_enabled": true
          },
          "sdv_strategy": {
            "approach": "hybrid",
            "sdv_percentage": null,
            "critical_data_points": [
              "Informed Consent",
              "Eligibility Criteria",
              "Primary Endpoint (DFS)",
              "SAEs",
              "Deaths",
              "Study Drug Administration"
            ],
            "sdv_timing": "hybrid"
          },
          "query_management": {
            "resolution_target_days": null,
            "escalation_threshold_days": null,
            "auto_query_triggers": [
              "Missing required field",
              "Inconsistent data"
            ]
          },
          "data_review": {
            "medical_review_frequency": null,
            "statistical_review_frequency": null,
            "data_review_committee": true
          },
          "provenance": {
            "section_number": "9.2",
            "page_number": 106,
            "text_snippet": "Perform source data verification (a comparison of the data in the eCRFs with the patient’s medical records at the hospital or practice, and other records relevant to the study) including verification of informed consent of participating patients. This will require direct access to all original records for each patient (e.g., clinic charts)."
          }
        },
        "database_management": {
          "instanceType": "DatabaseManagement",
          "database_design": {
            "external_data_sources": [
              "central_lab",
              "ECG",
              "IWRS",
              "ePRO"
            ],
            "calculated_fields": [
              "Creatinine Clearance"
            ],
            "derived_variables": [
              "Disease-free survival (DFS)",
              "Overall Survival (OS)",
              "Progression-free survival (PFS)",
              "Time to first subsequent therapy (TFST)",
              "Time to second subsequent therapy (TSST)"
            ]
          },
          "interim_locks": [
            {
              "id": "lock-001",
              "lock_name": "Unplanned Interim Analysis for Superiority (IDMC7)",
              "trigger": "IDMC recommendation after 7th meeting",
              "scope": "partial",
              "provenance": {
                "section_number": "1.4",
                "page_number": 35,
                "text_snippet": "Unplanned Interim Analysis of ADAURA (IDMC7)\nFollowing the recommendation of the IDMC after their 7th meeting, an interim analysis was conducted with a DCO of 17 January 2020 (Wu et al 2020)."
              }
            }
          ],
          "final_database_lock": {
            "trigger_event": "All data have been coded, validated, signed, and locked",
            "timeline_days_from_lplv": null,
            "prerequisites": [
              "All data coded",
              "All data validated",
              "All queries resolved",
              "SAE reconciliation completed",
              "Investigator signatures obtained"
            ],
            "signoff_required": [],
            "provenance": {
              "section_number": "9.4",
              "page_number": 108,
              "text_snippet": "When all data have been coded, validated, signed, and locked, clean file will be declared. Any treatment revealing data may thereafter be added and the final database will be locked."
            }
          },
          "provenance": {
            "section_number": "8.4.1",
            "page_number": 99,
            "text_snippet": "8.4.1.1 DFS\nDFS is defined as the time from the date of randomisation until the date of disease recurrence or death (by any cause in the absence of recurrence).\n8.4.1.2 OS\nOS is defined as the time from the date of randomisation until date of death due to any cause.\n8.4.1.3 Progression-free survival (PFS) (exploratory)\nPFS is defined as the time from the date of randomisation to the date of disease progression or death."
          }
        },
        "data_transfers": {
          "instanceType": "DataTransfers",
          "central_lab": {
            "vendor_name": null,
            "transfer_frequency": "per_visit",
            "transfer_method": "Physical sample shipment",
            "data_reconciliation": true
          },
          "imaging": {
            "vendor_name": null,
            "data_collected": [
              "CT scans",
              "MRI"
            ],
            "transfer_method": null
          },
          "epro": {
            "vendor_name": null,
            "transfer_frequency": "per_visit",
            "instruments_collected": [
              "SF-36"
            ]
          },
          "external_adjudication": null,
          "dsmb_exports": {
            "export_frequency": "per_meeting",
            "unblinded_access": true,
            "data_included": [
              "Safety data",
              "Adverse events",
              "Serious adverse events",
              "Futility analysis outcomes"
            ],
            "provenance": {
              "section_number": "6.10.1",
              "page_number": 91,
              "text_snippet": "An Independent Data Monitoring Committee (IDMC) will be convened and will meet approximately every 6 months for the first 2 years from the first patient randomised and approximately yearly thereafter. ... The IDMC will review safety assessments and make recommendations to continue, amend, or stop the study based on safety findings. Serious adverse events, adverse events, and other safety data will be reviewed... an IDMC will review the futility analysis outcomes..."
            }
          },
          "provenance": {
            "section_number": "9.4",
            "page_number": 108,
            "text_snippet": "The data collected through third party sources will be obtained and reconciled against study data."
          }
        },
        "data_archival": {
          "instanceType": "DataArchival",
          "retention_period_years": 25,
          "retention_basis": "AstraZeneca Global Retention and Disposal Schedule and local regulations",
          "archival_format": [
            "electronic"
          ],
          "archival_location": "sponsor",
          "destruction_policy": "No records may be destroyed during the retention period without the written approval of AstraZeneca.",
          "provenance": {
            "section_number": "9.2.3",
            "page_number": 107,
            "text_snippet": "Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator for a minimum of 25 years after study archiving or as required by local regulations, according to the AstraZeneca Global Retention and Disposal Schedule. No records may be destroyed during the retention period without the written approval of AstraZeneca."
          }
        },
        "extraction_statistics": {
          "has_edc_specifications": true,
          "has_data_standards": true,
          "has_sdv_strategy": true,
          "has_database_lock_plan": true,
          "integration_count": 4,
          "crf_module_count": 8
        },
        "provenance": {
          "section_number": "9",
          "page_number": 106,
          "text_snippet": "9. STUDY AND DATA MANAGEMENT"
        }
      },
      "_agentDocumentation": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications for EDC setup and data management planning.",
        "scope": "EDC requirements, CDISC standards versions, data entry timelines, query management, database lock procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines",
          "Set up CDISC standards compliance checks"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "siteOperationsLogistics": {
      "moduleId": "site_operations_logistics",
      "instanceType": "SiteOperationsLogistics",
      "data": {
        "id": "D5164C00001-site-operations-logistics",
        "instanceType": "SiteOperationsLogistics",
        "name": "D5164C00001 Site Operations & Logistics",
        "site_selection": {
          "instanceType": "SiteSelectionCriteria",
          "required_criteria": [
            {
              "id": "REQ-001",
              "criterion": "Access to Patient Population",
              "description": "Access to patients with completely resected Stage IB-IIIA non-squamous NSCLC with confirmed common sensitising EGFR mutations (Ex19Del or L858R).",
              "assessment_method": "Feasibility assessment",
              "minimum_requirement": "Sufficient patient volume to meet enrollment goals.",
              "provenance": {
                "section_number": "3.1",
                "page_number": 43,
                "text_snippet": "3. Histologically confirmed diagnosis of primary non-small cell lung cancer (NSCLC) on predominantly non-squamous histology\n5. Patients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.\n6. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R)..."
              }
            },
            {
              "id": "REQ-002",
              "criterion": "Facility and Equipment",
              "description": "Site must have access to required equipment and facilities for study procedures, including CT/MRI imaging, ECG, and laboratory testing.",
              "assessment_method": "Site qualification visit/questionnaire",
              "minimum_requirement": "Availability of all protocol-required equipment and facilities.",
              "provenance": {
                "section_number": "5",
                "page_number": 66,
                "text_snippet": "The imaging modalities used for radiological assessments will be CT scans of the chest and abdomen (including liver and adrenal glands) with contrast... A pre-surgical MRI or contrast CT scan of the brain is considered standard of care and must be done prior to surgery."
              }
            },
            {
              "id": "REQ-003",
              "criterion": "Qualified Personnel",
              "description": "Site must have a qualified Principal Investigator and sufficient staff (coordinators, nurses, pharmacy) to conduct the trial.",
              "assessment_method": "Review of CVs and site staff experience",
              "minimum_requirement": "PI and staff must be qualified by training and experience.",
              "provenance": {
                "section_number": "9.1",
                "page_number": 106,
                "text_snippet": "The Principal Investigator will ensure that appropriate training relevant to the study is given to all of these staff, and that any new information relevant to the performance of this study is forwarded to the staff involved. The Principal Investigator will maintain a record of all individuals involved in the study (medical, nursing, and other staff)."
              }
            },
            {
              "id": "REQ-004",
              "criterion": "Regulatory and Ethics Compliance",
              "description": "Site must be able to obtain local IRB/IEC approval and comply with all local regulatory requirements and ICH-GCP.",
              "assessment_method": "Review of past regulatory/inspection history",
              "minimum_requirement": "Demonstrated ability to comply with regulatory standards.",
              "provenance": {
                "section_number": "10",
                "page_number": 109,
                "text_snippet": "This study will be conducted in accordance with the protocol and with the following:\n- Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines\n- Applicable ICH GCP Guidelines\n- Applicable laws and regulations"
              }
            }
          ],
          "preferred_criteria": [],
          "exclusionary_criteria": [],
          "geographic_requirements": {
            "countries": [],
            "regions": [
              "Asia",
              "Non-Asian countries"
            ],
            "site_count_target": 210,
            "language_requirements": [],
            "provenance": {
              "section_number": null,
              "page_number": 8,
              "text_snippet": "This study will be global, with approximately 700 patients to be randomised from an estimated 210 sites over an estimated 28 months. Approximately 10-15% recruitment is anticipated from USA. Approximately 60% recruitment is anticipated to be from Asia."
            }
          },
          "facility_requirements": {
            "patient_population_access": "Access to patients with Stage IB-IIIA NSCLC with EGFR mutations.",
            "equipment_required": [
              "CT scanner",
              "MRI scanner",
              "ECG machine (digital capability for first year)",
              "Laboratory for clinical chemistry, haematology, and urinalysis"
            ],
            "laboratory_capabilities": "Local laboratory for standard safety assessments. Ability to collect, process, and ship samples to central laboratories.",
            "pharmacy_capabilities": "Secure, appropriate storage for investigational product.",
            "storage_capabilities": "Secure storage for study drugs as specified on the label.",
            "provenance": {
              "section_number": "5",
              "page_number": 66,
              "text_snippet": "The imaging modalities used for radiological assessments will be CT scans of the chest and abdomen... A pre-surgical MRI or contrast CT scan of the brain is considered standard of care... Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis will be taken... All study drugs should be kept in a secure place under appropriate storage conditions."
            }
          },
          "experience_requirements": {
            "therapeutic_area_experience": "Experience in conducting clinical trials for non-small cell lung cancer (NSCLC) is implicitly required.",
            "phase_experience": "Experience with Phase 3, randomized, placebo-controlled trials is implicitly required.",
            "enrollment_history": null,
            "gcp_compliance_record": "Adherence to ICH GCP guidelines is mandatory.",
            "provenance": {
              "section_number": "10",
              "page_number": 109,
              "text_snippet": "This study will be conducted in accordance with the protocol and with the following: ... Applicable ICH GCP Guidelines"
            }
          },
          "provenance": {
            "section_number": "3",
            "page_number": 43,
            "text_snippet": "SUBJECT SELECTION, ENROLMENT, RANDOMISATION, RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL"
          }
        },
        "regulatory_ethics": {
          "instanceType": "RegulatoryEthics",
          "regulatory_authorities": [
            {
              "id": "AUTH-001",
              "authority_name": "Food and Drug Administration (FDA)",
              "country_region": "USA",
              "submission_type": "IND",
              "submission_number": "117879",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "Investigational New Drug (IND) Number: 117879"
              }
            },
            {
              "id": "AUTH-002",
              "authority_name": "European Union Clinical Trials Registration (EU CTR)",
              "country_region": "EU",
              "submission_type": "EudraCT",
              "submission_number": "2015-001666-25",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "European Clinical Trials Database (EudraCT) Number: 2015-001666-25"
              }
            }
          ],
          "ethics_committees": [
            {
              "id": "EC-001",
              "committee_type": "IRB/IEC",
              "centralized_or_local": "local",
              "approval_requirements": "The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents must be submitted to an IRB/IEC by the investigator and reviewed and approved before the study is initiated.",
              "approval_timeline": null,
              "continuing_review_frequency": "annual",
              "provenance": {
                "section_number": "10.3",
                "page_number": 111,
                "text_snippet": "An Ethics Committee (EC)/IRB should approve the final study protocol, including the final version of the ICF and any other written information and/or materials to be provided to the patients... If required by local regulations, the protocol should be re-approved by the EC/IRB annually."
              }
            }
          ],
          "informed_consent": {
            "consent_type": "written",
            "languages_required": [],
            "reconsent_triggers": [
              "protocol_amendment"
            ],
            "assent_required": false,
            "electronic_consent_allowed": false,
            "provenance": {
              "section_number": "10.4",
              "page_number": 112,
              "text_snippet": "Ensure each patient provides signed and dated informed consent before conducting any procedure specifically for the study... If a protocol amendment requires a change to a site’s ICF, AstraZeneca representative and the site’s EC/IRB are to approve the revised ICF before the revised form is used."
            }
          },
          "data_privacy": {
            "applicable_regulations": [
              "ICH GCP",
              "Declaration of Helsinki",
              "Applicable local laws and regulations"
            ],
            "data_transfer_requirements": "Data associated with biological samples will be transferred from laboratory(ies) internal or external to AstraZeneca.",
            "anonymization_requirements": "For genetic samples, the DNA sample will be assigned a unique number replacing the information on the sample tube. The link between the patient code and the DNA number will be maintained in a secure, restricted-access system.",
            "provenance": {
              "section_number": "10.2",
              "page_number": 110,
              "text_snippet": "The ICF will incorporate (or, in some cases, be accompanied by a separate document incorporating) wording that complies with relevant data protection and privacy legislation."
            }
          },
          "provenance": {
            "section_number": "10",
            "page_number": 109,
            "text_snippet": "ETHICAL AND REGULATORY REQUIREMENTS"
          }
        },
        "site_personnel": {
          "instanceType": "SitePersonnel",
          "principal_investigator": {
            "qualifications_required": [
              "Qualified by training and experience"
            ],
            "responsibilities": [
              "Ensuring all staff involved in the study are familiar with safety reporting requirements",
              "Providing oversight of the conduct of the study at the site",
              "Adherence to regulatory requirements",
              "Ensuring appropriate training is given to all staff",
              "Maintaining a record of all individuals involved in the study"
            ],
            "delegation_restrictions": [],
            "time_commitment": null,
            "provenance": {
              "section_number": "9.1",
              "page_number": 106,
              "text_snippet": "The Principal Investigator will ensure that appropriate training relevant to the study is given to all of these staff... The Principal Investigator will maintain a record of all individuals involved in the study (medical, nursing, and other staff)."
            }
          },
          "sub_investigators": {
            "provenance": {
              "section_number": "9.1",
              "page_number": 106,
              "text_snippet": "The Principal Investigator will maintain a record of all individuals involved in the study (medical, nursing, and other staff)."
            }
          },
          "coordinators": {
            "provenance": {
              "section_number": "9.1",
              "page_number": 106,
              "text_snippet": "The Principal Investigator will maintain a record of all individuals involved in the study (medical, nursing, and other staff)."
            }
          },
          "other_personnel": [],
          "provenance": {
            "section_number": "9.1",
            "page_number": 106,
            "text_snippet": "Training of study site personnel"
          }
        },
        "training_requirements": {
          "instanceType": "TrainingRequirements",
          "protocol_training": {
            "required_for": [
              "PI",
              "All investigational staff"
            ],
            "format": "in_person",
            "duration": null,
            "assessment_required": false,
            "completion_deadline": "before_first_patient",
            "provenance": {
              "section_number": "9.1",
              "page_number": 106,
              "text_snippet": "Before the first patient is entered into the study, an AstraZeneca representative will review and discuss the requirements of the CSP and related documents with the investigational staff and also train them in any study specific procedures and the EDC systems utilised."
            }
          },
          "gcp_training": {
            "required": true,
            "frequency": null,
            "certification_required": false,
            "accepted_providers": [],
            "provenance": {
              "section_number": "10",
              "page_number": 109,
              "text_snippet": "This study will be conducted in accordance with the protocol and with the following: ... Applicable ICH GCP Guidelines"
            }
          },
          "specialized_training": [
            {
              "id": "TRAIN-001",
              "training_name": "EDC System Training",
              "required_for": [
                "All relevant investigational staff"
              ],
              "certification_required": false,
              "renewal_period": null,
              "provenance": {
                "section_number": "9.1",
                "page_number": 106,
                "text_snippet": "Before the first patient is entered into the study, an AstraZeneca representative will review and discuss the requirements of the CSP and related documents with the investigational staff and also train them in any study specific procedures and the EDC systems utilised."
              }
            },
            {
              "id": "TRAIN-002",
              "training_name": "IVRS/IWRS System Training",
              "required_for": [
                "All relevant investigational staff"
              ],
              "certification_required": false,
              "renewal_period": null,
              "provenance": {
                "section_number": "3.8",
                "page_number": 48,
                "text_snippet": "Routine procedures for this will be described in the IVRS/IWRS user manual that will be provided to each site."
              }
            },
            {
              "id": "TRAIN-003",
              "training_name": "PRO Questionnaire Administration",
              "required_for": [
                "All study personnel involved in PRO collection"
              ],
              "certification_required": false,
              "renewal_period": null,
              "provenance": {
                "section_number": "5.3.4.3",
                "page_number": 73,
                "text_snippet": "To ensure this, all study personnel will be trained to instruct the patient in a standardised way and further be responsible for providing all relevant instructions and training to the patients."
              }
            }
          ],
          "training_documentation": {
            "required": true,
            "storage_location": "Site files",
            "retention_period": "Minimum of 25 years after study archiving.",
            "provenance": {
              "section_number": "9.2.3",
              "page_number": 107,
              "text_snippet": "Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator for a minimum of 25 years after study archiving or as required by local regulations, according to the AstraZeneca Global Retention and Disposal Schedule."
            }
          },
          "provenance": {
            "section_number": "9.1",
            "page_number": 106,
            "text_snippet": "Training of study site personnel"
          }
        },
        "monitoring_plan": {
          "instanceType": "MonitoringPlan",
          "monitoring_approach": "traditional",
          "site_initiation_visit": {
            "required": true,
            "timing": "before_first_patient",
            "format": "on_site",
            "activities": [
              "Review and discuss requirements of the CSP and related documents",
              "Train staff in study specific procedures and EDC systems"
            ],
            "provenance": {
              "section_number": "9.1",
              "page_number": 106,
              "text_snippet": "Before the first patient is entered into the study, an AstraZeneca representative will review and discuss the requirements of the CSP and related documents with the investigational staff and also train them in any study specific procedures and the EDC systems utilised."
            }
          },
          "routine_monitoring": {
            "frequency": "Regular contacts and visits",
            "visit_type": "on_site",
            "sdv_percentage": 100,
            "sdv_scope": [
              "Informed consent",
              "Comparison of data in eCRFs with patient's medical records"
            ],
            "remote_monitoring_activities": [],
            "provenance": {
              "section_number": "9.2",
              "page_number": 106,
              "text_snippet": "During the study, an AstraZeneca representative will have regular contacts with the study site, including visits to: ... Perform source data verification (a comparison of the data in the eCRFs with the patient’s medical records at the hospital or practice, and other records relevant to the study) including verification of informed consent of participating patients. This will require direct access to all original records for each patient (e.g., clinic charts)."
            }
          },
          "triggered_monitoring": {},
          "close_out_visit": {
            "required": true,
            "timing": "Upon study completion at the site",
            "format": "on_site",
            "activities": [
              "Collection of all required documents",
              "Collection of study supplies"
            ],
            "provenance": {
              "section_number": null,
              "page_number": 123,
              "text_snippet": "A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed."
            }
          },
          "provenance": {
            "section_number": "9.2",
            "page_number": 106,
            "text_snippet": "Monitoring of the study"
          }
        },
        "site_activation_timeline": {
          "instanceType": "SiteActivationTimeline",
          "site_selection_phase": null,
          "feasibility_assessment": null,
          "contract_negotiation": null,
          "regulatory_submission": null,
          "ethics_approval": null,
          "site_training": null,
          "site_initiation_visit": null,
          "first_patient_ready": null,
          "critical_path_items": [
            "IRB/IEC approval",
            "Regulatory Authority approval",
            "Site training",
            "Study agreements in place"
          ],
          "provenance": {
            "section_number": "10",
            "page_number": 109,
            "text_snippet": "The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and approved by the IRB/IEC before the study is initiated... AstraZeneca will be responsible for obtaining the required authorisations to conduct the study from the concerned Regulatory Authority."
          }
        },
        "drug_supply_logistics": {
          "instanceType": "DrugSupplyLogistics",
          "packaging_labeling": {
            "blinding_requirements": "double_blind",
            "label_languages": [
              "Local language"
            ],
            "temperature_indicators": false,
            "tamper_evident": true,
            "kit_design": null,
            "provenance": {
              "section_number": "7.1",
              "page_number": 92,
              "text_snippet": "Tablets will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures... Bottle tampers should not be broken prior to dispensing the study drug to a patient... The label will include the Name of the Sponsor, Study Code, For Clinical Trial use only, and/or any other market specific requirements."
            }
          },
          "storage_distribution": {
            "storage_temperature": null,
            "distribution_model": "direct_to_site",
            "cold_chain_required": false,
            "shelf_life_months": null,
            "shipping_conditions": "As specified on investigational product label.",
            "provenance": {
              "section_number": "7.5",
              "page_number": 94,
              "text_snippet": "All study drugs should be kept in a secure place under appropriate storage conditions. The investigational product label on the bottles specifies the appropriate storage."
            }
          },
          "inventory_management": {
            "iwrs_rtsm_system": "IVRS/IWRS",
            "kit_design": "Bottles",
            "resupply_triggers": null,
            "resupply_threshold_days": null,
            "expiry_management": null,
            "provenance": {
              "section_number": "7.2",
              "page_number": 92,
              "text_snippet": "Individual bottles will be dispensed in accordance with the medication identification numbers provided by the IVRS/IWRS."
            }
          },
          "dispensing_schedule": [
            {
              "id": "DISP-001",
              "visit_name": "Randomisation",
              "cycle_day": "Day 1",
              "kits_dispensed": [
                "AZD9291 or matching placebo"
              ],
              "quantity_dispensed": "1 month supply",
              "titration_rules": null,
              "provenance": {
                "section_number": "7.2",
                "page_number": 92,
                "text_snippet": "Randomisation – enough study drug for 1 month"
              }
            },
            {
              "id": "DISP-002",
              "visit_name": "Week 4",
              "cycle_day": null,
              "kits_dispensed": [
                "AZD9291 or matching placebo"
              ],
              "quantity_dispensed": "2 month supply",
              "titration_rules": null,
              "provenance": {
                "section_number": "7.2",
                "page_number": 92,
                "text_snippet": "Week 4 visit – enough study drug for 2 months"
              }
            },
            {
              "id": "DISP-003",
              "visit_name": "Week 12 onwards",
              "cycle_day": null,
              "kits_dispensed": [
                "AZD9291 or matching placebo"
              ],
              "quantity_dispensed": "3 month supply",
              "titration_rules": null,
              "provenance": {
                "section_number": "7.2",
                "page_number": 92,
                "text_snippet": "Week 12 visit onwards – enough study drug for 3 months"
              }
            }
          ],
          "drug_accountability": {
            "accountability_frequency": "Each study visit",
            "accountability_method": "kit_count",
            "documentation_requirements": "Recorded in eCRF",
            "discrepancy_handling": null,
            "provenance": {
              "section_number": "7.7",
              "page_number": 95,
              "text_snippet": "The study personnel will account for all study drug dispensed to and returned from the patient."
            }
          },
          "drug_return_destruction": {
            "return_required": true,
            "return_timing": "At each visit",
            "destruction_method": "local_destruction",
            "destruction_documentation": "Certificates of delivery and destruction should be signed.",
            "environmental_requirements": null,
            "provenance": {
              "section_number": "7.7",
              "page_number": 95,
              "text_snippet": "The study personnel at the investigational site will account for all study drugs received at the site, unused study drugs, and for appropriate destruction. Certificates of delivery and destruction should be signed."
            }
          },
          "dosing_error_handling": {
            "overdose_procedures": "Monitor closely, manage with supportive care, follow up expectantly. Report on Overdose eCRF module.",
            "underdose_procedures": null,
            "missed_dose_procedures": "If within 12 hours of scheduled time, take the dose. If more than 12 hours, skip the dose and take the next dose at the scheduled time.",
            "dose_timing_windows": "12 hours",
            "provenance": {
              "section_number": "7.3",
              "page_number": 93,
              "text_snippet": "If a patient misses taking a scheduled dose, within a window of 12 hours, it is acceptable to take the dose. If it is more than 12 hours after the scheduled dose time, the missed dose should not be taken, and patients should be instructed to take the next dose at the next scheduled time."
            }
          },
          "comparator_medications": [
            {
              "id": "COMP-001",
              "medication_name": "Placebo",
              "source": "sponsor_provided",
              "provenance": {
                "section_number": "7.1",
                "page_number": 92,
                "text_snippet": "Placebo\nAZD9291-matching placebo"
              }
            }
          ],
          "emergency_unblinding": {
            "unblinding_allowed": true,
            "unblinding_triggers": [
              "medical_emergency"
            ],
            "unblinding_procedure": "Available to investigators from the IVRS/IWRS.",
            "who_can_unblind": [
              "Investigator"
            ],
            "documentation_required": "Investigator documents and reports the action to AstraZeneca representative.",
            "provenance": {
              "section_number": "3.8",
              "page_number": 48,
              "text_snippet": "The treatment code should not be broken except in medical emergencies when the appropriate management of the patient requires knowledge of the treatment randomisation. Additionally, at the request of the Investigator, following disease recurrence the patient can be unblinded to their treatment allocation to guide future anti-cancer therapy."
            }
          },
          "provenance": {
            "section_number": "7",
            "page_number": 92,
            "text_snippet": "INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS"
          }
        },
        "technology_systems": {
          "instanceType": "TechnologySystems",
          "edc_system": {
            "vendor_name": "PAREXEL (or alternate vendor)",
            "system_capabilities": [
              "data_collection",
              "query_handling",
              "audit_trail"
            ],
            "integration_requirements": [],
            "language_requirements": [],
            "provenance": {
              "section_number": "9.4",
              "page_number": 108,
              "text_snippet": "Data management will be performed by PAREXEL (or alternate vendor) according to the Data Management Plan... Data queries will be raised for inconsistent, impossible or missing data. All entries to the study database will be available in an audit trail."
            }
          },
          "iwrs_rtsm": {
            "vendor_name": null,
            "functions": [
              "randomization",
              "drug_dispensing",
              "unblinding"
            ],
            "integration_with_edc": false,
            "provenance": {
              "section_number": "3.6",
              "page_number": 48,
              "text_snippet": "Eligible patients will be centrally randomised to receive either 80 mg AZD9291 orally once daily or matching placebo in a 1:1 ratio using the IVRS/IWRS system."
            }
          },
          "epro_devices": {
            "required": false
          },
          "central_services": [
            {
              "id": "SVC-001",
              "service_type": "central_lab",
              "vendor_name": "Designated central laboratory",
              "data_flow": null,
              "turnaround_time": null,
              "provenance": {
                "section_number": "4.1",
                "page_number": 61,
                "text_snippet": "It is recommended that the screening assessments are performed in a stepwise process beginning with the confirmation of EGFR mutation status determined by the designated central laboratory."
              }
            },
            {
              "id": "SVC-002",
              "service_type": "central_ecg",
              "vendor_name": "External cardiologist",
              "data_flow": "Digital ECGs transferred electronically for central analysis.",
              "turnaround_time": null,
              "provenance": {
                "section_number": "5.2.3",
                "page_number": 71,
                "text_snippet": "Digital ECG will be transferred electronically for central analysis as described in the study specific ECG manual... Heart rate, PR, R-R, QRS, and QT (QTcF) intervals will be determined and reviewed by an external cardiologist."
              }
            },
            {
              "id": "SVC-003",
              "service_type": "bioanalytical_lab",
              "vendor_name": "Covance",
              "data_flow": null,
              "turnaround_time": null,
              "provenance": {
                "section_number": "5.4.2",
                "page_number": 75,
                "text_snippet": "Samples for determination of AZD9291 (and metabolite) concentrations in plasma will be collected and analysed by Covance on behalf of AstraZeneca."
              }
            }
          ],
          "provenance": {
            "section_number": "9.4",
            "page_number": 108,
            "text_snippet": "Data management"
          }
        },
        "equipment_facilities": {
          "instanceType": "EquipmentFacilities",
          "specialized_equipment": [
            {
              "id": "EQUIP-001",
              "equipment": "ECG machine",
              "required_or_preferred": "required",
              "specifications": "12-lead. Digital collection for the first year.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "5.2.3",
                "page_number": 70,
                "text_snippet": "Twelve-lead ECGs will be obtained after the patient has been resting semi-supine for at least 10 minutes prior to times indicated... For the first year (Week 48) of subject participation in the study, all ECG data will be collected digitally; thereafter standard /ECGs will be performed."
              }
            },
            {
              "id": "EQUIP-002",
              "equipment": "CT scanner",
              "required_or_preferred": "required",
              "specifications": "With contrast capability.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "5.1.1",
                "page_number": 66,
                "text_snippet": "The imaging modalities used for radiological assessments will be CT scans of the chest and abdomen (including liver and adrenal glands) with contrast."
              }
            },
            {
              "id": "EQUIP-003",
              "equipment": "MRI scanner",
              "required_or_preferred": "required",
              "specifications": "With contrast capability.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "5.1.1",
                "page_number": 66,
                "text_snippet": "Disease recurrence is defined as evidence of disease recurrence on CT or MRI scan and/or pathological disease on biopsy by investigational site assessment."
              }
            }
          ],
          "facility_requirements": {
            "patient_space": null,
            "storage_space": "Secure place for study drug storage.",
            "safety_equipment": [],
            "provenance": {
              "section_number": "7.5",
              "page_number": 94,
              "text_snippet": "All study drugs should be kept in a secure place under appropriate storage conditions."
            }
          },
          "provenance": {
            "section_number": "5",
            "page_number": 66,
            "text_snippet": "STUDY ASSESSMENTS"
          }
        },
        "vendor_coordination": [
          {
            "id": "VENDOR-001",
            "vendor_type": "CRO",
            "vendor_name": "PAREXEL (or alternate vendor)",
            "services_provided": [
              "Data management"
            ],
            "site_interface_required": true,
            "training_required": true,
            "contact_info": null,
            "provenance": {
              "section_number": "9.4",
              "page_number": 108,
              "text_snippet": "Data management will be performed by PAREXEL (or alternate vendor) according to the Data Management Plan."
            }
          },
          {
            "id": "VENDOR-002",
            "vendor_type": "central_lab",
            "vendor_name": "Designated central laboratory",
            "services_provided": [
              "EGFR mutation testing"
            ],
            "site_interface_required": true,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "4.1",
              "page_number": 61,
              "text_snippet": "It is recommended that the screening assessments are performed in a stepwise process beginning with the confirmation of EGFR mutation status determined by the designated central laboratory."
            }
          },
          {
            "id": "VENDOR-003",
            "vendor_type": "central_lab",
            "vendor_name": "Covance",
            "services_provided": [
              "PK sample analysis"
            ],
            "site_interface_required": true,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "5.4.2",
              "page_number": 75,
              "text_snippet": "Samples for determination of AZD9291 (and metabolite) concentrations in plasma will be collected and analysed by Covance on behalf of AstraZeneca."
            }
          },
          {
            "id": "VENDOR-004",
            "vendor_type": "other",
            "vendor_name": "Tata Consulting Services Data Entry Site (TCS DES)",
            "services_provided": [
              "Paper-based SAE, overdose, and pregnancy data entry if EDC is unavailable"
            ],
            "site_interface_required": true,
            "training_required": false,
            "contact_info": null,
            "provenance": {
              "section_number": "1.6",
              "page_number": 38,
              "text_snippet": "If the EDC system is not available, AstraZeneca will collect information on SAEs, overdose and pregnancy (as per Section 6.4, Section 6.5, and Section 6.6) via paper and emailed to Tata Consulting Services Data Entry Site (TCS DES) (also known as AZ DES)."
            }
          }
        ],
        "extraction_statistics": {
          "has_site_selection_criteria": true,
          "has_regulatory_info": true,
          "has_personnel_requirements": true,
          "has_training_requirements": true,
          "has_monitoring_plan": true,
          "has_activation_timeline": true,
          "has_drug_supply_info": true,
          "has_technology_systems": true,
          "has_dispensing_schedule": true,
          "has_drug_accountability": true,
          "has_emergency_unblinding": true,
          "site_count_target": 210,
          "country_count": 0,
          "vendor_count": 4,
          "comparator_medication_count": 1
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Revised Clinical Study Protocol\nDrug Substance AZD9291\nStudy Code D5164C00001\nEdition Number 6.0\nDate 09 August 2023"
        }
      },
      "_agentDocumentation": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements for site initiation planning and CTMS configuration.",
        "scope": "Site equipment, training requirements, drug storage, IP accountability, vendor coordination.",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "qualityManagement": {
      "moduleId": "quality_management",
      "instanceType": "QualityManagement",
      "data": {
        "id": "D5164C00001-quality-management",
        "instanceType": "QualityManagement",
        "name": "D5164C00001 Quality Management",
        "ich_m11_section": "6.3",
        "monitoring": {
          "monitoring_approach": {
            "instanceType": "MonitoringApproach",
            "strategy": "hybrid",
            "rationale": "A hybrid approach combining on-site monitoring, centralized data review, and risk-based principles is employed to ensure subject safety, data integrity, and regulatory compliance in accordance with ICH E6(R2). This focuses resources on critical data and processes.",
            "regulatory_framework": [
              "ICH_E6_R2",
              "FDA_RBM_Guidance",
              "TransCelerate_RBM"
            ],
            "adaptive_monitoring": true,
            "centralized_monitoring_enabled": true,
            "centralized_monitoring_tools": [
              "RBQM_platform",
              "statistical_monitoring",
              "KRI_dashboard"
            ],
            "provenance": {
              "kind": "explicit",
              "explicit": {
                "section_number": "9.2",
                "page_number": 106,
                "text_snippet": "During the study, an AstraZeneca representative will have regular contacts with the study site, including visits to: ... Confirm that the investigational team is adhering to the protocol, that data are being accurately and timely recorded in the eCRFs... Perform source data verification (a comparison of the data in the eCRFs with the patient’s medical records at the hospital or practice...)"
              }
            }
          },
          "sdv_strategy": {
            "instanceType": "SDVStrategy",
            "overall_approach": "risk_based",
            "default_sdv_percentage": 20,
            "critical_data_100_percent": [
              "informed_consent",
              "eligibility_criteria",
              "primary_endpoint",
              "SAEs",
              "withdrawal_reason",
              "randomization"
            ],
            "sdv_reduction_criteria": {
              "enabled": true,
              "minimum_subjects_enrolled": 10,
              "error_rate_threshold_percent": 3,
              "reduced_sdv_percentage": 10,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "SDV reduction criteria are not explicitly defined in the protocol. These values are derived from standard risk-based monitoring practices where sites demonstrating high quality can have monitoring intensity reduced.",
                  "supporting_context": [
                    "Section 9.2 describes a monitoring approach, implying quality oversight which is a prerequisite for adaptive strategies."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "sdv_escalation_criteria": {
              "error_rate_threshold_percent": 10,
              "escalated_sdv_percentage": 50,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "SDV escalation criteria are not explicitly defined in the protocol. These values are derived from standard risk-based monitoring practices where sites with poor performance receive increased oversight.",
                  "supporting_context": [
                    "Section 9.2 describes monitoring to ensure data accuracy, which implies that escalation would occur if accuracy is not maintained."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "remote_sdv_enabled": true,
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol mandates SDV for informed consent but does not specify an overall strategy or percentages. The risk-based approach and specific percentages are inferred from modern clinical trial conduct standards (ICH E6 R2) and the hybrid monitoring approach described. 100% SDV of consent is explicitly supported.",
                "supporting_context": [
                  "Section 9.2, page 106: 'Perform source data verification... including verification of informed consent of participating patients.'"
                ],
                "confidence": "medium"
              }
            }
          },
          "monitoring_visits": {
            "instanceType": "MonitoringVisits",
            "site_initiation_visit": {
              "required": true,
              "timing": "Before first subject enrolled",
              "format": "on_site",
              "key_activities": [
                "regulatory_binder_review",
                "protocol_training",
                "EDC_training",
                "IMP_handling_training"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "9.1",
                  "page_number": 106,
                  "text_snippet": "Before the first patient is entered into the study, an AstraZeneca representative will review and discuss the requirements of the CSP and related documents with the investigational staff and also train them in any study specific procedures and the EDC systems utilised."
                }
              }
            },
            "routine_monitoring": {
              "on_site_visit_frequency": "risk_based_adaptive",
              "remote_monitoring_frequency": "monthly",
              "on_site_activities": [
                "ICF_review",
                "source_data_verification",
                "AE_SAE_review",
                "drug_accountability"
              ],
              "remote_activities": [
                "data_listing_review",
                "KRI_monitoring",
                "query_management_review"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "9.2",
                  "page_number": 106,
                  "text_snippet": "During the study, an AstraZeneca representative will have regular contacts with the study site, including visits to: ... Confirm that the investigational team is adhering to the protocol, that data are being accurately and timely recorded in the eCRFs... Perform source data verification... that study drug accountability checks are being performed."
                }
              }
            },
            "triggered_visits": [
              {
                "id": "trigger-001",
                "trigger_type": "SAE_occurrence",
                "response_timeline_hours": 48,
                "actions": [
                  "phone_call_with_PI",
                  "root_cause_analysis",
                  "review_of_source_documents"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol mandates rapid reporting of SAEs (within 24 hours). A triggered visit or contact is a standard industry response to ensure proper documentation and subject safety, although not explicitly stated as a 'triggered visit' in the protocol.",
                    "supporting_context": [
                      "Section 6.4, page 84: 'If any SAE occurs in the course of the study, then Investigators or other site personnel inform the appropriate AstraZeneca representatives within one day, i.e., immediately but no later than 24 hours of when he or she becomes aware of it.'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "id": "trigger-002",
                "trigger_type": "KRI_threshold_breach",
                "response_timeline_hours": 72,
                "actions": [
                  "investigate_data_patterns",
                  "site_contact_to_understand_context",
                  "determine_need_for_on-site_visit"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "Triggered visits based on KRI breaches are a core component of risk-based monitoring. While the protocol does not explicitly mention KRIs or triggered visits, they are an inferred part of the quality management system needed to ensure the data integrity and safety oversight described.",
                    "supporting_context": [
                      "Section 9.2 describes monitoring to ensure data accuracy and protocol adherence, which is the purpose of KRIs and subsequent triggered actions."
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "close_out_visit": {
              "timing": "after_LPLV",
              "timing_days_after_event": 60,
              "format": "on_site",
              "activities": [
                "final_SDV",
                "essential_document_collection",
                "final_drug_accountability_and_destruction_reconciliation"
              ],
              "site_release_criteria": [
                "all_CRFs_complete",
                "all_queries_resolved",
                "final_IRB_report_submitted"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "Appendix A",
                  "page_number": 123,
                  "text_snippet": "A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed."
                }
              }
            },
            "provenance": {
              "kind": "explicit",
              "explicit": {
                "section_number": "9.2",
                "page_number": 106,
                "text_snippet": "Monitoring of the study"
              }
            }
          },
          "key_risk_indicators": [
            {
              "id": "KRI-001",
              "instanceType": "KeyRiskIndicator",
              "name": "Informed Consent Compliance",
              "category": "protocol_compliance",
              "metric": "Percentage of subjects with dated consent prior to any study procedures",
              "data_source": "EDC",
              "review_frequency": "weekly",
              "threshold_green": "100%",
              "threshold_amber": "95-99%",
              "threshold_red": "<95%",
              "action_amber": "Review with site, identify training gaps",
              "action_red": "Immediate site call, potential CAPA, increased monitoring",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the critical GCP requirement for informed consent. The protocol mandates consent prior to any procedures, making compliance a key area for monitoring, even though the KRI itself is not specified.",
                  "supporting_context": [
                    "Section 3.1, page 43: 'Provision of informed consent prior to any study specific procedures, sampling, and analyses'",
                    "Section 10.4, page 112: 'Ensure each patient provides signed and dated informed consent before conducting any procedure specifically for the study.'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-002",
              "instanceType": "KeyRiskIndicator",
              "name": "Primary Endpoint Data Completeness",
              "category": "data_integrity",
              "metric": "Percentage of missing DFS assessment scans at scheduled timepoints",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<2%",
              "threshold_amber": "2-5%",
              "threshold_red": ">5%",
              "action_amber": "Follow up with site to schedule missed assessments",
              "action_red": "Escalate to project manager, assess impact on data usability, potential triggered visit",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the importance of the primary endpoint (DFS) and the scheduled assessments required to measure it. Monitoring the completeness of these assessments is critical to study success, although the KRI is not explicitly listed.",
                  "supporting_context": [
                    "Section 2.1, page 40: 'Primary Objective: To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)'",
                    "Table 1, page 55: Specifies CT scans for disease control at Week 12, Week 24, and then every 24 weeks."
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-003",
              "instanceType": "KeyRiskIndicator",
              "name": "SAE Reporting Timeliness",
              "category": "patient_safety",
              "metric": "Average number of days from site awareness of SAE to entry in EDC",
              "data_source": "EDC",
              "review_frequency": "weekly",
              "threshold_green": "<=1 day",
              "threshold_amber": "1-2 days",
              "threshold_red": ">2 days",
              "action_amber": "Site reminder on reporting requirements",
              "action_red": "Immediate site call, retraining on safety reporting obligations, document deviation",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the explicit SAE reporting timeline in the protocol. Monitoring adherence to the 24-hour reporting requirement is a standard and critical risk indicator for patient safety and regulatory compliance.",
                  "supporting_context": [
                    "Section 6.4, page 84: 'If any SAE occurs in the course of the study, then Investigators or other site personnel inform the appropriate AstraZeneca representatives within one day, i.e., immediately but no later than 24 hours of when he or she becomes aware of it.'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-004",
              "instanceType": "KeyRiskIndicator",
              "name": "Major Protocol Deviation Rate",
              "category": "protocol_compliance",
              "metric": "Number of major protocol deviations per enrolled subject",
              "data_source": "CTMS",
              "review_frequency": "monthly",
              "threshold_green": "<0.05",
              "threshold_amber": "0.05-0.10",
              "threshold_red": ">0.10",
              "action_amber": "Review deviation trends with site",
              "action_red": "Investigate root cause, implement CAPA, consider enrollment hold",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is a standard measure of site quality and protocol adherence. While not explicitly defined, its use is inferred from the general requirement for investigators to adhere to the protocol as stated in the monitoring and ethics sections.",
                  "supporting_context": [
                    "Section 9.2, page 106: 'Confirm that the investigational team is adhering to the protocol...'"
                  ],
                  "confidence": "medium"
                }
              }
            },
            {
              "id": "KRI-005",
              "instanceType": "KeyRiskIndicator",
              "name": "Visit Compliance Rate",
              "category": "protocol_compliance",
              "metric": "Percentage of scheduled visits completed within the protocol-defined window",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": ">95%",
              "threshold_amber": "90-95%",
              "threshold_red": "<90%",
              "action_amber": "Discuss scheduling challenges with site staff",
              "action_red": "Identify root cause for missed visits, implement corrective actions",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the detailed 'Study plan and timing of procedures' tables. Adherence to the visit schedule is crucial for collecting safety and efficacy data at the correct timepoints, making it a logical KRI.",
                  "supporting_context": [
                    "Table 1, pages 53-57: 'Study plan up to completion of final DFS analysis' provides a detailed schedule of visits and assessments."
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-006",
              "instanceType": "KeyRiskIndicator",
              "name": "Screen Failure Rate",
              "category": "enrollment",
              "metric": "Percentage of screened subjects who are not randomized",
              "data_source": "CTMS",
              "review_frequency": "monthly",
              "threshold_green": "<30%",
              "threshold_amber": "30-50%",
              "threshold_red": ">50%",
              "action_amber": "Analyze screen failure reasons for trends",
              "action_red": "Escalate to study team to assess feasibility of inclusion/exclusion criteria or central lab turnaround time",
              "applies_to": "study_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the protocol's enrollment estimates, which imply a significant screen failure rate. Monitoring this rate against projections is a standard operational KRI to assess recruitment feasibility and potential issues with eligibility criteria.",
                  "supporting_context": [
                    "Section 1.6, page 36: 'it is estimated that 3200 patients will be screened to randomise approximately 700 patients.'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-007",
              "instanceType": "KeyRiskIndicator",
              "name": "Eligibility Deviation Rate",
              "category": "protocol_compliance",
              "metric": "Percentage of randomized subjects with an eligibility deviation",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "0%",
              "threshold_amber": ">0% and <=2%",
              "threshold_red": ">2%",
              "action_amber": "Review specific deviations with site",
              "action_red": "Immediate retraining on eligibility criteria, potential CAPA",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is derived from the strict rule that all subjects must meet all inclusion and no exclusion criteria. Monitoring deviations from this is critical for ensuring the integrity of the study population.",
                  "supporting_context": [
                    "Section 3, page 43: 'Each subject should meet all of the inclusion criteria and none of the exclusion criteria for this study. Under no circumstances can there be exceptions to this rule.'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "KRI-008",
              "instanceType": "KeyRiskIndicator",
              "name": "Adverse Event Reporting Rate",
              "category": "patient_safety",
              "metric": "Number of AEs reported per subject-month on study",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "Within expected range",
              "threshold_amber": "25% below expected range",
              "threshold_red": "50% below expected range",
              "action_amber": "Query site about potential under-reporting of AEs",
              "action_red": "Triggered call/visit to retrain on AE elicitation and reporting",
              "applies_to": "site_level",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This KRI is a standard safety oversight metric. While not explicitly defined, its use is inferred from the detailed sections on AE collection, which are critical for characterizing the drug's safety profile. A significantly low rate can indicate under-reporting.",
                  "supporting_context": [
                    "Section 6, page 79: 'SAFETY REPORTING AND MEDICAL MANAGEMENT'",
                    "Section 6.3, page 80: 'Recording of adverse events'"
                  ],
                  "confidence": "medium"
                }
              }
            }
          ],
          "quality_tolerance_limits": [
            {
              "id": "QTL-001",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Informed Consent Deviations",
              "category": "informed_consent",
              "acceptable_limit": "0% of subjects with consent obtained after initiation of study procedures",
              "acceptable_limit_numeric": 0,
              "alert_threshold": "1 subject with a deviation",
              "alert_threshold_numeric": 1,
              "action_threshold": "2 or more subjects with a deviation",
              "action_threshold_numeric": 2,
              "predefined_actions": [
                "root_cause_analysis",
                "CAPA_initiation",
                "site_retraining",
                "report_to_IRB"
              ],
              "escalation_path": [
                "project_manager",
                "sponsor_QA",
                "IRB_IEC"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the absolute requirement for informed consent prior to any study procedures, a fundamental principle of GCP. Any deviation is critical. While the term QTL is not used, the zero-tolerance nature of this requirement makes it a de facto QTL.",
                  "supporting_context": [
                    "Section 3.1, page 43: 'Provision of informed consent prior to any study specific procedures, sampling, and analyses'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-002",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Major Protocol Deviations Affecting Eligibility",
              "category": "eligibility",
              "acceptable_limit": "<1% of randomized subjects enrolled in violation of key eligibility criteria",
              "acceptable_limit_numeric": 1,
              "alert_threshold": "1 subject enrolled with major eligibility deviation",
              "alert_threshold_numeric": 1,
              "action_threshold": "2 or more subjects enrolled with major eligibility deviations",
              "action_threshold_numeric": 2,
              "predefined_actions": [
                "root_cause_analysis",
                "CAPA_initiation",
                "review_of_site_enrollment_procedures"
              ],
              "escalation_path": [
                "medical_monitor",
                "sponsor_QA"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the protocol's strict stance on eligibility. Enrolling ineligible subjects compromises the integrity of the study population and data. The limit is based on ICH E6(R2) principles for managing risks to critical data and processes.",
                  "supporting_context": [
                    "Section 3, page 43: 'Each subject should meet all of the inclusion criteria and none of the exclusion criteria for this study. Under no circumstances can there be exceptions to this rule.'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-003",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Primary Endpoint Data Quality",
              "category": "endpoint_collection",
              "acceptable_limit": ">95% of subjects have complete data for the primary endpoint (DFS) at the time of primary analysis",
              "acceptable_limit_numeric": 95,
              "alert_threshold": "Completeness falls below 98%",
              "alert_threshold_numeric": 98,
              "action_threshold": "Completeness falls below 96%",
              "action_threshold_numeric": 96,
              "predefined_actions": [
                "investigate_reasons_for_missing_data",
                "implement_data_retrieval_plan",
                "assess_impact_on_statistical_analysis"
              ],
              "escalation_path": [
                "lead_data_manager",
                "biostatistician",
                "steering_committee"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the critical importance of the primary endpoint, DFS. A high level of data completeness is essential for the statistical analysis to be valid and robust. The specific percentage is a standard industry tolerance limit for primary endpoint data.",
                  "supporting_context": [
                    "Section 2.1, page 40: 'Primary Objective: To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)'"
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-004",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Investigational Product Dosing Errors",
              "category": "patient_safety",
              "acceptable_limit": "<2% of subjects receive the wrong study treatment or dose",
              "acceptable_limit_numeric": 2,
              "alert_threshold": "1 subject receives wrong treatment",
              "alert_threshold_numeric": 1,
              "action_threshold": "2 or more subjects receive wrong treatment",
              "action_threshold_numeric": 2,
              "predefined_actions": [
                "immediate_unblinding_if_necessary",
                "root_cause_analysis_of_dispensing_process",
                "CAPA_initiation"
              ],
              "escalation_path": [
                "pharmacist",
                "medical_monitor",
                "sponsor_QA"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the need to ensure patient safety and maintain the integrity of the treatment arms. While the protocol discusses handling incorrectly randomized subjects, it does not set a specific tolerance limit. This limit is based on standard RBQM practices.",
                  "supporting_context": [
                    "Section 3.5, page 47: 'Procedures for handling incorrectly enrolled or randomised subjects'",
                    "Section 3.7, page 48: 'Methods for ensuring blinding'"
                  ],
                  "confidence": "medium"
                }
              }
            },
            {
              "id": "QTL-005",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Loss to Follow-up Rate",
              "category": "data_integrity",
              "acceptable_limit": "<10% of subjects lost to follow-up for the final OS analysis",
              "acceptable_limit_numeric": 10,
              "alert_threshold": "Projected LTFU rate exceeds 5%",
              "alert_threshold_numeric": 5,
              "action_threshold": "Projected LTFU rate exceeds 8%",
              "action_threshold_numeric": 8,
              "predefined_actions": [
                "review_patient_retention_strategies",
                "implement_enhanced_follow-up_procedures",
                "assess_impact_on_OS_analysis"
              ],
              "escalation_path": [
                "project_manager",
                "steering_committee"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the importance of the OS secondary endpoint and the high risk of patients being lost to follow-up over the study's long duration. A high LTFU rate can bias the OS analysis, so a tolerance limit is critical. The 10% value is a common, albeit challenging, industry standard.",
                  "supporting_context": [
                    "Section 1.7, page 38: 'Study extension for long-term OS follow-up'",
                    "Section 4.3.4, page 64: 'Survival follow–up (up to final OS analysis)'"
                  ],
                  "confidence": "high"
                }
              }
            }
          ],
          "findings_management": {
            "instanceType": "FindingsManagement",
            "finding_categories": [
              {
                "id": "finding-cat-001",
                "category": "critical",
                "definition": "A finding that adversely affects the rights, safety, or well-being of a subject, or the integrity of the study data.",
                "response_timeline_days": 1,
                "requires_capa": true,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This category is derived from standard GCP and risk management principles. It represents the highest level of issue, such as a serious breach, which requires immediate attention, although not explicitly defined in the protocol.",
                    "supporting_context": [
                      "Section 10.7, page 113: 'Regulatory reporting requirements for serious breaches'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "id": "finding-cat-002",
                "category": "major",
                "definition": "A finding that could potentially affect subject safety or data integrity, or represents a significant deviation from the protocol.",
                "response_timeline_days": 15,
                "requires_capa": false,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This category is derived from standard quality management systems. It represents significant but not immediately critical issues. The protocol's emphasis on adherence implies a system for categorizing and managing non-adherence.",
                    "supporting_context": [
                      "Section 9.2, page 106: 'Confirm that the investigational team is adhering to the protocol...'"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "id": "finding-cat-003",
                "category": "minor",
                "definition": "A finding that does not impact subject safety or data integrity, typically a documentation or process error.",
                "response_timeline_days": 30,
                "requires_capa": false,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This category is derived from standard quality management systems for clinical trials. It covers lower-level issues that require correction but do not pose a risk to subjects or data integrity. Such a category is necessary for an efficient monitoring process.",
                    "supporting_context": [
                      "Section 9.2, page 106: '...data are being accurately and timely recorded in the eCRFs...'"
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "capa_process": {
              "capa_triggers": [
                "critical_finding",
                "repeated_major_finding",
                "QTL_breach",
                "systemic_issue_identified"
              ],
              "response_timeline_days": 30,
              "verification_required": true,
              "tracking_system": "CTMS",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "A CAPA process is a fundamental component of a quality management system under ICH GCP, but it is not detailed in this protocol. The triggers and timelines are based on standard industry practice for addressing systemic or critical issues.",
                  "supporting_context": [
                    "Section 10, page 109: 'This study will be conducted in accordance with the protocol and with the following: ... Applicable ICH GCP Guidelines'"
                  ],
                  "confidence": "medium"
                }
              }
            },
            "protocol_deviation_management": {
              "deviation_categories": [
                "major",
                "minor"
              ],
              "internal_reporting_timeline_days": 5,
              "irb_reporting_required": true,
              "irb_reporting_timeline_days": 10,
              "root_cause_analysis_required": true,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "Protocol deviation management is a standard requirement, but specific processes are not detailed in the protocol. The requirement to report serious breaches to regulatory authorities implies a system for identifying, categorizing, and managing all deviations.",
                  "supporting_context": [
                    "Section 10.7, page 113: 'Prompt notification by the investigator to the sponsor of any (potential) serious breach of the protocol or regulations is essential...'"
                  ],
                  "confidence": "medium"
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The overall findings management process is not explicitly detailed in the protocol. It is inferred from the requirements of ICH GCP and the description of monitoring activities, which necessitate a structured process for handling identified issues.",
                "supporting_context": [
                  "Section 9.2, page 106: 'Monitoring of the study'",
                  "Section 10, page 109: 'ETHICAL AND REGULATORY REQUIREMENTS'"
                ],
                "confidence": "medium"
              }
            }
          },
          "monitoring_reports": {
            "report_types": [
              "Site Initiation Visit Report",
              "Monitoring Visit Report",
              "Remote Monitoring Report",
              "Site Close-out Visit Report"
            ],
            "submission_timeline_days": 14,
            "review_and_approval_workflow": [
              "Monitor",
              "Lead Monitor/CRA Manager",
              "Project Manager"
            ],
            "escalation_path_for_issues": "Issues identified in reports are escalated according to the Findings Management plan.",
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol does not specify the types, timelines, or review process for monitoring reports. This information is standard operational detail for any clinical trial and is derived based on common industry practices and GCP requirements for documenting monitoring activities.",
                "supporting_context": [
                  "Section 9.2, page 106, describes the monitoring visits that would necessitate these reports."
                ],
                "confidence": "medium"
              }
            }
          },
          "provenance": {
            "kind": "explicit",
            "explicit": {
              "section_number": "9.2",
              "page_number": 106,
              "text_snippet": "Monitoring of the study"
            }
          }
        },
        "rbqm": {
          "ract_register": {
            "critical_to_quality_factors": [
              {
                "ctq_id": "CTQ-001",
                "ctq_category": "Endpoint Integrity",
                "factor": "Accurate and consistent assessment of Disease-Free Survival (DFS) by investigators.",
                "insight_type": "explicit",
                "clinical_reasoning": "DFS is the primary endpoint. Inaccurate or inconsistent assessments due to imaging variability or misinterpretation of recurrence criteria would directly compromise the primary study outcome and the ability to determine the drug's efficacy.",
                "failure_mode": "Investigators inconsistently apply recurrence criteria or use different imaging modalities, leading to high variability and bias in DFS measurement.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 3,
                "risk_priority_number": 45,
                "affected_stakeholders": [
                  "Patient",
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Detailed protocol definitions for disease recurrence",
                  "Investigator meeting training on imaging schedules and assessment criteria"
                ],
                "detective_controls": [
                  "Centralized monitoring of imaging data for consistency",
                  "Statistical monitoring for outliers in event rates by site"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "2.1",
                    "page_number": 40,
                    "text_snippet": "Primary Objective: To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)"
                  }
                }
              },
              {
                "ctq_id": "CTQ-002",
                "ctq_category": "Patient Safety",
                "factor": "Timely identification and management of key drug-related toxicities (ILD/pneumonitis, QTc prolongation).",
                "insight_type": "explicit",
                "clinical_reasoning": "These are known, serious risks associated with the drug class. Failure to detect and manage them promptly could lead to severe patient harm or death, jeopardizing patient safety and the study's continuation.",
                "failure_mode": "Sites fail to perform scheduled ECGs or recognize early symptoms of ILD, leading to delayed intervention and progression to severe events.",
                "severity_score": 5,
                "probability_score": 2,
                "detectability_score": 2,
                "risk_priority_number": 20,
                "affected_stakeholders": [
                  "Patient",
                  "Site",
                  "DSMB"
                ],
                "preventive_controls": [
                  "Protocol-mandated safety monitoring schedule (ECG, symptom checks)",
                  "Specific guidance in protocol for management of ILD and QTc prolongation"
                ],
                "detective_controls": [
                  "Centralized review of ECG data",
                  "KRI for adherence to safety assessment schedule"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.9.5",
                    "page_number": 90,
                    "text_snippet": "QTc prolongation\nIn light of the potential for QT changes associated with AZD9291, electrolyte abnormalities...must be corrected... Patients with QTcF prolongation to >500 msec should have study treatment interrupted..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-003",
                "ctq_category": "GCP Compliance",
                "factor": "Correct enrollment of patients with centrally confirmed EGFR mutation status (Ex19del or L858R).",
                "insight_type": "explicit",
                "clinical_reasoning": "The study's scientific validity depends on treating the correct patient population. Enrolling EGFR-negative or wild-type patients would dilute the treatment effect and make the study results uninterpretable.",
                "failure_mode": "Sites randomize patients based on local test results before central confirmation is received, or administrative errors lead to enrollment of ineligible patients.",
                "severity_score": 5,
                "probability_score": 2,
                "detectability_score": 1,
                "risk_priority_number": 10,
                "affected_stakeholders": [
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Mandatory central laboratory confirmation of EGFR mutation prior to randomization",
                  "IVRS/IWRS system checks to prevent randomization without confirmed eligibility"
                ],
                "detective_controls": [
                  "Post-randomization audit of eligibility documentation"
                ],
                "mitigation_hierarchy_level": "Engineering",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "3.1",
                    "page_number": 43,
                    "text_snippet": "6. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R)..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-004",
                "ctq_category": "Data Quality",
                "factor": "Integrity of the double-blind throughout the study, until the final OS analysis.",
                "insight_type": "inferred",
                "clinical_reasoning": "Maintaining the blind is essential to prevent assessment bias, particularly for subjective endpoints and decisions regarding subsequent therapy, which could confound the Overall Survival (OS) analysis.",
                "failure_mode": "Premature or inappropriate unblinding of site staff or patients post-recurrence leads to biased treatment decisions and reporting of post-progression outcomes.",
                "severity_score": 4,
                "probability_score": 3,
                "detectability_score": 4,
                "risk_priority_number": 48,
                "affected_stakeholders": [
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Use of identical matching placebo",
                  "Controlled unblinding process via IVRS/IWRS for medical emergencies or post-recurrence treatment decisions"
                ],
                "detective_controls": [
                  "Monitoring for unusual patterns in subsequent therapy choices by site"
                ],
                "mitigation_hierarchy_level": "Engineering",
                "linked_risk_ids": [
                  "RISK-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "3.7",
                    "page_number": 48,
                    "text_snippet": "This is a double-blind study wherein each patient will receive either the active drug or matching placebo. The active drug and placebo tablets will be identical and presented in the same packaging to ensure blinding of the medication."
                  }
                }
              },
              {
                "ctq_id": "CTQ-005",
                "ctq_category": "GCP Compliance",
                "factor": "Obtaining valid informed consent from all participants prior to any study-related procedures.",
                "insight_type": "explicit",
                "clinical_reasoning": "Informed consent is the cornerstone of ethical clinical research. Failure to obtain it properly violates fundamental patient rights and GCP, rendering all collected data unusable and posing a major regulatory risk.",
                "failure_mode": "Site staff perform screening procedures before the ICF is signed and dated, or fail to properly explain the study to the patient.",
                "severity_score": 5,
                "probability_score": 2,
                "detectability_score": 2,
                "risk_priority_number": 20,
                "affected_stakeholders": [
                  "Patient",
                  "Site",
                  "Sponsor",
                  "IRB_IEC"
                ],
                "preventive_controls": [
                  "Mandatory GCP training for all site staff",
                  "Clear protocol instructions on the consent process"
                ],
                "detective_controls": [
                  "100% SDV of informed consent forms during monitoring visits",
                  "KRI tracking consent deviations"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-005"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "3.1",
                    "page_number": 43,
                    "text_snippet": "1. Provision of informed consent prior to any study specific procedures, sampling, and analyses"
                  }
                }
              },
              {
                "ctq_id": "CTQ-006",
                "ctq_category": "Data Quality",
                "factor": "Completeness of long-term survival follow-up data for the final OS analysis.",
                "insight_type": "inferred",
                "clinical_reasoning": "OS is a key secondary endpoint. A high rate of patients lost to follow-up over the extended period (up to 10 years) will introduce bias and reduce the statistical power to detect a survival benefit, potentially leading to an inconclusive result.",
                "failure_mode": "Sites fail to maintain contact with patients who have completed treatment, leading to a high percentage of patients lost to follow-up.",
                "severity_score": 4,
                "probability_score": 4,
                "detectability_score": 3,
                "risk_priority_number": 48,
                "affected_stakeholders": [
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Collecting multiple contact methods for patients at baseline",
                  "Optional consent for long-term follow-up study extension"
                ],
                "detective_controls": [
                  "Centralized tracking of patient status and follow-up attempts",
                  "KRI for rate of patients lost to follow-up"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-006"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "1.7",
                    "page_number": 38,
                    "text_snippet": "After the final OS analysis, a study extension has been added to allow the optional longer-term survival follow-up of patients in the ADAURA trial until approximately 10 years after the last patient is randomised, which will further characterise long-term patient outcomes in the adjuvant setting."
                  }
                }
              }
            ],
            "emergent_systemic_risks": [
              {
                "risk_id": "ESR-001",
                "risk_type": "cross_domain",
                "risk_description": "The provision of open-label osimertinib upon recurrence to all eligible patients (including placebo arm) creates a significant confounding factor for the Overall Survival (OS) endpoint, potentially masking a true survival benefit of adjuvant treatment.",
                "discovery_reasoning": "Identified from the protocol's allowance for open-label treatment post-recurrence (Section 3.3) and its interaction with the secondary objective of measuring OS (Section 2.2).",
                "affected_domains": [
                  "Study Design",
                  "Endpoints",
                  "Statistical Analysis"
                ],
                "trigger_conditions": "This risk manifests as patients in the placebo arm experience disease recurrence and are subsequently treated with the highly effective study drug.",
                "probability": "High",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Secondary OS Endpoint"
                ],
                "quantitative_estimate": "Potential to reduce observable OS hazard ratio by 30-50%",
                "preventive_redesign": "Not feasible post-IDMC recommendation. Original design might have restricted post-progression therapy, but this is ethically challenging.",
                "monitoring_approach": "Track all subsequent anti-cancer therapies for all patients meticulously.",
                "contingency_plan": "Utilize advanced statistical methods (e.g., RPSFT, IPCW) to adjust for the confounding effect of treatment crossover in the OS analysis.",
                "linked_ctq_ids": [
                  "CTQ-001",
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "3.3",
                    "page_number": 46,
                    "text_snippet": "Eligibility for post-recurrence open-label osimertinib\nIn addition to meeting inclusion/ exclusion criteria listed in Sections 3.1 and 3.2, patients who receive open-label osimertinib will also have to fulfil the following criteria."
                  }
                }
              },
              {
                "risk_id": "ESR-002",
                "risk_type": "temporal",
                "risk_description": "The long duration of the study (3 years treatment + long-term follow-up to 10 years) increases the risk of 'study fatigue' at sites, leading to declining data quality, visit compliance, and patient retention over time.",
                "discovery_reasoning": "Inferred from the extended study timelines described in the study design and follow-up sections (Section 1.6, 1.7).",
                "affected_domains": [
                  "Operational",
                  "Data Collection",
                  "Endpoints"
                ],
                "trigger_conditions": "Risk increases significantly after the 3-year treatment period ends and patients enter the long-term, lower-intensity follow-up phase.",
                "probability": "Likely",
                "impact_severity": "Major",
                "affected_objectives": [
                  "OS Endpoint Integrity",
                  "Data Quality"
                ],
                "quantitative_estimate": "Potential for >15% of patients to be lost to follow-up.",
                "preventive_redesign": "N/A",
                "monitoring_approach": "Implement a strategic KRI to track the rate of patients lost to follow-up and monitor site engagement metrics.",
                "contingency_plan": "Develop a robust patient retention program, including regular newsletters, and utilize central monitoring to identify disengaged sites for targeted intervention.",
                "linked_ctq_ids": [
                  "CTQ-006"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "1.7",
                    "page_number": 38,
                    "text_snippet": "After the final OS analysis, a study extension has been added to allow the optional longer-term survival follow-up of patients in the ADAURA trial until approximately 10 years after the last patient is randomised..."
                  }
                }
              },
              {
                "risk_id": "ESR-003",
                "risk_type": "interaction_effect",
                "risk_description": "The combination of a long recruitment period (28 months) and a time-to-event primary endpoint (DFS) makes the study vulnerable to changes in standard of care for NSCLC, which could affect investigator behavior and patient willingness to remain on placebo.",
                "discovery_reasoning": "Inferred by combining the recruitment timeline (Section 3.7) with the rapidly evolving landscape of oncology treatment.",
                "affected_domains": [
                  "Subject Population",
                  "Operational",
                  "Study Phase"
                ],
                "trigger_conditions": "A new, highly effective therapy for early-stage NSCLC is approved and becomes widely available during the study's conduct phase.",
                "probability": "Possible",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Enrollment Rate",
                  "Patient Retention"
                ],
                "quantitative_estimate": "Could lead to a 20% increase in withdrawal of consent from the placebo arm.",
                "preventive_redesign": "N/A",
                "monitoring_approach": "Monitor clinical trial registries and scientific publications for emerging data on competing therapies.",
                "contingency_plan": "Prepare communications for investigators and ethics committees to reinforce the study rationale. If impact is severe, the Steering Committee and Sponsor will re-evaluate study feasibility.",
                "linked_ctq_ids": [
                  "CTQ-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "3.7",
                    "page_number": 37,
                    "text_snippet": "Patients will be initially followed as per the study protocol until data cut-off for the primary analysis, estimated as 68-70 months following first subject randomised, based on a 28 month recruitment period."
                  }
                }
              }
            ],
            "strategic_risk_indicators": [
              {
                "kri_id": "SKRI-001",
                "kri_type": "leading_indicator",
                "category": "Risk Velocity",
                "metric": "Monthly rate of major protocol deviations related to eligibility criteria across all sites.",
                "rationale": "An increasing trend in eligibility deviations is a leading indicator of systemic issues with the screening process, site training, or protocol complexity. It predicts future data contamination and potential for QTL breaches.",
                "predictive_value": "Predicts risk to the scientific validity of the enrolled population (CTQ-003) and potential for future regulatory scrutiny.",
                "calculation_formula": "(Number of new major eligibility deviations in month X) / (Number of subjects randomized in month X)",
                "data_sources": [
                  "EDC",
                  "CTMS"
                ],
                "frequency": "Monthly",
                "thresholds": {
                  "green": {
                    "range": "<=1%",
                    "interpretation": "Process is stable"
                  },
                  "amber": {
                    "range": "1-3%",
                    "interpretation": "Potential systemic issue, investigate trend",
                    "escalation": "Project Manager"
                  },
                  "red": {
                    "range": ">3%",
                    "interpretation": "Systemic failure, immediate action required",
                    "escalation": "Steering Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-003",
                  "CTQ-005"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This strategic KRI is not in the protocol. It is derived as a high-level oversight tool to monitor the health of the enrollment process, directly linked to the critical factor of correct patient eligibility, which is heavily emphasized in the protocol.",
                    "supporting_context": [
                      "Section 3, page 43: 'Under no circumstances can there be exceptions to this rule [eligibility].'",
                      "Section 3.5, page 47: 'Procedures for handling incorrectly enrolled or randomised subjects'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "kri_id": "SKRI-002",
                "kri_type": "leading_indicator",
                "category": "Quality Trajectory",
                "metric": "Ratio of time to query resolution for critical data points (e.g., primary endpoint, SAEs) vs. non-critical data points.",
                "rationale": "This metric assesses if sites are prioritizing the most important data. A high ratio indicates that critical data queries are aging, which is a leading indicator of poor site engagement and future problems with database lock.",
                "predictive_value": "Predicts delays in database lock and potential for unresolved critical data issues at the time of analysis.",
                "calculation_formula": "(Average days to resolve critical queries) / (Average days to resolve non-critical queries)",
                "data_sources": [
                  "EDC"
                ],
                "frequency": "Monthly",
                "thresholds": {
                  "green": {
                    "range": "<=1.2",
                    "interpretation": "Sites are prioritizing appropriately"
                  },
                  "amber": {
                    "range": "1.2-1.5",
                    "interpretation": "Sites may need reminders on prioritizing critical queries",
                    "escalation": "Lead Data Manager"
                  },
                  "red": {
                    "range": ">1.5",
                    "interpretation": "Sites are not prioritizing critical data; targeted intervention needed",
                    "escalation": "Project Manager"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-001",
                  "CTQ-002"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This strategic KRI is not in the protocol. It is derived from standard data management and RBQM practices. It serves as a leading indicator of site engagement and data quality, which are implied requirements of the monitoring and data management sections.",
                    "supporting_context": [
                      "Section 9.4, page 108: 'Data queries will be raised for inconsistent, impossible or missing data.'",
                      "Section 9.2, page 106: '...data are being accurately and timely recorded in the eCRFs...'"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "kri_id": "SKRI-003",
                "kri_type": "leading_indicator",
                "category": "Operational Health",
                "metric": "Quarterly rate of patient withdrawal from the placebo arm (post-unblinding of initial results).",
                "rationale": "After initial positive results were announced, patients on placebo may be more likely to withdraw. A high withdrawal rate is a leading indicator of potential bias in the long-term OS analysis and threatens the study's ability to answer this key secondary question.",
                "predictive_value": "Predicts a high degree of missing data and confounding for the OS endpoint, potentially rendering the analysis inconclusive.",
                "calculation_formula": "(Number of placebo patients withdrawing in quarter X) / (Total placebo patients active at start of quarter X)",
                "data_sources": [
                  "EDC",
                  "CTMS"
                ],
                "frequency": "Quarterly",
                "thresholds": {
                  "green": {
                    "range": "<2%",
                    "interpretation": "Withdrawal rate is stable"
                  },
                  "amber": {
                    "range": "2-4%",
                    "interpretation": "Monitor trend, review retention efforts",
                    "escalation": "Project Manager"
                  },
                  "red": {
                    "range": ">4%",
                    "interpretation": "High risk to OS analysis; escalate to Steering Committee",
                    "escalation": "Steering Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-006",
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This KRI is derived from the unique situation of this study, where overwhelmingly positive interim results were released while the study continued blinded. This creates a significant risk of differential dropout in the placebo arm, which could bias the OS endpoint. Monitoring this is a critical strategic necessity.",
                    "supporting_context": [
                      "Section 1.4, page 35: 'Unplanned Interim Analysis of ADAURA (IDMC7)'",
                      "Section 3.11, page 51: 'Criteria for withdrawal from study'"
                    ],
                    "confidence": "high"
                  }
                }
              }
            ],
            "strategic_summary": {
              "overall_risk_posture": "High",
              "summary": "The study carries a high inherent risk due to its long duration, time-to-event primary endpoint, and the confounding factor of open-label crossover for the key secondary OS endpoint. Critical risks center on maintaining endpoint integrity (DFS/OS), ensuring patient safety (ILD, QTc), and upholding GCP standards (eligibility, consent). The quality management strategy relies heavily on robust preventative controls (central lab, IVRS checks) and detective controls (centralized monitoring, KRIs) to mitigate these risks and ensure the collection of high-quality, interpretable data.",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This summary is a synthesis of the risks and quality factors identified throughout the protocol. It is derived from the combination of the long study duration, the critical nature of the endpoints, the known safety risks, and the confounding factor of treatment crossover.",
                  "supporting_context": [
                    "Section 2.1 (Primary Endpoint)",
                    "Section 1.7 (Long-term follow-up)",
                    "Section 3.3 (Open-label crossover)",
                    "Section 6.9 (Specific safety risks)"
                  ],
                  "confidence": "high"
                }
              }
            }
          },
          "risk_governance": {
            "risk_assessment_matrix": {
              "scoring_methodology": {
                "probability_scale": {
                  "1": "Rare (<5%)",
                  "2": "Unlikely (5-20%)",
                  "3": "Possible (20-50%)",
                  "4": "Likely (50-80%)",
                  "5": "Almost Certain (>80%)"
                },
                "impact_scale": {
                  "1": "Negligible",
                  "2": "Minor",
                  "3": "Moderate",
                  "4": "Major",
                  "5": "Catastrophic"
                },
                "risk_levels": {
                  "1-4": "Low",
                  "5-9": "Medium",
                  "10-14": "High",
                  "15-25": "Critical"
                }
              },
              "identified_risks": [
                {
                  "risk_id": "RISK-001",
                  "risk_category": "Endpoints",
                  "risk_description": "Inconsistent investigator assessment of DFS leads to biased and variable primary endpoint data.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 33,
                  "linked_ctq_id": "CTQ-001",
                  "linked_mitigation_ids": [
                    "MIT-001",
                    "MIT-002"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.1.1",
                      "page_number": 66,
                      "text_snippet": "Disease-free survival is the primary endpoint in this study and is defined as the time from the date of randomisation until the date of disease recurrence or death from any cause in the absence of disease recurrence."
                    }
                  }
                },
                {
                  "risk_id": "RISK-002",
                  "risk_category": "Safety",
                  "risk_description": "Delayed detection and management of ILD/pneumonitis results in serious harm to subjects.",
                  "risk_owner": "Investigator",
                  "inherent_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 1,
                    "impact": 5,
                    "score": 5,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-002",
                  "linked_mitigation_ids": [
                    "MIT-003"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "6.9.6",
                      "page_number": 90,
                      "text_snippet": "Interstitial lung disease\nIf a new or worsening of pulmonary symptoms (e.g., dyspnoea) or occurrence of a radiological abnormality suggestive of ILD/pneumonitis is observed, an interruption in study drug dosing is recommended..."
                    }
                  }
                },
                {
                  "risk_id": "RISK-003",
                  "risk_category": "Subject Population",
                  "risk_description": "Enrollment of subjects who do not meet the specific EGFR mutation criteria.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 1,
                    "impact": 5,
                    "score": 5,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 67,
                  "linked_ctq_id": "CTQ-003",
                  "linked_mitigation_ids": [
                    "MIT-004"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "3.1",
                      "page_number": 43,
                      "text_snippet": "6. Confirmation by the central laboratory that the tumour harbours one of the 2 common EGFR mutations..."
                    }
                  }
                },
                {
                  "risk_id": "RISK-004",
                  "risk_category": "Blinding",
                  "risk_description": "Inappropriate unblinding compromises data integrity for secondary and exploratory endpoints.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 4,
                    "score": 12,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 4,
                    "score": 8,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 33,
                  "linked_ctq_id": "CTQ-004",
                  "linked_mitigation_ids": [
                    "MIT-005"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "3.8",
                      "page_number": 48,
                      "text_snippet": "The treatment code should not be broken except in medical emergencies when the appropriate management of the patient requires knowledge of the treatment randomisation."
                    }
                  }
                },
                {
                  "risk_id": "RISK-005",
                  "risk_category": "GCP Compliance",
                  "risk_description": "Failure to obtain valid informed consent prior to study procedures.",
                  "risk_owner": "Investigator",
                  "inherent_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 1,
                    "impact": 5,
                    "score": 5,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-005",
                  "linked_mitigation_ids": [
                    "MIT-006"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "10.4",
                      "page_number": 112,
                      "text_snippet": "Ensure each patient provides signed and dated informed consent before conducting any procedure specifically for the study."
                    }
                  }
                },
                {
                  "risk_id": "RISK-006",
                  "risk_category": "Data Collection",
                  "risk_description": "High rate of patients lost to follow-up compromises the validity of the long-term OS analysis.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 4,
                    "score": 16,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 3,
                    "impact": 4,
                    "score": 12,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 25,
                  "linked_ctq_id": "CTQ-006",
                  "linked_mitigation_ids": [
                    "MIT-007"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.1.3.1",
                      "page_number": 68,
                      "text_snippet": "Following the final OS analysis, patients who consent to participate in long-term OS follow-up will be followed yearly for survival until approximately 10 years after the last patient is randomised."
                    }
                  }
                },
                {
                  "risk_id": "RISK-007",
                  "risk_category": "Operational",
                  "risk_description": "Complex logistics of mandatory tumor sample collection, shipping, and central testing lead to delays and sample failures, impacting enrollment timelines.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 3,
                    "score": 12,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 3,
                    "score": 6,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-003",
                  "linked_mitigation_ids": [
                    "MIT-008"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "4.1.3",
                      "page_number": 62,
                      "text_snippet": "Mandatory screening tumour biopsy sample for mutation analysis\nTumour sample must be formalin fixed and paraffin embedded (FFPE). ... Sites should ship the FFPE tumour sample to the testing laboratory as soon as it is available."
                    }
                  }
                },
                {
                  "risk_id": "RISK-008",
                  "risk_category": "Endpoints",
                  "risk_description": "Crossover to open-label osimertinib in the placebo arm confounds the OS analysis.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 5,
                    "impact": 4,
                    "score": 20,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 5,
                    "impact": 3,
                    "score": 15,
                    "level": "Critical"
                  },
                  "risk_reduction_percentage": 25,
                  "linked_ctq_id": "CTQ-001",
                  "linked_mitigation_ids": [
                    "MIT-009",
                    "MIT-010"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "1.3",
                      "page_number": 34,
                      "text_snippet": "Rationale for osimertinib upon recurrence... open label osimertinib will be made available to patients who at the time of disease recurrence are living with advanced/metastatic EGFRm NSCLC."
                    }
                  }
                }
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not contain a formal risk assessment matrix. This matrix and its scores are derived by applying a standard risk assessment methodology to the critical processes and potential failure modes identified within the protocol text.",
                  "supporting_context": [
                    "Section 2 (Objectives)",
                    "Section 3 (Eligibility)",
                    "Section 5 (Assessments)",
                    "Section 6 (Safety)"
                  ],
                  "confidence": "high"
                }
              }
            },
            "mitigation_strategies": [
              {
                "mitigation_id": "MIT-001",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "control_type": "Preventive",
                "control_category": "Training",
                "strategy_description": "Conduct comprehensive training for all investigators on the specific protocol definitions of disease recurrence and imaging guidelines during investigator meetings.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of training records and post-training assessments.",
                "verification_frequency": "Once per site",
                "resource_requirements": "Investigator meeting time and materials.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "9.1",
                    "page_number": 106,
                    "text_snippet": "Before the first patient is entered into the study, an AstraZeneca representative will review and discuss the requirements of the CSP and related documents with the investigational staff and also train them in any study specific procedures..."
                  }
                }
              },
              {
                "mitigation_id": "MIT-002",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "control_type": "Detective",
                "control_category": "Centralized Monitoring",
                "strategy_description": "Perform centralized statistical monitoring of site-level DFS event rates to identify outliers that may indicate inconsistent endpoint assessment.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of centralized monitoring reports and follow-up actions.",
                "verification_frequency": "Monthly",
                "resource_requirements": "Statistical monitoring software and biostatistician time.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "Centralized statistical monitoring is not explicitly mentioned. This mitigation is a standard component of a modern RBQM approach, inferred from the general requirement to ensure data accuracy and the use of an EDC system which enables such activities.",
                    "supporting_context": [
                      "Section 9.2, page 106: '...data are being accurately and timely recorded in the eCRFs...'",
                      "Section 9.4, page 108: 'Data management will be performed by PAREXEL...'"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "mitigation_id": "MIT-003",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "control_type": "Preventive",
                "control_category": "Protocol Design",
                "strategy_description": "Protocol specifies clear actions for managing suspected ILD/pneumonitis and QTc prolongation, including treatment interruption and mandatory specialist consultation.",
                "implementation_phase": "Protocol Design",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Monitor review of adherence to management guidelines for relevant AEs.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "None beyond standard monitoring.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.9",
                    "page_number": 88,
                    "text_snippet": "Management of investigational product-related toxicities"
                  }
                }
              },
              {
                "mitigation_id": "MIT-004",
                "linked_risk_ids": [
                  "RISK-003",
                  "RISK-007"
                ],
                "control_type": "Preventive",
                "control_category": "Technology/System",
                "strategy_description": "Implement an IVRS/IWRS system that requires confirmation of central lab eligibility results before a randomization number can be issued.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "User acceptance testing (UAT) of the IVRS/IWRS system.",
                "verification_frequency": "Prior to study start",
                "resource_requirements": "IVRS vendor costs and UAT resources.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol states that central lab confirmation is required and that an IVRS/IWRS will be used for randomization. This mitigation strategy connects these two facts, inferring that the IVRS/IWRS will be used as the control gate, which is standard practice.",
                    "supporting_context": [
                      "Section 3.1 (6), page 43: 'Confirmation by the central laboratory...'",
                      "Section 3.4 (5), page 47: 'Obtain a unique randomisation number via IVRS/IWRS.'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "mitigation_id": "MIT-005",
                "linked_risk_ids": [
                  "RISK-004"
                ],
                "control_type": "Preventive",
                "control_category": "Process Control",
                "strategy_description": "Establish a formal, controlled process for unblinding requests post-recurrence, managed through the IVRS/IWRS to limit premature disclosure to essential personnel.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "Medium",
                "verification_method": "Audit trail review of unblinding requests in the IVRS/IWRS.",
                "verification_frequency": "Quarterly",
                "resource_requirements": "IVRS configuration.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "3.8",
                    "page_number": 48,
                    "text_snippet": "Individual treatment codes, indicating the treatment randomisation for each randomised patient, will be available to the investigators from the IVRS/IWRS. ... Additionally, at the request of the Investigator, following disease recurrence the patient can be unblinded..."
                  }
                }
              },
              {
                "mitigation_id": "MIT-006",
                "linked_risk_ids": [
                  "RISK-005"
                ],
                "control_type": "Detective",
                "control_category": "Monitoring",
                "strategy_description": "Perform 100% SDV of all informed consent forms at the first routine monitoring visit to ensure compliance from the start.",
                "implementation_phase": "Conduct",
                "responsible_party": "Monitor",
                "effectiveness_rating": "High",
                "verification_method": "Review of monitoring visit reports.",
                "verification_frequency": "First monitoring visit",
                "resource_requirements": "Monitor time.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "9.2",
                    "page_number": 106,
                    "text_snippet": "Perform source data verification... including verification of informed consent of participating patients."
                  }
                }
              },
              {
                "mitigation_id": "MIT-007",
                "linked_risk_ids": [
                  "RISK-006"
                ],
                "control_type": "Corrective",
                "control_category": "Patient Engagement",
                "strategy_description": "Implement a patient retention plan for the long-term follow-up phase, including multiple contact methods and checking public death registries for vital status.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor/Site",
                "effectiveness_rating": "Medium",
                "verification_method": "Tracking the rate of successful follow-up contacts.",
                "verification_frequency": "Annually",
                "resource_requirements": "Site and central staff time for follow-up activities.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "4.3.4",
                    "page_number": 64,
                    "text_snippet": "Survival information may be obtained via telephone contact with the patient, patient’s family or by contact with the patient’s current physician. ... The status of ongoing, withdrawn... and “lost to follow-up” patients... should be obtained by the site personnel by... checking publicly available death registries."
                  }
                }
              },
              {
                "mitigation_id": "MIT-008",
                "linked_risk_ids": [
                  "RISK-007"
                ],
                "control_type": "Preventive",
                "control_category": "Logistics Management",
                "strategy_description": "Provide sites with pre-paid shipping kits and detailed instructions for tumor sample handling and shipment to the central lab. Establish a dedicated central lab contact for site queries.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor/Central Lab",
                "effectiveness_rating": "Medium",
                "verification_method": "Tracking sample query rates and turnaround times from the central lab.",
                "verification_frequency": "Monthly",
                "resource_requirements": "Lab kits, vendor management.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This mitigation strategy is not explicitly detailed but is inferred from the mandatory requirement to ship tumor samples to a central lab. Providing kits and clear instructions is a standard operational practice to ensure the success of such a critical logistical process.",
                    "supporting_context": [
                      "Section 4.1.3, page 62: 'Mandatory screening tumour biopsy sample for mutation analysis. ... Sites should ship the FFPE tumour sample to the testing laboratory as soon as it is available.'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "mitigation_id": "MIT-009",
                "linked_risk_ids": [
                  "RISK-008"
                ],
                "control_type": "Corrective",
                "control_category": "Statistical Analysis",
                "strategy_description": "Pre-specify in the Statistical Analysis Plan (SAP) the use of appropriate statistical methods (e.g., Rank Preserving Structural Failure Time) to adjust for treatment switching at the OS analysis.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor/Biostatistician",
                "effectiveness_rating": "Medium",
                "verification_method": "Final SAP approval.",
                "verification_frequency": "Once, before database lock",
                "resource_requirements": "Specialized biostatistical expertise.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "8.5.2.2",
                    "page_number": 104,
                    "text_snippet": "Additional exploratory analysis of overall survival adjusting for the impact of subjects randomised to placebo who subsequently receive an EGFR-TKI... Methods such as Rank Preserving Structural Failure Time (RPSFT)... and other methods in development may be explored."
                  }
                }
              },
              {
                "mitigation_id": "MIT-010",
                "linked_risk_ids": [
                  "RISK-008"
                ],
                "control_type": "Detective",
                "control_category": "Data Management",
                "strategy_description": "Ensure meticulous collection of data on all post-progression anti-cancer therapies for all subjects in both arms of the study.",
                "implementation_phase": "Conduct",
                "responsible_party": "Site/Data Management",
                "effectiveness_rating": "High",
                "verification_method": "Data review and query process for subsequent treatment forms.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "Site and data management time.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.3.3",
                    "page_number": 72,
                    "text_snippet": "Post study treatment discontinuation anti-cancer procedures and treatment\nAny subsequent anti-cancer procedures and therapies given to the patient will be captured via eCRF."
                  }
                }
              }
            ],
            "safety_signal_detection": {
              "statistical_methods": [
                {
                  "method_id": "SSD-001",
                  "method_name": "AE Incidence Monitoring",
                  "method_description": "Regular monitoring of incidence rates for pre-specified adverse events of special interest (e.g., ILD, cardiac events) compared between treatment arms.",
                  "application": "Detecting potential safety signals for known risks.",
                  "data_requirements": [
                    "AE data from EDC",
                    "Subject exposure data"
                  ],
                  "provenance": {
                    "kind": "derived",
                    "derived": {
                      "reasoning": "This method is not explicitly described but is a standard function of an IDMC. The protocol establishes an IDMC to review safety data, which implies the use of standard statistical methods like incidence monitoring to fulfill this charter.",
                      "supporting_context": [
                        "Section 6.10.1, page 91: 'The IDMC will review safety assessments and make recommendations... Serious adverse events, adverse events, and other safety data will be reviewed...'"
                      ],
                      "confidence": "high"
                    }
                  }
                }
              ],
              "stopping_rules": [
                {
                  "rule_id": "STOP-001",
                  "rule_type": "Safety",
                  "condition": "A statistically and clinically significant increase in the incidence of fatal or life-threatening AEs in the active arm compared to placebo, as determined by the IDMC.",
                  "threshold": "Defined in the IDMC Charter",
                  "action": "IDMC may recommend pausing or terminating the study.",
                  "decision_authority": "IDMC",
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "6.10.1",
                      "page_number": 91,
                      "text_snippet": "The IDMC will review safety assessments and make recommendations to continue, amend, or stop the study based on safety findings."
                    }
                  }
                },
                {
                  "rule_id": "STOP-002",
                  "rule_type": "Futility",
                  "condition": "The conditional power to demonstrate a statistically significant benefit in the primary endpoint (DFS) falls below a pre-defined threshold.",
                  "threshold": "Defined in the IDMC Charter",
                  "action": "IDMC may recommend stopping the study for futility.",
                  "decision_authority": "IDMC",
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "8.5.4",
                      "page_number": 105,
                      "text_snippet": "The IDMC will conduct a futility analysis. Further details will be documented in the IDMC Charter... An IDMC will review the futility outcomes and provide a recommendation for whether the study should continue, stop or be modified in some way."
                    }
                  }
                }
              ],
              "dsmb_interface": {
                "dsmb_required": true,
                "meeting_frequency": "Every 6 months for the first 2 years, then yearly",
                "review_scope": [
                  "Safety",
                  "Efficacy",
                  "Enrollment",
                  "Data Quality"
                ],
                "unblinding_criteria": "The IDMC will have access to unblinded data for their reviews as specified in the IDMC charter. The unplanned interim analysis for efficacy was conducted based on IDMC recommendation.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.10.1",
                    "page_number": 91,
                    "text_snippet": "An Independent Data Monitoring Committee (IDMC) will be convened and will meet approximately every 6 months for the first 2 years from the first patient randomised and approximately yearly thereafter. ... The IDMC will review safety assessments... Furthermore, an IDMC will review the futility analysis outcomes..."
                  }
                }
              }
            },
            "issue_management_cascade": {
              "level_1_site": "Issues identified by site staff are managed locally and documented. Escalate to Monitor if protocol guidance is needed or if it impacts subject safety/data.",
              "level_2_monitor": "Monitor resolves issues during routine contacts. Escalates unresolved, significant, or systemic issues to the Project Manager.",
              "level_3_project_manager": "PM manages cross-functional issue resolution. Escalates risks to study integrity, budget, or timelines to the Steering Committee.",
              "level_4_steering_committee": "Provides ultimate oversight and makes strategic decisions on major issues, including those recommended by the IDMC.",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "An issue management cascade is not defined in the protocol. This structure is derived from standard clinical operations practice, outlining the typical chain of command for resolving issues from the site level up to study leadership.",
                  "supporting_context": [
                    "Section 9.2, page 106, describes the monitor's role as a point of contact for the site.",
                    "Section 6.10.1, page 91, establishes the IDMC as a high-level oversight committee."
                  ],
                  "confidence": "medium"
                }
              }
            }
          },
          "technology_config": {
            "edc_system": "PAREXEL",
            "iwrs_system": "Specified",
            "safety_database": "AstraZeneca Global Safety Database",
            "ctms_system": "Specified",
            "rbqm_platform": "Inferred external or in-house platform",
            "provenance": {
              "kind": "explicit",
              "explicit": {
                "section_number": "9.4",
                "page_number": 108,
                "text_snippet": "Data management will be performed by PAREXEL (or alternate vendor) according to the Data Management Plan."
              }
            }
          },
          "provenance": {
            "kind": "derived",
            "derived": {
              "reasoning": "The protocol does not have a dedicated 'Risk-Based Quality Management' section. The RBQM content is derived by identifying critical-to-quality factors from the protocol's objectives, endpoints, and procedures, and then applying a standard RBQM framework (risk assessment, mitigation, governance) as required by modern GCP standards.",
              "supporting_context": [
                "Section 2 (Study Objectives)",
                "Section 3 (Subject Selection)",
                "Section 5 (Study Assessments)",
                "Section 6 (Safety Reporting)",
                "Section 9 (Study and Data Management)"
              ],
              "confidence": "high"
            }
          }
        },
        "extraction_statistics": {
          "has_monitoring_approach": true,
          "has_sdv_strategy": true,
          "has_monitoring_visits": true,
          "kri_count": 8,
          "qtl_count": 5,
          "ctq_count": 6,
          "emergent_risk_count": 3,
          "mitigation_strategy_count": 10,
          "identified_risks_count": 8,
          "has_ract_register": true,
          "has_risk_governance": true
        },
        "provenance": {
          "kind": "derived",
          "derived": {
            "reasoning": "The overall Quality Management plan is synthesized from multiple sections of the protocol, primarily Section 9 'Study and Data Management' and Section 6 'Safety Reporting'. These sections describe the components of quality oversight (monitoring, data management, safety surveillance) which are consolidated here.",
            "supporting_context": [
              "Section 6: SAFETY REPORTING AND MEDICAL MANAGEMENT",
              "Section 9: STUDY AND DATA MANAGEMENT"
            ],
            "confidence": "high"
          }
        }
      },
      "_agentDocumentation": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including RBQM, KRIs, and QTLs for CTMS monitoring configuration.",
        "scope": "Monitoring approach, RBQM, Key Risk Indicators, Quality Tolerance Limits, SDV extent, audit procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan"
        ],
        "keyInsights": [
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "CTMS_KRI_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Configure KRI monitoring thresholds",
                "sourceDataPath": "kris[]",
                "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring schedules",
          "Set up KRI dashboards"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json",
        "automationRules": [
          {
            "ruleId": "CTMS_KRI_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Configure KRI monitoring thresholds",
            "sourceDataPath": "kris[]",
            "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_QM_ALL_001",
            "name": "All Agents → Complete RBQM Dashboard",
            "agentsInvolved": [
              "quality_management",
              "adverse_events",
              "safety_decision_points",
              "data_management"
            ],
            "description": "KRI definitions + safety events + data quality = comprehensive central monitoring",
            "combinedInsight": "Site-level risk scores based on all protocol-defined indicators",
            "automationEnabled": "Automated site risk scoring and monitoring prioritization",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "withdrawalProcedures": {
      "moduleId": "withdrawal_procedures",
      "instanceType": "WithdrawalProcedures",
      "data": {
        "id": "WP-001",
        "instanceType": "WithdrawalProcedures",
        "name": "Withdrawal and Discontinuation Procedures",
        "description": "Procedural specifications for subject withdrawal and discontinuation",
        "discontinuation_types": [
          {
            "id": "DT-001",
            "type_name": {
              "code": "TREATMENT_DISCONTINUATION",
              "decode": "Treatment Discontinuation"
            },
            "definition": "Patients may be discontinued from IP or open-label osimertinib for reasons including patient decision, adverse event, pregnancy, disease recurrence, or completion of the 3-year treatment period.",
            "allows_continued_followup": true,
            "provenance": {
              "section_number": "3.10",
              "page_number": 50,
              "text_snippet": "Patients may be discontinued from IP or open-label osimertinib in the following situations:\n• Patient decision. The patient is at any time free to discontinue his/her participation in the study, without prejudice\n• Adverse event\n• Pregnancy\n• Severe non-compliance with the study protocol as judged by the Investigator and/or AstraZeneca representative\n• Patients who are incorrectly initiated on IP\n• Disease recurrence (for select patients who might have the option of open-label osimertinib upon"
            }
          },
          {
            "id": "DT-002",
            "type_name": {
              "code": "STUDY_WITHDRAWAL",
              "decode": "Study Withdrawal"
            },
            "definition": "Patients are free to withdraw from the study at any time (investigational product and assessments), without prejudice to further treatment.",
            "allows_continued_followup": false,
            "provenance": {
              "section_number": "3.11.2",
              "page_number": 51,
              "text_snippet": "Subjects are free to withdraw from the study at any time (investigational product and assessments), without prejudice to further treatment."
            }
          },
          {
            "id": "DT-003",
            "type_name": {
              "code": "PARTIAL_WITHDRAWAL",
              "decode": "Partial Withdrawal"
            },
            "definition": "If patients wish to withdraw their consent to both study drug and study assessments, they should be asked if they are willing to continue with survival follow-up (which can be conducted by telephone).",
            "allows_continued_followup": true,
            "provenance": {
              "section_number": "3.11",
              "page_number": 51,
              "text_snippet": "If patients wish to withdraw their consent to both study drug and study assessments, they should be asked if they are willing to continue with survival follow-up (which can be conducted by telephone)."
            }
          }
        ],
        "consent_withdrawal": {
          "right_to_withdraw": "At any time, patients are free to withdraw from the study without prejudice to further treatment.",
          "withdrawal_process": "If patients wish to withdraw their consent to further participation in the study entirely, including survival follow-up, this should be clearly documented in the patient notes, “Informed Consent Form addendum – options for withdrawal of consent” and in the clinical study database.",
          "data_handling_options": [
            {
              "option": {
                "code": "SUBJECT_CHOICE",
                "decode": "Subject Choice"
              },
              "description": "Patients are presented with options for withdrawal of consent via an addendum, including continuing with survival follow-up only or withdrawing entirely."
            },
            {
              "option": {
                "code": "RETAIN_ALL",
                "decode": "Retain All Data"
              },
              "description": "In the event that the patient has actively withdrawn consent to the processing of their personal data, the vital status of the patient can be obtained by site personnel from publicly available resources where it is possible to do so under applicable local laws."
            }
          ],
          "sample_handling": "If a patient withdraws consent to the use of donated biological samples, the samples will be repatriated /destroyed, and the action documented. If samples are already analysed, AstraZeneca is not obliged to destroy the results of this research.",
          "consequences": "The patient is at any time free to discontinue his/her participation in the study, without prejudice.",
          "provenance": {
            "section_number": "3.11",
            "page_number": 51,
            "text_snippet": "At any time, patients are free to withdraw from the study without prejudice to further treatment. A patient who decides to discontinue IP treatment and follow –up assessments will always be asked about the reason(s) and the presence of any AEs. If possible, they will be seen and assessed by an Investigator. Adverse events will be followed up (See Section 6.3.2); all IPs should be returned by the patient or caretaker."
          }
        },
        "discontinuation_visit": {
          "timing": "A Discontinuation visit will be performed only for the patients who prematurely discontinued treatment. The visit will be conducted as soon as possible after the patient received the last dose of investigational product.",
          "timing_days_from_last_dose": null,
          "required_assessments": [
            {
              "id": "ASS-001",
              "assessment_type": {
                "code": "AE_REVIEW",
                "decode": "Adverse Event Review"
              },
              "assessment_name": "Reason(s) for discontinuation and presence of any AEs",
              "mandatory": true
            },
            {
              "id": "ASS-002",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "Return of all unused study drugs",
              "mandatory": true
            }
          ],
          "documentation_requirements": [],
          "provenance": {
            "section_number": "3.10.1",
            "page_number": 50,
            "text_snippet": "A patient that decides to discontinue IP will always be asked about the reason(s) for discontinuation of IP and the presence of any AEs. The patient or representative will return all unused study drugs. This will also apply to patients on open-label osimertinib. As long as the patient does not withdraw consent for the study, visits will be continued according to study plan."
          }
        },
        "post_discontinuation_followup": {
          "safety_followup": {
            "duration_days": 28,
            "duration_description": "As a minimum, telephone contact should be made with the patient 28 days (+ 7 days) following the discontinuation of study drug.",
            "assessments": [
              "Collect new AEs",
              "Follow up on any ongoing AEs",
              "Collect concomitant medications (including any subsequent cancer therapy)"
            ],
            "contact_method": {
              "code": "PHONE",
              "decode": "Telephone"
            }
          },
          "survival_followup": {
            "required": true,
            "frequency": "Every 24 weeks up to 5 years (264 weeks) after randomisation and yearly thereafter.",
            "duration": "Until the study is closed.",
            "information_collected": [
              "Survival status",
              "Anti-cancer therapy, radiotherapy and surgery",
              "Serious Adverse event collection (causally related)",
              "Subsequent response and progression data (PFS)"
            ]
          },
          "ae_followup": {
            "ongoing_ae_followup": true,
            "followup_until": "Any AEs that are unresolved at the patient’s last visit in the study are followed up by the Investigator for as long as medically indicated."
          },
          "provenance": {
            "section_number": "4.3",
            "page_number": 63,
            "text_snippet": "4.3.2 Twenty-eight day follow–up\nAs a minimum, telephone contact should be made with the patient 28 days (+ 7 days) following the discontinuation of study drug to collect new AEs and follow up on any ongoing AEs and concomitant medications (including any subsequent cancer therapy). Refer to Section 6.3 for full details on AE recordings during follow-up.\n\n4.3.4 Survival follow–up (up to final OS analysis)\nAssessments for survival should be made every 24 weeks up to 5 years (264 weeks) after"
          }
        },
        "lost_to_followup": {
          "definition": "The protocol does not provide a specific definition for 'lost to follow-up'. It outlines procedures to ascertain the status of ongoing, withdrawn, and 'lost to follow-up' patients at the time of analysis.",
          "missed_visits_threshold": null,
          "contact_attempts_required": null,
          "contact_methods": [
            {
              "code": "OTHER",
              "decode": "Other"
            }
          ],
          "documentation_required": [
            "Checking the patient’s notes",
            "Checking hospital records",
            "Contacting the patient’s current physician",
            "Checking publicly available death registries"
          ],
          "provenance": {
            "section_number": "3.11",
            "page_number": 51,
            "text_snippet": "For the OS endpoints, the status of ongoing, withdrawn (from the study), and “lost to follow-up” patients at the time of the primary analysis and final OS analysis, and also at the time of the long-term OS analysis for patients who consent to long-term OS follow-up, should be obtained by the site personnel by checking the patient’s notes, hospital records, contacting the patient’s current physician, and checking publicly available death registries."
          }
        },
        "replacement_strategy": {
          "allows_replacement": false,
          "replacement_conditions": [],
          "timing_cutoff": "Withdrawn patients will not be replaced.",
          "randomization_handling": null,
          "stratification_maintenance": false,
          "provenance": {
            "section_number": "3.11",
            "page_number": 51,
            "text_snippet": "Withdrawn patients will not be replaced."
          }
        },
        "administrative_withdrawal": {
          "reasons": [
            {
              "id": "AWR-001",
              "reason_type": {
                "code": "SPONSOR_DECISION",
                "decode": "Sponsor Decision"
              },
              "description": "The study may be stopped if, in the judgment of AstraZeneca, study patients are placed at undue risk because of clinically significant findings."
            },
            {
              "id": "AWR-002",
              "reason_type": {
                "code": "SITE_CLOSURE",
                "decode": "Site Closure"
              },
              "description": "Early closure of a study site may occur due to failure of the investigator to comply with the protocol, inadequate recruitment, or discontinuation of further study intervention development."
            },
            {
              "id": "AWR-003",
              "reason_type": {
                "code": "STUDY_TERMINATION",
                "decode": "Study Termination"
              },
              "description": "AstraZeneca may terminate the entire study prematurely if concerns for safety arise."
            }
          ],
          "notification_requirements": "If the study is prematurely terminated or suspended, the sponsor shall promptly inform the investigators, the IECs/IRBs, and the regulatory authorities. The investigator shall promptly inform the participant.",
          "irb_notification": true,
          "provenance": {
            "section_number": "3.12",
            "page_number": 52,
            "text_snippet": "The study may be stopped if, in the judgment of AstraZeneca, study patients are placed at undue risk because of clinically significant findings that:\n• Meet individual stopping criteria or are otherwise considered significant.\n• Are assessed as causally related to study drug.\n• Are not considered to be consistent with continuation of the study."
          }
        },
        "data_retention": {
          "retention_period_years": 25,
          "retention_policy": "Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator for a minimum of 25 years after study archiving or as required by local regulations.",
          "analysis_populations": [
            {
              "population": {
                "code": "ITT",
                "decode": "Intent-to-Treat"
              },
              "inclusion_criteria": "The full analysis set (FAS) will include all randomised patients. Treatment groups will be compared on the basis of randomised study treatment, regardless of the treatment actually received."
            },
            {
              "population": {
                "code": "SAFETY",
                "decode": "Safety"
              },
              "inclusion_criteria": "The safety analysis set (SAS) will consist of all patients who received at least one dose of study treatment."
            }
          ],
          "provenance": {
            "section_number": "9.2.3",
            "page_number": 107,
            "text_snippet": "Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the investigator for a minimum of 25 years after study archiving or as required by local regulations, according to the AstraZeneca Global Retention and Disposal Schedule."
          }
        },
        "retention_strategies": {
          "prevention_measures": [],
          "incentives": [],
          "re_consent_procedures": null
        },
        "provenance": {
          "section_number": "3",
          "page_number": 43,
          "text_snippet": "3. SUBJECT SELECTION, ENROLMENT, RANDOMISATION, RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL"
        }
      },
      "_agentDocumentation": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures for EDC disposition forms and protocol deviation tracking.",
        "scope": "Discontinuation types, consent withdrawal, early termination visits, survival follow-up, lost to follow-up.",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition forms",
          "Configure survival follow-up tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "imagingCentralReading": {
      "moduleId": "imaging_central_reading",
      "instanceType": "ImagingCentralReading",
      "data": {
        "id": "D5164C00001-imaging-central-reading",
        "instanceType": "ImagingCentralReading",
        "name": "D5164C00001 Imaging & Central Reading",
        "description": "Tumor assessment and imaging specifications for the ADAURA study.",
        "provenance": {
          "section_number": "Title Page",
          "page_number": 1,
          "text_snippet": "A Phase III, Double-blind, Randomised, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)"
        },
        "response_criteria": {
          "primary_criteria": "Protocol-defined Disease Recurrence",
          "criteria_version": null,
          "secondary_criteria": [],
          "modifications": "Disease-Free Survival (DFS) is the primary endpoint, defined by investigator assessment of disease recurrence or death from any cause. This is an adjuvant setting trial, so standard RECIST response categories (CR, PR, SD) are not applicable for the primary analysis.",
          "provenance": {
            "section_number": "5.1.1",
            "page_number": 66,
            "text_snippet": "Disease-free survival is the primary endpoint in this study and is defined as the time from the date of randomisation until the date of disease recurrence or death from any cause in the absence of disease recurrence. Disease recurrence is defined as evidence of disease recurrence on CT or MRI scan and/or pathological disease on biopsy by investigational site assessment."
          }
        },
        "imaging_modalities": [
          {
            "modality_id": "IMG-001",
            "modality_type": "CT",
            "body_regions": [
              "chest",
              "abdomen",
              "liver",
              "adrenal glands"
            ],
            "contrast_required": true,
            "contrast_type": "IV contrast",
            "slice_thickness": null,
            "technical_requirements": "The imaging method used at baseline (CT or MRI) must be used at each subsequent follow-up assessment. In case of contrast intolerance, CT chest without contrast and MRI abdomen with contrast is preferred; non-contrast abdominal CT is also acceptable.",
            "preferred_modality": true,
            "provenance": {
              "section_number": "5.1.1",
              "page_number": 66,
              "text_snippet": "The imaging modalities used for radiological assessments will be CT scans of the chest and abdomen (including liver and adrenal glands) with contrast. In the rare case where a patient is intolerant of the contrast medium the preferred imaging would be CT chest without contrast and MRI abdomen with contrast; however a non-contrast abdominal CT will also be accepted. The methods used at baseline (CT or MRI) must be used at each subsequent follow-up assessments."
            }
          },
          {
            "modality_id": "IMG-002",
            "modality_type": "MRI",
            "body_regions": [
              "brain"
            ],
            "contrast_required": true,
            "contrast_type": "Gadolinium",
            "slice_thickness": null,
            "technical_requirements": "MRI or contrast CT of the brain is required. Must be performed at baseline (if not done pre-surgically) and at the time of recurrence.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "5.1.1",
              "page_number": 66,
              "text_snippet": "A pre-surgical MRI or contrast CT scan of the brain is considered standard of care and must be done prior to surgery. Patients in whom this was not done prior to surgery may still be enrolled providing that appropriate imaging is performed prior to randomisation."
            }
          },
          {
            "modality_id": "IMG-003",
            "modality_type": "CT",
            "body_regions": [
              "brain"
            ],
            "contrast_required": true,
            "contrast_type": "IV contrast",
            "slice_thickness": null,
            "technical_requirements": "Contrast CT or MRI of the brain is required. Must be performed at baseline (if not done pre-surgically) and at the time of recurrence.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "5.1.1",
              "page_number": 66,
              "text_snippet": "A pre-surgical MRI or contrast CT scan of the brain is considered standard of care and must be done prior to surgery. Patients in whom this was not done prior to surgery may still be enrolled providing that appropriate imaging is performed prior to randomisation."
            }
          }
        ],
        "assessment_schedule": {
          "baseline_window": "Within 28 days prior to treatment initiation.",
          "on_treatment_frequency": "At Week 12, Week 24, and then every 24 weeks until 5 years, then yearly thereafter until disease recurrence.",
          "first_assessment_timing": "Week 12",
          "post_treatment_schedule": "Patients who discontinue treatment prior to recurrence will continue to be imaged on the same schedule (every 24 weeks until 5 years, then yearly).",
          "confirmatory_scan_required": false,
          "confirmatory_scan_window": null,
          "assessment_timepoints": [
            "Baseline",
            "Week 12",
            "Week 24",
            "Every 24 weeks until 5 years",
            "Yearly thereafter"
          ],
          "provenance": {
            "section_number": "5.1.1",
            "page_number": 67,
            "text_snippet": "The baseline assessments should be performed within 28 days prior to study drug initiation. Subsequent assessments are to be performed at 12 week, 24 week and then every 24 weeks until 5 years (264 weeks), and then yearly thereafter relative randomisation, until disease recurrence is recorded."
          }
        },
        "lesion_requirements": {
          "measurable_disease_definition": "Not applicable. Patients must have had complete surgical resection and have no evidence of disease at baseline.",
          "target_lesion_minimum_size": null,
          "lymph_node_criteria": null,
          "max_target_lesions": null,
          "max_target_lesions_per_organ": null,
          "non_target_lesion_definition": null,
          "non_measurable_disease": [],
          "provenance": {
            "section_number": "3.1",
            "page_number": 43,
            "text_snippet": "7. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour."
          }
        },
        "response_categories": [
          {
            "category_code": "RECURRENCE",
            "category_name": "Disease Recurrence",
            "definition": "Evidence of disease recurrence on CT or MRI scan and/or pathological disease on biopsy by investigational site assessment. Dating of recurrence is based on the date of the first positive imaging record.",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "Appearance of any new lesion consistent with tumor.",
            "provenance": {
              "section_number": "5.1.1",
              "page_number": 66,
              "text_snippet": "Disease recurrence is defined as evidence of disease recurrence on CT or MRI scan and/or pathological disease on biopsy by investigational site assessment."
            }
          },
          {
            "category_code": "DISEASE-FREE",
            "category_name": "Disease-Free",
            "definition": "Absence of disease recurrence.",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "No new lesions.",
            "provenance": {
              "section_number": "5.1.1",
              "page_number": 66,
              "text_snippet": "Disease-free survival is the primary endpoint in this study and is defined as the time from the date of randomisation until the date of disease recurrence or death from any cause in the absence of disease recurrence."
            }
          }
        ],
        "central_reading": {
          "bicr_required": false,
          "bicr_purpose": "The primary endpoint of DFS is based on investigator site assessment. A retrospective radiology review of all cases may be undertaken, but there is no prospective BICR.",
          "reading_methodology": null,
          "reader_qualifications": null,
          "blinding_requirements": null,
          "adjudication_process": null,
          "vendor_name": null,
          "turnaround_time": null,
          "provenance": {
            "section_number": "8.5.1",
            "page_number": 103,
            "text_snippet": "There is no prospective central radiology review planned for this study. A central review of equivocal cases by a review committee may be conducted. A retrospective radiology review of all cases may also be undertaken."
          }
        },
        "image_submission": {
          "submission_method": null,
          "format_requirements": null,
          "anonymization_requirements": null,
          "submission_timeline": null,
          "quality_requirements": null,
          "provenance": {
            "section_number": "5",
            "page_number": 66,
            "text_snippet": "The Electronic Data Capture system will be used for data collection and query handling. The investigator will ensure that data are recorded on the electronic Case Report Forms as specified in the study protocol and in accordance with the instructions provided."
          }
        },
        "special_assessments": [
          {
            "assessment_id": "SA-001",
            "assessment_name": "Echocardiogram/MUGA scan",
            "purpose": "To assess Left Ventricular Ejection Fraction (LVEF) for cardiac safety.",
            "methodology": "The modality used (Echocardiogram or MUGA) must be consistent throughout the study.",
            "schedule": "Screening, Week 12, then every 12 weeks until treatment completion or discontinuation.",
            "provenance": {
              "section_number": "5.2.4",
              "page_number": 71,
              "text_snippet": "An Echocardiogram or MUGA scan to assess LVEF will be performed at the visits as shown in the Study Plan (Table 1). The modality of the cardiac function assessments must be consistent throughout i.e., if echocardiogram is used for the screening assessment then echocardiogram should also be used for subsequent scans."
            }
          }
        ],
        "immune_related_criteria": {
          "irecist_used": false,
          "pseudoprogression_handling": null,
          "confirmation_requirements": null,
          "treatment_beyond_progression": null,
          "provenance": {
            "section_number": "5.1.1",
            "page_number": 66,
            "text_snippet": "Disease-free survival is the primary endpoint in this study and is defined as the time from the date of randomisation until the date of disease recurrence or death from any cause in the absence of disease recurrence. Disease recurrence is defined as evidence of disease recurrence on CT or MRI scan and/or pathological disease on biopsy by investigational site assessment."
          }
        },
        "extraction_statistics": {
          "has_response_criteria": true,
          "has_bicr": false,
          "has_immune_criteria": false,
          "modality_count": 3,
          "response_category_count": 2
        }
      },
      "_agentDocumentation": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications for oncology and imaging-endpoint studies.",
        "scope": "Response criteria (RECIST, RANO), imaging modalities, central vs local reading, adjudication procedures.",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IMAGING_RESP_001",
                "ruleType": "derivation",
                "targetSystem": "Central Imaging",
                "description": "Configure central imaging for response assessment",
                "sourceDataPath": "response_criteria",
                "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json",
        "automationRules": [
          {
            "ruleId": "IMAGING_RESP_001",
            "ruleType": "derivation",
            "targetSystem": "Central Imaging",
            "description": "Configure central imaging for response assessment",
            "sourceDataPath": "response_criteria",
            "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_IMG_EP_001",
            "name": "Imaging + Endpoints → Response-Based Efficacy",
            "agentsInvolved": [
              "imaging_central_reading",
              "endpoints_estimands_sap"
            ],
            "description": "Response criteria + primary endpoint = complete efficacy assessment workflow",
            "combinedInsight": "RECIST definitions + ORR/PFS endpoints = Imaging-derived efficacy programming",
            "automationEnabled": "Central imaging outputs directly feed efficacy analysis datasets",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "pkpdSampling": {
      "moduleId": "pkpd_sampling",
      "instanceType": "PKPDSampling",
      "data": {
        "id": "D5164C00001-pkpd-sampling",
        "instanceType": "PKPDSampling",
        "name": "D5164C00001 PK/PD Sampling",
        "description": "Pharmacokinetic and pharmacodynamic sampling requirements for AZD9291 (osimertinib) in patients with Stage IB-IIIA Non-small Cell Lung Carcinoma.",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "Revised Clinical Study Protocol\nDrug Substance AZD9291\nStudy Code D5164C00001\nEdition Number 6.0\nDate 09 August 2023"
        },
        "pk_sampling": {
          "pk_sampling_required": true,
          "pk_sampling_purpose": "To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites, to be analysed using a population PK approach, and to explore the relationship between PK and selected efficacy, safety, and/or PRO endpoints.",
          "provenance": {
            "section_number": "2.2",
            "page_number": 40,
            "text_snippet": "To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites (AZ5104 and AZ7550)\nPK data from this study will be analysed using a population PK approach and reported separately to the Clinical Study Report (CSR)."
          },
          "analytes": [
            {
              "analyte_id": "ANALYTE-001",
              "analyte_name": "AZD9291",
              "analyte_type": "parent_drug",
              "matrix": "plasma",
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites (AZ5104 and AZ7550)"
              }
            },
            {
              "analyte_id": "ANALYTE-002",
              "analyte_name": "AZ5104",
              "analyte_type": "metabolite",
              "matrix": "plasma",
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites (AZ5104 and AZ7550)"
              }
            },
            {
              "analyte_id": "ANALYTE-003",
              "analyte_name": "AZ7550",
              "analyte_type": "metabolite",
              "matrix": "plasma",
              "provenance": {
                "section_number": "2.2",
                "page_number": 40,
                "text_snippet": "To characterise the pharmacokinetics (PK) of AZD9291 and its metabolites (AZ5104 and AZ7550)"
              }
            }
          ],
          "sampling_schedule": [
            {
              "schedule_id": "SCHED-001",
              "visit_name": "Week 4",
              "timepoints": [
                {
                  "timepoint_name": "Pre-dose",
                  "nominal_time": "0h"
                },
                {
                  "timepoint_name": "0.5-1.5 hours post-dose",
                  "nominal_time": "0.5-1.5h"
                },
                {
                  "timepoint_name": "2-4 hours post-dose",
                  "nominal_time": "2-4h"
                }
              ],
              "sample_type": "intensive",
              "provenance": {
                "section_number": "5.4.1",
                "page_number": 74,
                "text_snippet": "Pharmacokinetics blood sampling (2 mL each) will be performed for all patients at pre-dose, 0.5 to 1.5 hours, and 2 to 4 hours post dose on Week 4, Week 24, Week 48 and Week 96. Week 96 PK sample post IDMC7 analysis will not be collected."
              }
            },
            {
              "schedule_id": "SCHED-002",
              "visit_name": "Week 24",
              "timepoints": [
                {
                  "timepoint_name": "Pre-dose",
                  "nominal_time": "0h"
                },
                {
                  "timepoint_name": "0.5-1.5 hours post-dose",
                  "nominal_time": "0.5-1.5h"
                },
                {
                  "timepoint_name": "2-4 hours post-dose",
                  "nominal_time": "2-4h"
                }
              ],
              "sample_type": "intensive",
              "provenance": {
                "section_number": "5.4.1",
                "page_number": 74,
                "text_snippet": "Pharmacokinetics blood sampling (2 mL each) will be performed for all patients at pre-dose, 0.5 to 1.5 hours, and 2 to 4 hours post dose on Week 4, Week 24, Week 48 and Week 96. Week 96 PK sample post IDMC7 analysis will not be collected."
              }
            },
            {
              "schedule_id": "SCHED-003",
              "visit_name": "Week 48",
              "timepoints": [
                {
                  "timepoint_name": "Pre-dose",
                  "nominal_time": "0h"
                },
                {
                  "timepoint_name": "0.5-1.5 hours post-dose",
                  "nominal_time": "0.5-1.5h"
                },
                {
                  "timepoint_name": "2-4 hours post-dose",
                  "nominal_time": "2-4h"
                }
              ],
              "sample_type": "intensive",
              "provenance": {
                "section_number": "5.4.1",
                "page_number": 74,
                "text_snippet": "Pharmacokinetics blood sampling (2 mL each) will be performed for all patients at pre-dose, 0.5 to 1.5 hours, and 2 to 4 hours post dose on Week 4, Week 24, Week 48 and Week 96. Week 96 PK sample post IDMC7 analysis will not be collected."
              }
            }
          ],
          "intensive_pk_visits": [
            "Week 4",
            "Week 24",
            "Week 48"
          ],
          "sparse_pk_visits": [],
          "sample_volume": "2 mL each",
          "sample_volumeProvenance": {
            "section_number": "5.4.1",
            "page_number": 74,
            "text_snippet": "Pharmacokinetics blood sampling (2 mL each) will be performed for all patients at pre-dose, 0.5 to 1.5 hours, and 2 to 4 hours post dose on Week 4, Week 24, Week 48 and Week 96."
          },
          "total_pk_samples": 9
        },
        "pk_parameters": {
          "primary_parameters": [],
          "secondary_parameters": [],
          "calculation_method": "Population PK approach",
          "provenance": {
            "section_number": "8.4.3",
            "page_number": 101,
            "text_snippet": "Pharmacokinetic data from this study will be analysed using a population PK approach, which may include exploring the influence of covariates on PK, if the data allow. The data collected in this study may also be combined with similar data from other studies and explored using population PK and/or pharmacokinetic-pharmacodynamic methods."
          }
        },
        "population_pk": {
          "pop_pk_planned": true,
          "modeling_approach": "Population PK",
          "covariates": [],
          "objectives": [
            "To analyze PK data using a population PK approach.",
            "To explore the influence of covariates on PK.",
            "To correlate PK with other primary, secondary, and exploratory endpoints."
          ],
          "provenance": {
            "section_number": "8.4.3",
            "page_number": 101,
            "text_snippet": "Pharmacokinetic data from this study will be analysed using a population PK approach, which may include exploring the influence of covariates on PK, if the data allow. The data collected in this study may also be combined with similar data from other studies and explored using population PK and/or pharmacokinetic-pharmacodynamic methods. The results of any such analyses will be reported separately from the CSR."
          }
        },
        "pd_assessments": {
          "pd_assessments_required": false,
          "provenance": {
            "section_number": "5.5",
            "page_number": 76,
            "text_snippet": "Pharmacodynamics (not applicable)"
          }
        },
        "immunogenicity": {
          "ada_testing_required": false,
          "provenance": {
            "section_number": null,
            "page_number": 16,
            "text_snippet": "The term 'immunogenicity' is not mentioned in the protocol's table of contents or main body, indicating that immunogenicity assessments are not planned for this study."
          }
        },
        "sample_handling": {
          "collection_tubes": null,
          "processing_requirements": "Details on sample processing, handling, shipment, and storage are provided in the Laboratory Manual.",
          "storage_conditions": "Details on sample processing, handling, shipment, and storage are provided in the Laboratory Manual.",
          "shipping_requirements": "Details on sample processing, handling, shipment, and storage are provided in the Laboratory Manual.",
          "central_lab": "Covance",
          "provenance": {
            "section_number": "5.4.2",
            "page_number": 75,
            "text_snippet": "Samples for determination of AZD9291 (and metabolite) concentrations in plasma will be collected and analysed by Covance on behalf of AstraZeneca. Full details of the analytical method used will be described in a separate bioanalytical report."
          }
        },
        "special_populations": {
          "provenance": {
            "section_number": null,
            "page_number": 16,
            "text_snippet": "The protocol does not contain a specific section detailing pharmacokinetic sampling in special populations such as patients with renal or hepatic impairment."
          }
        },
        "extraction_statistics": {
          "has_pk_sampling": true,
          "has_pd_assessments": false,
          "has_immunogenicity": false,
          "has_population_pk": true,
          "analyte_count": 3,
          "biomarker_count": 0,
          "total_pk_timepoints": 9
        }
      },
      "_agentDocumentation": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications for clinical pharmacology studies.",
        "scope": "PK sampling timepoints, PD biomarker sampling, bioanalytical methods, population PK specifications.",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    }
  },
  "provenanceSummary": {
    "totalPagesReferenced": 85,
    "pageRange": [
      1,
      147
    ],
    "sectionPageCounts": {
      "studyMetadata": 7,
      "studyDesign": 12,
      "endpointsEstimandsSAP": 14,
      "adverseEvents": 9,
      "safetyDecisionPoints": 8,
      "concomitantMedications": 8,
      "biospecimenHandling": 12,
      "laboratorySpecifications": 17,
      "informedConsent": 34,
      "proSpecifications": 7,
      "dataManagement": 14,
      "siteOperationsLogistics": 23,
      "qualityManagement": 21,
      "withdrawalProcedures": 6,
      "imagingCentralReading": 6,
      "pkpdSampling": 7
    },
    "pageToSections": {
      "1": [
        "studyMetadata",
        "studyDesign",
        "endpointsEstimandsSAP",
        "informedConsent",
        "siteOperationsLogistics",
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "7": [
        "studyMetadata"
      ],
      "8": [
        "studyMetadata",
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "9": [
        "studyMetadata",
        "studyDesign"
      ],
      "11": [
        "adverseEvents",
        "laboratorySpecifications",
        "proSpecifications"
      ],
      "13": [
        "studyMetadata",
        "studyDesign"
      ],
      "14": [
        "studyDesign",
        "informedConsent"
      ],
      "16": [
        "pkpdSampling"
      ],
      "27": [
        "informedConsent"
      ],
      "31": [
        "endpointsEstimandsSAP",
        "informedConsent"
      ],
      "32": [
        "adverseEvents"
      ],
      "34": [
        "qualityManagement"
      ],
      "35": [
        "informedConsent",
        "dataManagement"
      ],
      "36": [
        "informedConsent"
      ],
      "37": [
        "informedConsent",
        "qualityManagement"
      ],
      "38": [
        "studyDesign",
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "39": [
        "studyDesign"
      ],
      "40": [
        "endpointsEstimandsSAP",
        "qualityManagement",
        "pkpdSampling"
      ],
      "41": [
        "endpointsEstimandsSAP"
      ],
      "42": [
        "endpointsEstimandsSAP"
      ],
      "43": [
        "studyMetadata",
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement",
        "withdrawalProcedures",
        "imagingCentralReading"
      ],
      "44": [
        "studyMetadata",
        "concomitantMedications",
        "laboratorySpecifications"
      ],
      "45": [
        "laboratorySpecifications"
      ],
      "46": [
        "laboratorySpecifications",
        "qualityManagement"
      ],
      "48": [
        "studyDesign",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "49": [
        "concomitantMedications",
        "informedConsent"
      ],
      "50": [
        "endpointsEstimandsSAP",
        "safetyDecisionPoints",
        "withdrawalProcedures"
      ],
      "51": [
        "informedConsent",
        "withdrawalProcedures"
      ],
      "52": [
        "safetyDecisionPoints",
        "dataManagement",
        "withdrawalProcedures"
      ],
      "53": [
        "studyDesign",
        "biospecimenHandling",
        "informedConsent",
        "dataManagement"
      ],
      "54": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "dataManagement"
      ],
      "55": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "dataManagement"
      ],
      "56": [
        "biospecimenHandling",
        "informedConsent",
        "proSpecifications",
        "dataManagement"
      ],
      "58": [
        "informedConsent",
        "proSpecifications"
      ],
      "61": [
        "laboratorySpecifications",
        "siteOperationsLogistics"
      ],
      "62": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "dataManagement",
        "qualityManagement"
      ],
      "63": [
        "studyDesign",
        "informedConsent",
        "withdrawalProcedures"
      ],
      "64": [
        "informedConsent",
        "qualityManagement"
      ],
      "66": [
        "endpointsEstimandsSAP",
        "siteOperationsLogistics",
        "qualityManagement",
        "imagingCentralReading"
      ],
      "67": [
        "imagingCentralReading"
      ],
      "68": [
        "endpointsEstimandsSAP",
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "qualityManagement"
      ],
      "69": [
        "biospecimenHandling",
        "laboratorySpecifications"
      ],
      "70": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "71": [
        "informedConsent",
        "siteOperationsLogistics",
        "imagingCentralReading"
      ],
      "72": [
        "informedConsent",
        "proSpecifications",
        "qualityManagement"
      ],
      "73": [
        "proSpecifications",
        "siteOperationsLogistics"
      ],
      "74": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "proSpecifications",
        "pkpdSampling"
      ],
      "75": [
        "siteOperationsLogistics",
        "pkpdSampling"
      ],
      "76": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "pkpdSampling"
      ],
      "77": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent"
      ],
      "78": [
        "biospecimenHandling",
        "informedConsent"
      ],
      "79": [
        "adverseEvents"
      ],
      "80": [
        "adverseEvents"
      ],
      "82": [
        "adverseEvents"
      ],
      "83": [
        "safetyDecisionPoints",
        "laboratorySpecifications",
        "informedConsent"
      ],
      "84": [
        "adverseEvents",
        "dataManagement"
      ],
      "88": [
        "studyDesign",
        "safetyDecisionPoints",
        "qualityManagement"
      ],
      "89": [
        "studyDesign",
        "safetyDecisionPoints",
        "concomitantMedications",
        "laboratorySpecifications",
        "informedConsent"
      ],
      "90": [
        "adverseEvents",
        "safetyDecisionPoints",
        "concomitantMedications",
        "laboratorySpecifications",
        "informedConsent",
        "qualityManagement"
      ],
      "91": [
        "adverseEvents",
        "safetyDecisionPoints",
        "laboratorySpecifications",
        "informedConsent",
        "dataManagement",
        "qualityManagement"
      ],
      "92": [
        "studyDesign",
        "siteOperationsLogistics"
      ],
      "93": [
        "siteOperationsLogistics"
      ],
      "94": [
        "siteOperationsLogistics"
      ],
      "95": [
        "concomitantMedications",
        "siteOperationsLogistics"
      ],
      "96": [
        "endpointsEstimandsSAP"
      ],
      "98": [
        "endpointsEstimandsSAP"
      ],
      "99": [
        "endpointsEstimandsSAP",
        "dataManagement"
      ],
      "101": [
        "pkpdSampling"
      ],
      "102": [
        "endpointsEstimandsSAP"
      ],
      "103": [
        "endpointsEstimandsSAP",
        "imagingCentralReading"
      ],
      "104": [
        "endpointsEstimandsSAP",
        "proSpecifications",
        "qualityManagement"
      ],
      "105": [
        "qualityManagement"
      ],
      "106": [
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "107": [
        "dataManagement",
        "siteOperationsLogistics",
        "withdrawalProcedures"
      ],
      "108": [
        "adverseEvents",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "109": [
        "siteOperationsLogistics"
      ],
      "110": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "111": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "112": [
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "123": [
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "133": [
        "biospecimenHandling"
      ],
      "140": [
        "safetyDecisionPoints"
      ],
      "145": [
        "concomitantMedications"
      ],
      "146": [
        "concomitantMedications"
      ],
      "147": [
        "concomitantMedications"
      ]
    }
  },
  "agentDocumentation": {
    "description": "Agent documentation for downstream system automation. Each agent's documentation describes its purpose, key insights, downstream system integrations, and automation use cases.",
    "agents": {
      "data_management": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications for EDC setup and data management planning.",
        "scope": "EDC requirements, CDISC standards versions, data entry timelines, query management, database lock procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines",
          "Set up CDISC standards compliance checks"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "pkpd_sampling": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications for clinical pharmacology studies.",
        "scope": "PK sampling timepoints, PD biomarker sampling, bioanalytical methods, population PK specifications.",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "informed_consent": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements for ICF template generation and IRB submission.",
        "scope": "Key risks, potential benefits, treatment alternatives, compensation, genetic/biobanking consents, witness requirements.",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "site_operations_logistics": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements for site initiation planning and CTMS configuration.",
        "scope": "Site equipment, training requirements, drug storage, IP accountability, vendor coordination.",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "withdrawal_procedures": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures for EDC disposition forms and protocol deviation tracking.",
        "scope": "Discontinuation types, consent withdrawal, early termination visits, survival follow-up, lost to follow-up.",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition forms",
          "Configure survival follow-up tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "quality_management": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including RBQM, KRIs, and QTLs for CTMS monitoring configuration.",
        "scope": "Monitoring approach, RBQM, Key Risk Indicators, Quality Tolerance Limits, SDV extent, audit procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan"
        ],
        "keyInsights": [
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "CTMS_KRI_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Configure KRI monitoring thresholds",
                "sourceDataPath": "kris[]",
                "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring schedules",
          "Set up KRI dashboards"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json",
        "automationRules": [
          {
            "ruleId": "CTMS_KRI_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Configure KRI monitoring thresholds",
            "sourceDataPath": "kris[]",
            "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_QM_ALL_001",
            "name": "All Agents → Complete RBQM Dashboard",
            "agentsInvolved": [
              "quality_management",
              "adverse_events",
              "safety_decision_points",
              "data_management"
            ],
            "description": "KRI definitions + safety events + data quality = comprehensive central monitoring",
            "combinedInsight": "Site-level risk scores based on all protocol-defined indicators",
            "automationEnabled": "Automated site risk scoring and monitoring prioritization",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "imaging_central_reading": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications for oncology and imaging-endpoint studies.",
        "scope": "Response criteria (RECIST, RANO), imaging modalities, central vs local reading, adjudication procedures.",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IMAGING_RESP_001",
                "ruleType": "derivation",
                "targetSystem": "Central Imaging",
                "description": "Configure central imaging for response assessment",
                "sourceDataPath": "response_criteria",
                "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json",
        "automationRules": [
          {
            "ruleId": "IMAGING_RESP_001",
            "ruleType": "derivation",
            "targetSystem": "Central Imaging",
            "description": "Configure central imaging for response assessment",
            "sourceDataPath": "response_criteria",
            "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_IMG_EP_001",
            "name": "Imaging + Endpoints → Response-Based Efficacy",
            "agentsInvolved": [
              "imaging_central_reading",
              "endpoints_estimands_sap"
            ],
            "description": "Response criteria + primary endpoint = complete efficacy assessment workflow",
            "combinedInsight": "RECIST definitions + ORR/PFS endpoints = Imaging-derived efficacy programming",
            "automationEnabled": "Central imaging outputs directly feed efficacy analysis datasets",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "biospecimen_handling": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements for central lab and biobank setup.",
        "scope": "Specimen types, tube types/volumes, processing instructions, storage conditions, shipping requirements, biobanking.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate lab kit contents from specimen requirements",
                "sourceDataPath": "specimens[]",
                "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate lab kit contents from specimen requirements",
            "sourceDataPath": "specimens[]",
            "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_BIO_SOA_001",
            "name": "Specimens + SOA → Visit-Based Lab Kits",
            "agentsInvolved": [
              "biospecimen_handling",
              "soa_schedule"
            ],
            "description": "Specimen requirements + visit schedule = visit-specific lab kit configurations",
            "combinedInsight": "What samples at which visits = Complete lab kit manifest per visit",
            "automationEnabled": "Central lab auto-generates visit-specific kit labels",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "adverse_events": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_AE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate AE dates within collection period",
                "sourceDataPath": "ae_definitions",
                "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
                "example": "AE start date must be >= first dose date for TEAE flag"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_SAE_001",
                "ruleType": "alert",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure SAE detection and expedited reporting workflow",
                "sourceDataPath": "sae_criteria.criteria[]",
                "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
                "example": "Death → 24hr initial report, 7-day follow-up"
              },
              {
                "ruleId": "EDC_SAE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Enforce SAE documentation requirements",
                "sourceDataPath": "sae_criteria",
                "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_TIMELINE_001",
                "ruleType": "workflow",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure safety reporting timeline workflows",
                "sourceDataPath": "reporting_procedures",
                "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_AESI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Prompt for AESI-specific data collection",
                "sourceDataPath": "aesi_list[]",
                "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
                "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_DLT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure DLT-based dose escalation rules",
                "sourceDataPath": "dlt_criteria",
                "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
                "example": "3+3 design with 28-day DLT window"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_AE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate AE dates within collection period",
            "sourceDataPath": "ae_definitions",
            "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
            "example": "AE start date must be >= first dose date for TEAE flag"
          },
          {
            "ruleId": "SAFETY_SAE_001",
            "ruleType": "alert",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure SAE detection and expedited reporting workflow",
            "sourceDataPath": "sae_criteria.criteria[]",
            "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
            "example": "Death → 24hr initial report, 7-day follow-up"
          },
          {
            "ruleId": "EDC_SAE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Enforce SAE documentation requirements",
            "sourceDataPath": "sae_criteria",
            "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
            "example": null
          },
          {
            "ruleId": "SAFETY_TIMELINE_001",
            "ruleType": "workflow",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure safety reporting timeline workflows",
            "sourceDataPath": "reporting_procedures",
            "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
            "example": null
          },
          {
            "ruleId": "EDC_AESI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Prompt for AESI-specific data collection",
            "sourceDataPath": "aesi_list[]",
            "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
            "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
          },
          {
            "ruleId": "IRT_DLT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure DLT-based dose escalation rules",
            "sourceDataPath": "dlt_criteria",
            "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
            "example": "3+3 design with 28-day DLT window"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_AE_SAFETY_001",
            "name": "AE Grading + Safety Thresholds → Automated Dose Decisions",
            "agentsInvolved": [
              "adverse_events",
              "safety_decision_points"
            ],
            "description": "CTCAE grades combined with safety thresholds enable automated dose recommendations",
            "combinedInsight": "Grade 3 neutropenia + safety rules = Hold dose, check ANC in 1 week",
            "automationEnabled": "EDC displays recommended action when AE grade is entered",
            "exampleOutput": "{\"ae\": \"Neutropenia Grade 3\", \"action\": \"Hold dose\", \"recheck\": \"7 days\", \"resume_criteria\": \"ANC >= 1500\"}"
          },
          {
            "synergyId": "SYN_AE_CM_001",
            "name": "AE + Concomitant Meds → Drug Interaction Alerts",
            "agentsInvolved": [
              "adverse_events",
              "concomitant_medications"
            ],
            "description": "AE patterns combined with prohibited medications enables interaction detection",
            "combinedInsight": "QT prolongation AE + QT-prolonging concomitant med = Potential drug interaction",
            "automationEnabled": "Real-time drug interaction alert when entering concomitant medications",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_AE_001",
            "name": "CTCAE Version Consistency",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "consistency",
            "description": "Verify CTCAE version is specified and consistent throughout",
            "checkLogic": "ctcae_version IS NOT NULL AND ctcae_version == data_standards.ctcae_version",
            "severity": "error"
          },
          {
            "ruleId": "VAL_AE_002",
            "name": "AESI-SAE Overlap",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "completeness",
            "description": "Check if AESIs have SAE reporting guidance",
            "checkLogic": "FOR EACH aesi: EXISTS sae_guidance OR aesi.always_serious == true",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Safety Database (Pharmacovigilance)",
            "configType": "protocol_profile",
            "description": "Safety database protocol-specific configuration",
            "dataSources": [
              "sae_criteria.criteria[]",
              "reporting_procedures",
              "aesi_list[]",
              "dlt_criteria"
            ],
            "outputFormat": "Safety database import (Argus, ARISg, Oracle Empirica)",
            "exampleConfig": {
              "sae_criteria": [
                {
                  "criterion": "Death",
                  "code": "C48275",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Life-threatening",
                  "code": "C84266",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Hospitalization",
                  "code": "C84268",
                  "timeline_hours": 72
                }
              ],
              "aesi_list": [
                {
                  "term": "Hepatotoxicity",
                  "meddra_codes": [
                    "10019670"
                  ],
                  "enhanced_collection": true
                }
              ],
              "meddra_version": "26.0",
              "ctcae_version": "5.0"
            }
          }
        ]
      },
      "study_metadata": {
        "agentId": "study_metadata",
        "displayName": "Study Metadata",
        "instanceType": "Study",
        "wave": 0,
        "priority": 0,
        "purpose": "Extracts foundational study-level metadata that all other agents depend on.\n    This agent runs first and provides the context (protocol ID, phase, therapeutic area,\n    population characteristics) that enables accurate extraction by downstream agents.",
        "scope": "- Protocol identification (NCT, EudraCT, IND numbers)\n    - Study phase, type, and design overview\n    - Sponsor information\n    - Target population characteristics (disease, age, sex, biomarkers)\n    - Key milestones and timelines\n    - Design metadata (randomization, blinding, enrollment targets)",
        "keySectionsAnalyzed": [
          "Title Page / Cover",
          "Synopsis",
          "Section 1: Introduction and Background",
          "Section 3: Study Objectives",
          "Section 4: Study Design",
          "Section 5: Study Population"
        ],
        "keyInsights": [
          {
            "name": "Protocol Identifiers",
            "description": "NCT number, EudraCT, IND numbers for regulatory cross-referencing",
            "dataPath": "studyIdentifiers[]",
            "downstreamUses": [
              "CTMS study registration",
              "Regulatory submission linking",
              "ClinicalTrials.gov sync"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "CTMS_REG_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Auto-populate CTMS study record from protocol identifiers",
                "sourceDataPath": "studyIdentifiers[].identifier",
                "ruleLogic": "FOR EACH id IN studyIdentifiers: SET ctms.registry[id.type] = id.identifier",
                "example": "NCT number → CTMS.NCT_ID field"
              }
            ],
            "validationChecks": [
              "All identifiers must match ClinicalTrials.gov registry"
            ]
          },
          {
            "name": "Study Phase",
            "description": "Clinical trial phase with NCI Thesaurus code",
            "dataPath": "studyPhase",
            "downstreamUses": [
              "Regulatory pathway determination",
              "Site qualification criteria",
              "Budget estimation"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_PHASE_001",
                "ruleType": "validation",
                "targetSystem": "Interactive Response Technology",
                "description": "Validate IRT complexity requirements based on phase",
                "sourceDataPath": "studyPhase.decode",
                "ruleLogic": "IF phase IN ['Phase 1', 'Phase 1/2'] THEN require dose_escalation_module",
                "example": "Phase 1 → Enable dose escalation cohort management"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Target Population",
            "description": "Disease, age range, sex, biomarker requirements, performance status",
            "dataPath": "studyPopulation",
            "downstreamUses": [
              "Site feasibility scoring",
              "Patient recruitment targeting",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_ELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate age range edit check for eligibility form",
                "sourceDataPath": "studyPopulation.ageRange",
                "ruleLogic": "IF subject_age < min_age OR subject_age > max_age THEN RAISE eligibility_failure",
                "example": "Age 18-75 → Edit check: BRTHDT must result in age between 18 and 75 at screening"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Study Milestones",
            "description": "Screening period, enrollment duration, treatment duration, follow-up",
            "dataPath": "studyMilestones",
            "downstreamUses": [
              "CTMS timeline configuration",
              "Site contract milestones",
              "Resource planning"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Design Metadata",
            "description": "Randomization ratio, blinding type, target enrollment, countries",
            "dataPath": "studyDesignInfo",
            "downstreamUses": [
              "IRT configuration",
              "Drug supply planning",
              "Regulatory strategy"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_RAND_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT randomization ratio",
                "sourceDataPath": "studyDesignInfo.randomizationRatio",
                "ruleLogic": "SET irt.allocation_ratio = randomizationRatio; SET irt.block_size = CALCULATE(ratio)",
                "example": "2:1 ratio → IRT blocks of 3 or 6"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System",
          "Interactive Response Technology",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Pre-populate EDC study header and demographics forms",
          "Configure CTMS study record with identifiers and milestones",
          "Set IRT enrollment caps by country/region",
          "Generate ClinicalTrials.gov registration data",
          "Auto-configure site feasibility questionnaires"
        ],
        "integration": {
          "dependsOn": [],
          "enriches": [
            "arms_design",
            "endpoints_estimands_sap",
            "eligibility_criteria"
          ],
          "crossReferences": [
            "quality_management",
            "data_management"
          ]
        },
        "cdiscDomains": [
          "DM",
          "DS"
        ],
        "regulatoryRelevance": "Foundation for ICH M11 sections 1-5, CTD Module 5",
        "schemaFile": "study_metadata_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_STUDY_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate study-level EDC configuration",
            "sourceDataPath": "*",
            "ruleLogic": "CREATE study_config FROM (protocolId, studyTitle, studyPhase, therapeuticArea)",
            "example": null
          },
          {
            "ruleId": "CTMS_REG_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Auto-populate CTMS study record from protocol identifiers",
            "sourceDataPath": "studyIdentifiers[].identifier",
            "ruleLogic": "FOR EACH id IN studyIdentifiers: SET ctms.registry[id.type] = id.identifier",
            "example": "NCT number → CTMS.NCT_ID field"
          },
          {
            "ruleId": "IRT_PHASE_001",
            "ruleType": "validation",
            "targetSystem": "Interactive Response Technology",
            "description": "Validate IRT complexity requirements based on phase",
            "sourceDataPath": "studyPhase.decode",
            "ruleLogic": "IF phase IN ['Phase 1', 'Phase 1/2'] THEN require dose_escalation_module",
            "example": "Phase 1 → Enable dose escalation cohort management"
          },
          {
            "ruleId": "EDC_ELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate age range edit check for eligibility form",
            "sourceDataPath": "studyPopulation.ageRange",
            "ruleLogic": "IF subject_age < min_age OR subject_age > max_age THEN RAISE eligibility_failure",
            "example": "Age 18-75 → Edit check: BRTHDT must result in age between 18 and 75 at screening"
          },
          {
            "ruleId": "IRT_RAND_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT randomization ratio",
            "sourceDataPath": "studyDesignInfo.randomizationRatio",
            "ruleLogic": "SET irt.allocation_ratio = randomizationRatio; SET irt.block_size = CALCULATE(ratio)",
            "example": "2:1 ratio → IRT blocks of 3 or 6"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_META_ARMS_001",
            "name": "Study Context + Arms → IRT Complete Configuration",
            "agentsInvolved": [
              "study_metadata",
              "arms_design"
            ],
            "description": "Combining study design info with arm definitions enables complete IRT setup",
            "combinedInsight": "Randomization ratio + arm definitions + stratification = Complete IRT randomization module",
            "automationEnabled": "One-click IRT vendor specification generation",
            "exampleOutput": "{\"randomization\": {\"ratio\": \"2:1\", \"arms\": [\"Drug A\", \"Placebo\"], \"stratification\": [\"ECOG\", \"Prior Therapy\"]}}"
          },
          {
            "synergyId": "SYN_META_ELIG_001",
            "name": "Population + Eligibility → Smart Screening",
            "agentsInvolved": [
              "study_metadata",
              "eligibility_criteria",
              "laboratory_specifications"
            ],
            "description": "Population characteristics + criteria + lab values = intelligent screening tool",
            "combinedInsight": "Age/sex + inclusion/exclusion + lab ranges = Complete eligibility calculator",
            "automationEnabled": "Site-facing eligibility screening app with real-time validation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_META_001",
            "name": "Phase-Design Consistency",
            "agentsInvolved": [
              "study_metadata",
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify study phase is consistent with arm complexity",
            "checkLogic": "IF phase='Phase 1' THEN arms.count SHOULD BE <= 3",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "study_header",
            "description": "EDC study-level configuration derived from metadata",
            "dataSources": [
              "protocolId",
              "studyTitle",
              "studyPhase",
              "sponsorName"
            ],
            "outputFormat": "EDC vendor import format (Medidata Rave, Oracle InForm, Veeva Vault)",
            "exampleConfig": {
              "study_id": "{protocolId}",
              "study_name": "{studyTitle}",
              "phase": "{studyPhase.decode}",
              "sponsor": "{sponsorName}",
              "therapeutic_area": "{therapeuticArea}"
            }
          }
        ]
      },
      "arms_design": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm × epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Generate IRT arm configuration from study arms",
                "sourceDataPath": "studyArms[]",
                "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
                "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
              },
              {
                "ruleId": "EDC_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate treatment assignment dropdown options",
                "sourceDataPath": "studyArms[].name",
                "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DISP_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT dispensing rules from dosing regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
                "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
                "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
              },
              {
                "ruleId": "EDC_DOSE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dispensed dose against protocol regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
                "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT stratification from protocol factors",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
                "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
              },
              {
                "ruleId": "EDC_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate stratification CRF fields",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DOSEMOD_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dose modification follows protocol levels",
                "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
                "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Randomization & Trial Supply Management",
                "description": "Generate kit configuration and depot requirements",
                "sourceDataPath": "designMetadata.drugSupply",
                "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Generate IRT arm configuration from study arms",
            "sourceDataPath": "studyArms[]",
            "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
            "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
          },
          {
            "ruleId": "EDC_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate treatment assignment dropdown options",
            "sourceDataPath": "studyArms[].name",
            "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
            "example": null
          },
          {
            "ruleId": "IRT_DISP_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT dispensing rules from dosing regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
            "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
            "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
          },
          {
            "ruleId": "EDC_DOSE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dispensed dose against protocol regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
            "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
            "example": null
          },
          {
            "ruleId": "IRT_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT stratification from protocol factors",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
            "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
          },
          {
            "ruleId": "EDC_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate stratification CRF fields",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
            "example": null
          },
          {
            "ruleId": "EDC_DOSEMOD_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dose modification follows protocol levels",
            "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
            "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
            "example": null
          },
          {
            "ruleId": "IRT_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Randomization & Trial Supply Management",
            "description": "Generate kit configuration and depot requirements",
            "sourceDataPath": "designMetadata.drugSupply",
            "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_ARMS_SAFETY_001",
            "name": "Dosing + Safety Rules → Complete Dose Management",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining dosing regimens with safety thresholds and lab triggers enables intelligent dose management",
            "combinedInsight": "Protocol doses + reduction levels + lab thresholds = Automated dose recommendation engine",
            "automationEnabled": "EDC can suggest appropriate dose level based on current labs and AEs",
            "exampleOutput": "{\"current_dose\": \"400mg\", \"recommended_action\": \"REDUCE to 300mg\", \"trigger\": \"ANC < 1000\", \"confidence\": 0.95}"
          },
          {
            "synergyId": "SYN_ARMS_SOA_001",
            "name": "Arms + SOA → Visit-Based Dispensing",
            "agentsInvolved": [
              "arms_design",
              "soa_schedule"
            ],
            "description": "Arm-specific dosing matched to visit schedule enables precise dispensing rules",
            "combinedInsight": "Which drug, what dose, at which visits = Complete dispensing matrix",
            "automationEnabled": "IRT auto-dispense based on visit and arm assignment",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_ARMS_001",
            "name": "Arm Allocation Total",
            "agentsInvolved": [
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify arm allocations sum to 100%",
            "checkLogic": "SUM(studyArms[].allocationPercentage) == 100",
            "severity": "error"
          },
          {
            "ruleId": "VAL_ARMS_002",
            "name": "Dose Levels Consistency",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels in arms match safety decision points",
            "checkLogic": "arms.doseModifications.levels SUBSET_OF safety.dose_modification_levels.levels",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Interactive Response Technology",
            "configType": "randomization_module",
            "description": "Complete IRT randomization configuration",
            "dataSources": [
              "studyArms[].id",
              "studyArms[].name",
              "studyArms[].allocationPercentage",
              "designMetadata.stratificationFactors[]",
              "designMetadata.randomizationRatio"
            ],
            "outputFormat": "IRT vendor import (Medidata RTSM, Oracle Siebel CTMS, Parexel ClinPhone)",
            "exampleConfig": {
              "study_arms": [
                {
                  "code": "A",
                  "name": "Drug A + Chemo",
                  "ratio": 2
                },
                {
                  "code": "B",
                  "name": "Placebo + Chemo",
                  "ratio": 1
                }
              ],
              "stratification_factors": [
                {
                  "name": "ECOG Status",
                  "levels": [
                    "0-1",
                    "2"
                  ]
                },
                {
                  "name": "Prior Therapy",
                  "levels": [
                    "Yes",
                    "No"
                  ]
                }
              ],
              "block_size": [
                3,
                6
              ],
              "randomization_method": "permuted_block"
            }
          }
        ]
      },
      "safety_decision_points": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DOSELEVEL_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure allowed dose levels in IRT",
                "sourceDataPath": "dose_modification_levels.levels[]",
                "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
                "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_DECISION_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate edit checks from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
                "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
              },
              {
                "ruleId": "ALERT_DECISION_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Configure real-time safety alerts from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STOP_001",
                "ruleType": "workflow",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure enrollment stops based on stopping rules",
                "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
                "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_ORGAN_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate lab-triggered dose recommendations",
                "sourceDataPath": "organ_specific_adjustments[]",
                "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
                "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_DOSELEVEL_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure allowed dose levels in IRT",
            "sourceDataPath": "dose_modification_levels.levels[]",
            "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
            "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
          },
          {
            "ruleId": "EDC_DECISION_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate edit checks from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
            "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
          },
          {
            "ruleId": "ALERT_DECISION_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Configure real-time safety alerts from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
            "example": null
          },
          {
            "ruleId": "IRT_STOP_001",
            "ruleType": "workflow",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure enrollment stops based on stopping rules",
            "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
            "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
            "example": null
          },
          {
            "ruleId": "EDC_ORGAN_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate lab-triggered dose recommendations",
            "sourceDataPath": "organ_specific_adjustments[]",
            "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
            "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_SAFETY_LAB_001",
            "name": "Safety Thresholds + Lab Specs → Smart Lab Alerts",
            "agentsInvolved": [
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining safety thresholds with lab panel definitions enables intelligent lab alerting",
            "combinedInsight": "Which labs to monitor + what thresholds trigger action = Complete lab safety system",
            "automationEnabled": "EDC auto-calculates if labs trigger dose modification upon data entry",
            "exampleOutput": "{\"lab\": \"ANC\", \"value\": 800, \"threshold\": \"<1000\", \"action\": \"Hold dose\", \"triggered\": true}"
          },
          {
            "synergyId": "SYN_SAFETY_ARMS_001",
            "name": "Safety Rules + Arms → Arm-Specific Modifications",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "description": "Safety rules applied to specific arm dosing enables precise modification tracking",
            "combinedInsight": "Which dose level applies to which arm = Accurate dose tracking per subject",
            "automationEnabled": "IRT knows exact dose options for each arm based on safety rules",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_SAFETY_001",
            "name": "Dose Level Consistency",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels align with arm dosing regimens",
            "checkLogic": "FOR EACH level: level.absolute_dose IN arms.interventions.possible_doses",
            "severity": "error"
          },
          {
            "ruleId": "VAL_SAFETY_002",
            "name": "Stopping Rule Completeness",
            "agentsInvolved": [
              "safety_decision_points"
            ],
            "validationType": "completeness",
            "description": "Verify all stopping rules have clear conditions and actions",
            "checkLogic": "FOR EACH stop_rule: condition IS NOT NULL AND action IS NOT NULL",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "edit_check_library",
            "description": "Complete set of safety-related edit checks",
            "dataSources": [
              "decision_points[].decision_rules[]",
              "dose_modification_levels.levels[]",
              "organ_specific_adjustments[]"
            ],
            "outputFormat": "EDC edit check specification (Medidata, Oracle, Veeva)",
            "exampleConfig": {
              "edit_checks": [
                {
                  "id": "EC_ALT_001",
                  "condition": "ALT > 5 * ULN",
                  "action": "FIRE",
                  "message": "ALT elevation requires dose hold per protocol section 6.2",
                  "severity": "HARD_STOP"
                },
                {
                  "id": "EC_ANC_001",
                  "condition": "ANC < 1000",
                  "action": "FIRE",
                  "message": "Neutropenia requires dose modification per Table 6-1",
                  "severity": "SOFT_STOP"
                }
              ]
            }
          }
        ]
      },
      "pro_specifications": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome specifications for ePRO/eCOA vendor configuration.",
        "scope": "PRO instruments, ePRO system config, ClinRO/ObsRO/PerfO instruments, daily diaries, compliance thresholds.",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EPRO_CONFIG_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Patient-Reported Outcomes",
                "description": "Generate ePRO vendor configuration from PRO specifications",
                "sourceDataPath": "pro_instruments[]",
                "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "EPRO_CONFIG_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Patient-Reported Outcomes",
            "description": "Generate ePRO vendor configuration from PRO specifications",
            "sourceDataPath": "pro_instruments[]",
            "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_PRO_SOA_001",
            "name": "PRO + SOA → Complete ePRO Schedule",
            "agentsInvolved": [
              "pro_specifications",
              "soa_schedule"
            ],
            "description": "PRO instruments + visit timing = exact ePRO administration schedule",
            "combinedInsight": "Which PRO at which visit with what window = Complete ePRO schedule",
            "automationEnabled": "ePRO system auto-schedules assessments based on subject visit dates",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "endpoints_estimands_sap": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_EP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADaM ADEFF specification from primary endpoint",
                "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
                "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAP_EST_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate SAP estimand section from extracted estimands",
                "sourceDataPath": "protocol_endpoints.estimands[]",
                "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_POP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADSL population flags from definitions",
                "sourceDataPath": "protocol_endpoints.analysis_populations[]",
                "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
                "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json",
        "automationRules": [
          {
            "ruleId": "ADAM_EP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADaM ADEFF specification from primary endpoint",
            "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
            "example": null
          },
          {
            "ruleId": "SAP_EST_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate SAP estimand section from extracted estimands",
            "sourceDataPath": "protocol_endpoints.estimands[]",
            "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
            "example": null
          },
          {
            "ruleId": "ADAM_POP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADSL population flags from definitions",
            "sourceDataPath": "protocol_endpoints.analysis_populations[]",
            "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
            "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_EP_SOA_001",
            "name": "Endpoints + SOA → Assessment Schedule Validation",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "soa_schedule"
            ],
            "description": "Endpoint timepoints matched to SOA visits ensures all assessments are scheduled",
            "combinedInsight": "Primary endpoint at Week 12 + SOA Week 12 visit with efficacy assessment = Validated schedule",
            "automationEnabled": "Auto-verify SOA includes all required endpoint assessments",
            "exampleOutput": null
          },
          {
            "synergyId": "SYN_EP_AE_001",
            "name": "Endpoints + AEs + Withdrawal → Complete Estimand Definition",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "adverse_events",
              "withdrawal_procedures"
            ],
            "description": "Combining endpoint definitions with AE handling and withdrawal reasons enables complete ICE specification",
            "combinedInsight": "What happens to endpoint when subject discontinues due to AE = Complete intercurrent event strategy",
            "automationEnabled": "Generate regulatory-ready estimand framework documentation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_EP_001",
            "name": "Endpoint-Objective Linkage",
            "agentsInvolved": [
              "endpoints_estimands_sap"
            ],
            "validationType": "completeness",
            "description": "Every endpoint must link to at least one objective",
            "checkLogic": "FOR EACH endpoint: EXISTS objective WHERE endpoint.id IN objective.endpoint_ids",
            "severity": "error"
          }
        ],
        "systemConfigurations": []
      },
      "laboratory_specifications": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, eligibility criteria, and lab-triggered dose modifications for central lab and EDC setup.",
        "scope": "Lab panels, individual tests, eligibility lab criteria, lab-triggered dose modifications, hepatotoxicity monitoring.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_PANEL_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate central lab requisition from panel definitions",
                "sourceDataPath": "panels[]",
                "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_LABELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate screening labs against eligibility criteria",
                "sourceDataPath": "eligibility_lab_criteria[]",
                "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
                "example": "ANC >= 1500/µL required for eligibility"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry",
          "Create eligibility screening lab checklists"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_PANEL_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate central lab requisition from panel definitions",
            "sourceDataPath": "panels[]",
            "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
            "example": null
          },
          {
            "ruleId": "EDC_LABELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate screening labs against eligibility criteria",
            "sourceDataPath": "eligibility_lab_criteria[]",
            "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
            "example": "ANC >= 1500/µL required for eligibility"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_LAB_SAFETY_001",
            "name": "Lab Panels + Safety Thresholds → Lab Alert System",
            "agentsInvolved": [
              "laboratory_specifications",
              "safety_decision_points"
            ],
            "description": "Lab test definitions + safety thresholds = complete lab alerting system",
            "combinedInsight": "Normal ranges + dose modification thresholds = Tiered lab alerts (normal, caution, action required)",
            "automationEnabled": "EDC displays color-coded lab values with action recommendations",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "concomitant_medications": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_PROHIB_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Alert when prohibited medication is entered",
                "sourceDataPath": "prohibited_medications[]",
                "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
                "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_WASHOUT_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate washout period for prior medications",
                "sourceDataPath": "washout_requirements[]",
                "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
                "example": "Prior chemotherapy end date + 28 days must be before first dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DDI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Real-time drug interaction checking",
                "sourceDataPath": "drug_interactions[]",
                "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_PREMED_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Verify required premedications were administered",
                "sourceDataPath": "required_medications[]",
                "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
                "example": "Diphenhydramine 50mg IV required 30 min before infusion"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_PROHIB_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Alert when prohibited medication is entered",
            "sourceDataPath": "prohibited_medications[]",
            "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
            "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
          },
          {
            "ruleId": "EDC_WASHOUT_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate washout period for prior medications",
            "sourceDataPath": "washout_requirements[]",
            "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
            "example": "Prior chemotherapy end date + 28 days must be before first dose"
          },
          {
            "ruleId": "EDC_DDI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Real-time drug interaction checking",
            "sourceDataPath": "drug_interactions[]",
            "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
            "example": null
          },
          {
            "ruleId": "EDC_PREMED_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Verify required premedications were administered",
            "sourceDataPath": "required_medications[]",
            "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
            "example": "Diphenhydramine 50mg IV required 30 min before infusion"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_CM_ELIG_001",
            "name": "Washouts + Eligibility → Complete Screening Tool",
            "agentsInvolved": [
              "concomitant_medications",
              "eligibility_criteria"
            ],
            "description": "Washout requirements combined with eligibility criteria enables smart screening",
            "combinedInsight": "Prior therapy exclusions + washout periods = Earliest eligible date calculator",
            "automationEnabled": "Site tool that calculates when patient becomes eligible based on prior meds",
            "exampleOutput": "{\"prior_med\": \"Irinotecan\", \"last_dose\": \"2024-01-15\", \"washout\": \"28 days\", \"earliest_eligible\": \"2024-02-12\"}"
          }
        ],
        "validationRules": [],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "drug_dictionary_config",
            "description": "Configure drug dictionary with protocol-specific flags",
            "dataSources": [
              "prohibited_medications[]",
              "restricted_medications[]",
              "drug_interactions[]"
            ],
            "outputFormat": "WHODrug/MedDRA mapping with protocol flags",
            "exampleConfig": {
              "drug_flags": [
                {
                  "atc_class": "L01",
                  "flag": "PRIOR_CHEMO",
                  "washout_days": 28
                },
                {
                  "drug_name": "Ketoconazole",
                  "flag": "CYP3A4_INHIBITOR",
                  "status": "PROHIBITED"
                }
              ]
            }
          }
        ]
      }
    },
    "downstreamSystemCoverage": {
      "Electronic Data Capture": [
        "data_management",
        "pkpd_sampling",
        "informed_consent",
        "withdrawal_procedures",
        "quality_management",
        "imaging_central_reading",
        "biospecimen_handling",
        "adverse_events",
        "study_metadata",
        "arms_design",
        "safety_decision_points",
        "pro_specifications",
        "endpoints_estimands_sap",
        "laboratory_specifications",
        "concomitant_medications"
      ],
      "Clinical Trial Management System": [
        "data_management",
        "site_operations_logistics",
        "withdrawal_procedures",
        "quality_management",
        "adverse_events",
        "study_metadata"
      ],
      "Central Laboratory": [
        "pkpd_sampling",
        "biospecimen_handling",
        "laboratory_specifications"
      ],
      "Trial Master File": [
        "informed_consent",
        "site_operations_logistics"
      ],
      "Regulatory Submission Systems": [
        "informed_consent",
        "study_metadata",
        "endpoints_estimands_sap"
      ],
      "Central Imaging": [
        "imaging_central_reading"
      ],
      "Biospecimen Repository": [
        "biospecimen_handling"
      ],
      "Safety Database (Pharmacovigilance)": [
        "adverse_events",
        "safety_decision_points",
        "concomitant_medications"
      ],
      "Interactive Response Technology": [
        "study_metadata",
        "arms_design",
        "safety_decision_points"
      ],
      "Interactive Web Response System": [
        "arms_design"
      ],
      "Randomization & Trial Supply Management": [
        "arms_design"
      ],
      "Drug Supply Management": [
        "arms_design"
      ],
      "Electronic Patient-Reported Outcomes": [
        "pro_specifications"
      ],
      "Electronic Clinical Outcome Assessment": [
        "pro_specifications"
      ]
    },
    "automationCategories": {
      "CDISC Data Standards Mapping": [
        {
          "agent": "data_management",
          "insight": "CDISC Standards",
          "priority": "high"
        },
        {
          "agent": "imaging_central_reading",
          "insight": "Response Criteria",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Primary Endpoints",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Estimands",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Analysis Populations",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Statistical Methods",
          "priority": "high"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Subgroup Analyses",
          "priority": "medium"
        }
      ],
      "Laboratory Panel Configuration": [
        {
          "agent": "pkpd_sampling",
          "insight": "PK Sampling Schedule",
          "priority": "high"
        },
        {
          "agent": "biospecimen_handling",
          "insight": "Specimen Collection Requirements",
          "priority": "critical"
        },
        {
          "agent": "laboratory_specifications",
          "insight": "Laboratory Panels",
          "priority": "critical"
        }
      ],
      "Regulatory Document Generation": [
        {
          "agent": "informed_consent",
          "insight": "Key Risks",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Protocol Identifiers",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Study Phase",
          "priority": "critical"
        }
      ],
      "EDC Form Design & Edit Checks": [
        {
          "agent": "informed_consent",
          "insight": "Optional Consents",
          "priority": "high"
        },
        {
          "agent": "withdrawal_procedures",
          "insight": "Discontinuation Types",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "AE Collection Period",
          "priority": "critical"
        },
        {
          "agent": "pro_specifications",
          "insight": "PRO Instruments",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Required Premedications",
          "priority": "high"
        }
      ],
      "Site Training Materials": [
        {
          "agent": "site_operations_logistics",
          "insight": "Equipment Requirements",
          "priority": "medium"
        }
      ],
      "Safety Monitoring Rules": [
        {
          "agent": "quality_management",
          "insight": "Key Risk Indicators",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "SAE Criteria",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "Reporting Timelines",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "AESI List",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "DLT Criteria",
          "priority": "high"
        },
        {
          "agent": "arms_design",
          "insight": "Dose Modification Rules",
          "priority": "high"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Dose Reduction Levels",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Decision Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Stopping Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Organ-Specific Adjustments",
          "priority": "high"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Drug Interactions",
          "priority": "high"
        }
      ],
      "Eligibility Verification": [
        {
          "agent": "study_metadata",
          "insight": "Target Population",
          "priority": "critical"
        },
        {
          "agent": "laboratory_specifications",
          "insight": "Eligibility Lab Criteria",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Prohibited Medications",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Washout Requirements",
          "priority": "critical"
        }
      ],
      "Visit Schedule Programming": [
        {
          "agent": "study_metadata",
          "insight": "Study Milestones",
          "priority": "high"
        }
      ],
      "Randomization Configuration": [
        {
          "agent": "study_metadata",
          "insight": "Design Metadata",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Study Arms",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Stratification Factors",
          "priority": "critical"
        }
      ],
      "Drug Supply & Kit Management": [
        {
          "agent": "arms_design",
          "insight": "Dosing Regimens",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Drug Supply Configuration",
          "priority": "high"
        }
      ]
    },
    "integrationGraph": {
      "nodes": [
        {
          "id": "data_management",
          "displayName": "Data Management",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "pkpd_sampling",
          "displayName": "PK/PD Sampling",
          "wave": 2,
          "priority": 3
        },
        {
          "id": "informed_consent",
          "displayName": "Informed Consent Elements",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "site_operations_logistics",
          "displayName": "Site Operations & Logistics",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "withdrawal_procedures",
          "displayName": "Withdrawal Procedures",
          "wave": 2,
          "priority": 2
        },
        {
          "id": "quality_management",
          "displayName": "Quality Management",
          "wave": 2,
          "priority": 1
        },
        {
          "id": "imaging_central_reading",
          "displayName": "Imaging & Central Reading",
          "wave": 2,
          "priority": 3
        },
        {
          "id": "biospecimen_handling",
          "displayName": "Biospecimen Handling",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "adverse_events",
          "displayName": "Adverse Events",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "study_metadata",
          "displayName": "Study Metadata",
          "wave": 0,
          "priority": 0
        },
        {
          "id": "arms_design",
          "displayName": "Treatment Arms & Study Design",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "safety_decision_points",
          "displayName": "Safety Decision Points",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "pro_specifications",
          "displayName": "PRO/eCOA Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "endpoints_estimands_sap",
          "displayName": "Endpoints, Estimands & SAP",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "laboratory_specifications",
          "displayName": "Laboratory Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "concomitant_medications",
          "displayName": "Concomitant Medications",
          "wave": 1,
          "priority": 1
        }
      ],
      "edges": [
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "depends_on"
        },
        {
          "source": "data_management",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "pkpd_sampling",
          "type": "depends_on"
        },
        {
          "source": "pkpd_sampling",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "pkpd_sampling",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "pkpd_sampling",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "informed_consent",
          "type": "depends_on"
        },
        {
          "source": "informed_consent",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "site_operations_logistics",
          "type": "depends_on"
        },
        {
          "source": "site_operations_logistics",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "site_operations_logistics",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "withdrawal_procedures",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "quality_management",
          "target": "data_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "imaging_central_reading",
          "type": "depends_on"
        },
        {
          "source": "imaging_central_reading",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "imaging_central_reading",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "biospecimen_handling",
          "type": "depends_on"
        },
        {
          "source": "biospecimen_handling",
          "target": "laboratory_specifications",
          "type": "enriches"
        },
        {
          "source": "biospecimen_handling",
          "target": "pkpd_sampling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "adverse_events",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "safety_decision_points",
          "type": "cross_references"
        },
        {
          "source": "adverse_events",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "depends_on"
        },
        {
          "source": "arms_design",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "pkpd_sampling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "biospecimen_handling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "arms_design",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "safety_decision_points",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "safety_decision_points",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "laboratory_specifications",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "pro_specifications",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "pro_specifications",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "imaging_central_reading",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "laboratory_specifications",
          "type": "depends_on"
        },
        {
          "source": "laboratory_specifications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "concomitant_medications",
          "type": "depends_on"
        },
        {
          "source": "concomitant_medications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "concomitant_medications",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "concomitant_medications",
          "target": "arms_design",
          "type": "cross_references"
        }
      ]
    }
  }
}